0001493152-22-008404.txt : 20220331 0001493152-22-008404.hdr.sgml : 20220331 20220331154202 ACCESSION NUMBER: 0001493152-22-008404 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220331 DATE AS OF CHANGE: 20220331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: eWELLNESS HEALTHCARE Corp CENTRAL INDEX KEY: 0001550020 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 451560906 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55203 FILM NUMBER: 22792131 BUSINESS ADDRESS: STREET 1: 1126 S FEDERAL HIGHWAY, SUITE 464 CITY: FT LAUDERDALE STATE: FL ZIP: 33316 BUSINESS PHONE: 855-470-1700 MAIL ADDRESS: STREET 1: 1126 S FEDERAL HIGHWAY, SUITE 464 CITY: FT LAUDERDALE STATE: FL ZIP: 33316 FORMER COMPANY: FORMER CONFORMED NAME: Dignyte, Inc. DATE OF NAME CHANGE: 20120515 10-K 1 form10-k.htm
0001550020 false FY 0001550020 2021-01-01 2021-12-31 0001550020 2021-06-30 0001550020 2022-03-31 0001550020 2021-12-31 0001550020 2020-12-31 0001550020 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001550020 us-gaap:SeriesAPreferredStockMember 2020-12-31 0001550020 us-gaap:SeriesCPreferredStockMember 2021-12-31 0001550020 us-gaap:SeriesCPreferredStockMember 2020-12-31 0001550020 us-gaap:SeriesDPreferredStockMember 2021-12-31 0001550020 us-gaap:SeriesDPreferredStockMember 2020-12-31 0001550020 us-gaap:SeriesEPreferredStockMember 2021-12-31 0001550020 us-gaap:SeriesEPreferredStockMember 2020-12-31 0001550020 2020-01-01 2020-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2019-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2019-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2019-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2019-12-31 0001550020 us-gaap:CommonStockMember 2019-12-31 0001550020 EWLL:SharesToBeIssuedMember 2019-12-31 0001550020 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001550020 us-gaap:RetainedEarningsMember 2019-12-31 0001550020 2019-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2020-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2020-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2020-12-31 0001550020 us-gaap:CommonStockMember 2020-12-31 0001550020 EWLL:SharesToBeIssuedMember 2020-12-31 0001550020 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001550020 us-gaap:RetainedEarningsMember 2020-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2020-01-01 2020-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2020-01-01 2020-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2020-01-01 2020-12-31 0001550020 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001550020 EWLL:SharesToBeIssuedMember 2020-01-01 2020-12-31 0001550020 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001550020 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-01-01 2021-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2021-01-01 2021-12-31 0001550020 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001550020 EWLL:SharesToBeIssuedMember 2021-01-01 2021-12-31 0001550020 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001550020 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2021-12-31 0001550020 us-gaap:CommonStockMember 2021-12-31 0001550020 EWLL:SharesToBeIssuedMember 2021-12-31 0001550020 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001550020 us-gaap:RetainedEarningsMember 2021-12-31 0001550020 EWLL:ServicesAgreementMember EWLL:BistromaticsIncMember 2020-09-15 0001550020 EWLL:ServicesAgreementMember EWLL:BistromaticsIncMember 2020-09-14 2020-09-15 0001550020 2021-04-18 0001550020 2021-04-19 0001550020 2021-04-18 2021-04-19 0001550020 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001550020 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001550020 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001550020 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001550020 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001550020 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001550020 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2021-01-01 2021-12-31 0001550020 us-gaap:FurnitureAndFixturesMember srt:MaximumMember 2021-01-01 2021-12-31 0001550020 us-gaap:ComputerEquipmentMember srt:MinimumMember 2021-01-01 2021-12-31 0001550020 us-gaap:ComputerEquipmentMember srt:MaximumMember 2021-01-01 2021-12-31 0001550020 us-gaap:SoftwareDevelopmentMember 2021-01-01 2021-12-31 0001550020 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001550020 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001550020 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001550020 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001550020 us-gaap:ConvertibleDebtSecuritiesMember 2021-01-01 2021-12-31 0001550020 us-gaap:ConvertibleDebtSecuritiesMember 2020-01-01 2020-12-31 0001550020 EWLL:OfficersAndDirectorsMember 2021-12-31 0001550020 EWLL:OfficersAndDirectorsMember 2020-12-31 0001550020 EWLL:SettlementAndCompromiseAgreementMember 2020-09-30 0001550020 us-gaap:ConvertibleNotesPayableMember 2021-12-31 0001550020 EWLL:TwelvePercentConvertiblePromissoryNoteMember 2020-03-31 0001550020 EWLL:TwelvePercentConvertiblePromissoryNoteMember 2020-03-01 2020-03-31 0001550020 EWLL:TwelvePercentConvertiblePromissoryNoteMember 2020-12-31 0001550020 EWLL:TwoThousandNineteenConvertibleNotesMember 2020-12-31 0001550020 EWLL:OfficersDirectorsAndConsultantsMember 2019-12-31 0001550020 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001550020 EWLL:BoardOfDirectorsMember us-gaap:SeriesCPreferredStockMember 2021-04-30 0001550020 EWLL:BoardOfDirectorsMember us-gaap:SeriesDPreferredStockMember 2021-04-30 0001550020 EWLL:BoardOfDirectorsMember us-gaap:SeriesEPreferredStockMember 2021-04-30 0001550020 EWLL:SeriesEConvertiblePreferredStockMember 2021-05-03 2021-05-04 0001550020 EWLL:SeriesEConvertiblePreferredStockMember 2021-05-04 0001550020 EWLL:SeriesDVotingPreferredStockMember 2021-05-12 0001550020 EWLL:SeriesCConvertiblePreferredStockMember 2021-05-20 0001550020 EWLL:SeriesEConvertiblePreferredStockMember 2021-07-01 0001550020 us-gaap:CommonStockMember EWLL:BoardOfDirectorsMember 2020-02-10 2020-02-12 0001550020 us-gaap:CommonStockMember EWLL:BoardOfDirectorsMember 2019-01-01 2019-12-31 0001550020 us-gaap:CommonStockMember 2020-02-14 0001550020 EWLL:ConvertibleNotesMember 2020-01-01 2020-12-31 0001550020 EWLL:ConvertibleNotesMember 2020-12-31 0001550020 2020-01-29 2020-01-30 0001550020 EWLL:TwelveMonthAdvisoryServicesAgreementMember 2020-01-01 2020-01-31 0001550020 EWLL:TwelveMonthAdvisoryServicesAgreementMember 2020-01-01 2020-12-31 0001550020 EWLL:ConsultantMember 2020-01-01 2020-12-31 0001550020 EWLL:PreferredSeriesEConversionMember 2021-01-01 2021-12-31 0001550020 EWLL:VendorMember 2020-08-11 2020-08-12 0001550020 EWLL:FormerConsultantMember us-gaap:SubsequentEventMember 2022-03-13 2022-03-14 0001550020 EWLL:FirstPaymentMember us-gaap:SubsequentEventMember 2022-03-13 2022-03-14 0001550020 EWLL:EverySixtyDaysThereafterMember us-gaap:SubsequentEventMember 2022-03-13 2022-03-14 0001550020 EWLL:DerivativeLiabilityMember 2021-01-01 2021-12-31 0001550020 EWLL:DerivativeLiabilityMember 2020-01-01 2020-12-31 0001550020 EWLL:NotesMember 2019-12-31 0001550020 EWLL:WarrantsDerivativeMember 2019-12-31 0001550020 EWLL:NotesMember 2020-01-01 2020-12-31 0001550020 EWLL:WarrantsDerivativeMember 2020-01-01 2020-12-31 0001550020 EWLL:NotesMember 2020-12-31 0001550020 EWLL:WarrantsDerivativeMember 2020-12-31 0001550020 EWLL:NotesMember 2021-01-01 2021-12-31 0001550020 EWLL:WarrantsDerivativeMember 2021-01-01 2021-12-31 0001550020 EWLL:NotesMember 2021-12-31 0001550020 EWLL:WarrantsDerivativeMember 2021-12-31 0001550020 EWLL:DerivativeLiabilityMember 2021-12-31 0001550020 EWLL:DerivativeLiabilityMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001550020 EWLL:DerivativeLiabilityMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001550020 EWLL:DerivativeLiabilityMember us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001550020 us-gaap:SeriesEPreferredStockMember 2021-01-01 2021-12-31 0001550020 us-gaap:SeriesEPreferredStockMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure EWLL:Trading

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-K

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2021

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number 000-55203

 

 

eWELLNESS HEALTHCARE CORPORATION

(Exact name of registrant as specified in its charter)

 

Nevada   90-1073143
(State or other jurisdiction of
incorporation or organization)		   (I.R.S. Employer
Identification No.)

 

1125 S Federal Hwy #464, Fort Lauderdale, FL   33316
(Address of principal executive offices)   (Zip Code)

 

(855) 470-1700

(Registrant’s telephone number, including area code)

 

Securities registered under Section 12(b) of the Act: None

 

Securities registered under Section 12(g) of the Act: Common stock, $0.001 par value

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

 

Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

 

Yes ☐ No ☒

 

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

 

Yes ☒ No ☐

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☒

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
   
Non-accelerated filer ☐ (Do not check if a smaller reporting company) Smaller reporting company ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes ☐ No ☒

 

Emerging growth company ☐

 

Yes ☐ No ☒

 

The aggregate market value of the 17,707,683,628 voting and non-voting common equity held by non-affiliates on June 30, 2021 (the last trading date in June 2021) computed by reference to the closing price of $.0006 on such date or the average bid and asked prices of such common equity as of the last business day of the registrant’s most recently completed second fiscal quarter was $10,624,610.

 

The number of shares of Common stock, $0.001 par value, outstanding on March 31, 2022 is 18,507,683,627.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

None

 

 

 

 

 

 

eWellness Healthcare Corporation

Form 10-K

For the Year Ended December 31, 2021

 

Table of Contents

 

    Page
  Part I  
Item 1 Business 4
Item 1A Risk Factors 4
Item 1B Unresolved Staff Comments 11
Item 2 Properties 11
Item 3 Legal Proceedings 11
Item 4 Mine Safety Disclosures 12
     
  Part II
Item 5 Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 12
Item 6 Selected Financial Data 13
Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations 13
Item 7A Quantitative and Qualitative Disclosures About Market Risk 15
Item 8 Consolidated Financial Statements and Supplementary Data 15
Item 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 16
Item 9A Controls and Procedures 16
Item 9B Other Information 18
     
  Part III  
Item 10 Directors, Executive Officers and Corporate Governance 18
Item 11 Executive Compensation 21
Item 12 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 22
Item 13 Certain Relationships and Related Transactions 22
Item 14 Principal Accountant Fees and Services 23
     
  Part IV  
Item 15 Exhibits, Financial Statement Schedules 24
Signatures 25

 

 2 

 

 

FORWARD-LOOKING STATEMENTS

 

This document contains “forward-looking statements”. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objections of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing.

 

Forward-looking statements may include the words “may,” “could,” “estimate,” “intend,” “continue,” “believe,” “expect” or “anticipate” or other similar words. These forward-looking statements present our estimates and assumptions only as of the date of this report. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the dates on which they are made.

 

Throughout this Annual Report references to “we”, “our”, “us”, “eWellness”, “the Company”, and similar terms refer to eWellness Healthcare Corporation and its wholly owned subsidiary.

 

 3 

 

 

PART I

 

ITEM 1. BUSINESS

 

The Company Background and Nature of Business

 

eWellness Healthcare Corporation (the “eWellness”, “Company”, “we”, “us”, “our”) was incorporated in the State of Nevada on April 7, 2011.

 

eWellness Healthcare Corporation is the first physical therapy telehealth company to offer real-time distance monitored assessments and treatments. On September 15, 2020, the Company and Bistromatics signed an agreement that transferred all worldwide marketing and Intellectual Property Rights or claims to the Company’s Phzio, Phzio TeleRehab and MSK 360 platforms to Bistromatics in return for a 15% ownership in Bistromatics. This agreement eliminated all past due professional fees of $748,832. The transfer of rights was completed on December 31, 2020.

 

During the last quarter of 2020 and the first quarter of 2021, the Company’s Board of Directors and management determined that while it would continue its efforts and resources involving physical therapy and telemedicine, it would also pursue other health-related business opportunities. With the Company’s announced plan to diversify its health-related business beyond its telemedicine operations, which telemedicine operations will continue, the Company on May 18, 2021, entered into an Agreement and Plan of Merger by and between the Company, EWLL Acquisition (a new wholly owned subsidiary of the Company) and a recently formed private Nevada company controlled by a third party, American Health Protection, Inc.(“AMHP”). pursuant to which AMHP merged with EWLL Acquisition, with AMHP being the surviving entity and becoming a wholly owned subsidiary of the Company. On July 14, 2021, the Company filed the requisite Articles of Merger with the State of Nevada and, as a result, AMHP became a wholly owned subsidiary of the Company and EWLL Acquisition ceased to exist.

 

On April 19, 2021, the Company filed a DEF 14C to disclose to the stockholders the ratification and approval by Joint Written Consent, based upon the unanimous approval by our Board of Directors and the consent of the Majority Consenting Stockholders, of the corporate actions to file an amendment to its Amended and Restated Articles of Incorporation to: (i) change the name of the Company from eWellness Healthcare Corporation to American Health Protection Corp. (“Name Change”); (ii) change the par value of the Company’s common stock and preferred stock from $0.001 per share to $0.0001 per share (“Par Value Change”); and (iii) implement the 1:2,000 reverse split of our Common Stock and the shares underlying conversion of the Company’s securities convertible into Common Stock together with the shares reserved for such conversions, on a one for two thousand (1:2,000) basis (“Reverse Split”). The Name Change, Par Value Change and Reverse Split are sometimes referred to as the “Corporate Actions”, which Corporate Actions must be approved by FINRA. The application for approval of these actions to FINRA has not yet been filed.

 

As stated in the DEF 14C, the Name Change from eWellness Healthcare Corporation to American Health Protection Corp. was to reflect the Company’s plan to diversify its business operations from the telemedicine business and the proprietary PHZIO System to include other health related services to its primary target market focused on small and mid-sized corporate clients. The Par Value Change of the Company’s Common Stock and Preferred Stock from $0.001 per share to $0.0001 per share was the result that for more than the past six months (preceding the filing of the DEF 14C), the price of its Common Stock on the OTC Markets had been less than the $0.001 par value of its Common Stock. As a result, the Company had not been able to raise capital by the issuance of shares of Common Stock at less than the $0.001 par value and, in addition, the Company could not raise capital through the issuance of shares of convertible Preferred Stock having a conversion price of less than the $0.001 par value of the Common Stock. Lastly, the rationale for the Reverse Split of the outstanding shares of Common Stock on a one for two thousand (1:2,000) basis was needed because the outstanding shares and shares reserved for convertible debt conversion resulted in no shares being available for capital raise purposes.

 

Employees

 

At the year ended December 31, 2021, we had 2 employees and various consultants.

 

Transfer Agent

 

The transfer agent of the Company’s stock is VStock Transfer LLC, 18 Lafayette Place, Woodmere, NY 11598, (212) 828-8436.

 

NOTES REGARDING FORWARD-LOOKING STATEMENTS

 

The statements contained in this annual report are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. These include statements about the Company’s expectations, beliefs, intentions or strategies for the future, which are indicated by words or phrases such as “anticipate,” “expect,” “intend,” “plan,” “will,” “the Company believes,” “management believes” and similar words or phrases. The forward-looking statements are based on the Company’s current expectations and are subject to certain risks, uncertainties and assumptions. The Company’s actual results could differ materially from results anticipated in these forward-looking statements. All forward-looking statements included in this document are based on information available to the Company on the date hereof, and the Company assumes no obligation to update any such forward-looking statements.

 

Item 1A. RISK FACTORS

 

Investing in our securities involves a great deal of risk. Careful consideration should be made of the following factors as well as other information included in this Annual Report before deciding to purchase our common stock. Our business, financial condition or results of operations could be affected materially and adversely by any or all of these risks.

 

 4 

 

 

THE FOLLOWING MATTERS MAY HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL CONDITION, LIQUIDITY, RESULTS OF OPERATIONS OR PROSPECTS, FINANCIAL OR OTHERWISE. REFERENCE TO THIS CAUTIONARY STATEMENT IN THE CONTEXT OF A FORWARD-LOOKING STATEMENT OR STATEMENTS SHALL BE DEEMED TO BE A STATEMENT THAT ANY ONE OR MORE OF THE FOLLOWING FACTORS MAY CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN SUCH FORWARD-LOOKING STATEMENT OR STATEMENTS.

 

Risks Related to our Financial Condition

 

Our Independent Registered Public Accounting Firm has expressed substantial doubt as to our ability to continue as a going concern.

 

The audited financial statements have been prepared assuming that we will continue as a going concern and do not include any adjustments that might result if we cease to continue as a going concern. We believe that to continue as a going concern we will need approximately $500,000 per year simply to cover the administrative, legal and accounting fees. We plan to fund these expenses primarily through cash flow, the sale of restricted shares of our common stock and the issuance of convertible notes.

 

Based on our financial statements for the years ended December 31, 2021 and 2020, our independent registered public accounting firm has expressed substantial doubt as to our ability to continue as a going concern. To date we have not generated any revenue.

 

Investing in our securities involves a great deal of risk. Careful consideration should be made of the following factors as well as other information included in this Prospectus before deciding to purchase our common stock. Our business, financial condition or results of operations could be affected materially and adversely by any or all these risks.

 

We may need to raise additional capital to fund continuing operations and an inability to raise the necessary capital or to do so on acceptable terms could threaten the success of our business.

 

To date, our operations have been funded entirely from the proceeds from equity and debt financings or loans from our management. We currently anticipate that our available capital resources will be insufficient to meet our expected working capital and capital expenditure requirements for the near future. We anticipate that we will require an additional $1.5 million during the next twelve months to satisfy our business plan. However, such resources may not be sufficient to fund the long-term growth of our business. If we determine that it is necessary to raise additional funds, we may choose to do so through strategic collaborations, licensing arrangements through our “White Labelling” strategy, public or private equity or debt financing, a bank line of credit, or other arrangements.

 

We cannot be sure that any additional funding will be available on terms favorable to us or at all. Any additional equity financing may be dilutive to our shareholders, new equity securities may have rights, preferences or privileges senior to those of existing holders of our shares of Common stock. Debt or equity financing may subject us to restrictive covenants and significant interest costs. If we obtain funding through a strategic collaboration or licensing arrangement, we may be required to relinquish our rights to our product or marketing territories. If we are unable to obtain the financing necessary to support our operations, we may be required to defer, reduce or eliminate certain planned expenditures or significantly curtail our operations.

 

We have a history of net losses; we may never achieve or sustain profitability or positive cash flow from operations.

 

We have incurred net losses in each fiscal year since our inception, including net losses of $451,707 for the year ended December 31, 2021 and $8,771,527 for the year ended December 31, 2020. As of the year ended December 31, 2021, we had an accumulated deficit of $40,069,797. We expect to continue to incur substantial expenditures to develop and market our services and could continue to incur losses and negative operating cash flow for the foreseeable future. We may never achieve profitability or positive cash flow in the future, and even if we do, we may not be able to continue being profitable.

 

 5 

 

 

We will need to increase the size of our organization and may experience difficulties in managing growth.

 

At present, we are a small company. We expect to experience a period of expansion in headcount, infrastructure and overhead and anticipate that further expansion will be required to address potential growth and market opportunities. Future growth will impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate new managers. Our future financial performance and its ability to compete effectively will depend, in part, on its ability to manage any future growth effectively.

 

Dependence on Key Existing and Future Personnel

 

Our success will depend, to a large degree, upon the efforts and abilities of our officers and key management employees. The loss of the services of one or more of our key employees could have a material adverse effect on our operations. In addition, as our business model is implemented, we will need to recruit and retain additional management and key employees in virtually all phases of our operations. Key employees will require a strong background in our industry. We cannot assure that we will be able to successfully attract and retain key personnel.

 

Currently, our management’s participation in our business and operations is limited

 

To date, we have been unable to offer cash compensation to our officers due to our lack of revenue. Accordingly, each of the Company’s executive officers maintain jobs outside of their position at eWellness. Although each of our executive officers have prepared to devote their efforts, on a full-time basis, towards our objectives once we can afford executive compensation commensurate with that being paid in the marketplace, until such time, our officers will not devote their full time and attention to the operations of the Company. None of our officers have committed a specific portion of their time or an approximate number of hours per week in writing to the objectives of the company and no assurances can be given as to when we will be financially able to engage our officers on a full-time basis and therefore, until such time, it is possible that the inability of such persons to devote their full-time attention to the Company may result in delays in progress toward implementing our business plan.

 

Risks Related to Regulation

 

We incur significant costs as a result of operating as a public company and our management will have to devote substantial time to public company compliance obligations

 

The Sarbanes-Oxley Act of 2002, as well as rules subsequently implemented by the Securities and Exchange Commission (“SEC”), and the stock exchange, has imposed various requirements on public companies, including requiring changes in corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance requirements and any new requirements that the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 may impose on public companies. Moreover, these rules and regulations, along with compliance with accounting principles and regulatory interpretations of such principles, have increased and will continue to increase our legal, accounting and financial compliance costs and have made and will continue to make some activities more time consuming and costly. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantial costs to maintain the same or similar coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or our board committees, or as executive officers. We will evaluate the need to hire additional accounting and financial staff with appropriate public company experience and technical accounting and financial knowledge. We estimate the additional costs we expect to incur as a result of being a public company to be up to $500,000 annually.

 

Part of the requirements as a public company will be to document and test our internal control procedures in order to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act of 2002, which requires annual management assessments of the effectiveness of our internal controls over financial reporting and a report by our independent registered public accounting firm addressing these assessments. The process of designing and implementing effective internal controls is a continuous effort that requires us to anticipate and react to changes in our business and the economic and regulatory environments and to expend significant resources to maintain a system of internal controls that is adequate to satisfy our reporting obligations as a public company.

 

 6 

 

 

Effective internal controls are necessary for us to provide reliable financial reports and to effectively prevent fraud. We maintain a system of internal control over financial reporting, which is defined as a process designed by, or under the supervision of, our principal executive officer and principal financial officer, or persons performing similar functions, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

 

We cannot assure you that we will not, in the future, identify areas requiring improvement in our internal control over financial reporting. We cannot assure that the measures we will take to remediate any areas in need of improvement will be successful or that we will implement and maintain adequate controls over our financial processes and reporting in the future as we continue our growth. If we are unable to maintain appropriate internal financial reporting controls and procedures, it could cause us to fail to meet our reporting obligations, result in the restatement of our financial statements, harm our operating results, subject us to regulatory scrutiny and sanction, cause investors to lose confidence in our reported financial information and have a negative effect on the market price for shares of our common stock.

 

If we fail to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired.

 

As a public company, we are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and the Sarbanes-Oxley Act which requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In order to maintain and improve the effectiveness of our disclosure controls and procedures and internal control over financial reporting, we have expended, and anticipate that we will continue to expend, significant resources, including accounting-related costs and significant management oversight.

 

Our management concluded that our disclosure controls and procedures were not effective as of December 31, 2021. Any failure to develop or maintain effective controls or any difficulties encountered in their implementation or improvement could cause us to fail to meet our reporting obligations and may result in a restatement of our financial statements for prior periods. If we fail to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired, which could result in loss of investor confidence and could have an adverse effect on our stock price.

 

Risks Relating to Our Securities

 

There is a limited market for our common stock, and there may never be, an active market for our common stock and we cannot assure you that the common stock will remain liquid or that it will continue to be listed on a securities exchange.

 

Our common stock is listed on the pink sheets and trades under the symbol “EWLLD”. An investor may find it difficult to obtain accurate quotations as to the market value of the common stock and trading of our common stock may be extremely sporadic. For example, several days may pass before any shares may be traded. A more active market for the common stock may never develop. In addition, if we fail to meet the criteria set forth in SEC regulations, various requirements would be imposed by law on broker-dealers who sell our securities to persons other than established customers and accredited investors. Consequently, such regulations may deter broker-dealers from recommending or selling the common stock, which may further affect its liquidity. This would also make it more difficult for us to raise additional capital.

 

Until our common stock is listed on the NASDAQ or another stock exchange, we expect that our common stock will continue to be eligible to trade on the OTC Bulletin Board, another over-the-counter quotation system, or on the “pink sheets,” where our stockholders may find it more difficult to dispose of shares or obtain accurate quotations as to the market value of our common stock.

 

 7 

 

 

Our Common stock is subject to the “Penny Stock” rules of the SEC and the trading market in our stock is limited, which makes transactions in our stock cumbersome and may reduce the value of an investment.

 

The Securities and Exchange Commission has adopted Rule 15g-9 which establishes the definition of a “penny stock,” for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require:

 

  ● That a broker or dealer approve a person’s account for transactions in penny stocks; and
     
  ● The broker or dealer receives from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.

 

In order to approve a person’s account for transactions in penny stocks, the broker or dealer must:

 

  ● Obtain financial information and investment experience objectives of the person; and
     
  ● Make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.

 

The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the Commission relating to the penny stock market, which, in highlight form:

 

  ● Sets forth the basis on which the broker or dealer made the suitability determination; and
     
  ● That the broker or dealer received a signed, written agreement from the investor prior to the transaction.

 

Generally, brokers may be less willing to execute transactions in securities subject to the “penny stock” rules. This may make it more difficult for investors to dispose of our Common stock and cause a decline in the market value of our stock.

 

Disclosure also must be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements must be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.

 

Financial Industry Regulatory Authority, Inc. (“FINRA”) sales practice requirements may limit a shareholder’s ability to buy and sell our common stock.

 

In addition to the “penny stock” rules described above, FINRA has adopted rules that require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for at least some customers. FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our Common stock, which may limit your ability to buy and sell our stock and have an adverse effect on the market for our shares.

 

Our common stock is thinly traded, sale of your holding may take a considerable amount of time.

 

Our shares of our common stock are thinly traded on the OTCQB Market, meaning that the number of persons interested in purchasing our common stock at or near bid prices at any given time may be relatively small or non-existent. Consequently, there may be periods of several days or more when trading activity in our shares is minimal or non-existent, as compared to a seasoned issuer which has a large and steady volume of trading activity that will generally support continuous sales without an adverse effect on share price. We cannot give you any assurance that a broader or more active public trading market for our common stock will develop or be sustained, or that current trading levels will be sustained. Due to these conditions, we can give you no assurance that you will be able to sell your shares at or near bid prices or at all if you need money or otherwise desire to liquidate your shares.

 

 8 

 

 

Shares eligible for future sale may adversely affect the market.

 

From time to time, certain of our stockholders may be eligible to sell all or some of their shares of common stock by means of ordinary brokerage transactions in the open market pursuant to Rule 144 promulgated under the Securities Act, subject to certain limitations. In general, pursuant to amended Rule 144, non-affiliate stockholders may sell freely after six months subject only to the current public information requirement. Affiliates may sell after six months subject to the Rule 144 volume, manner of sale (for equity securities), current public information and notice requirements. Any substantial sales of our common stock pursuant to Rule 144 may have a material adverse effect on the market price of our common stock.

 

If we fail to maintain effective internal controls over financial reporting, the price of our common stock may be adversely affected.

 

Our internal control over financial reporting may have weaknesses and conditions that could require correction or remediation, the disclosure of which may have an adverse impact on the price of our common stock. We are required to establish and maintain appropriate internal controls over financial reporting. Failure to establish those controls, or any failure of those controls once established, could adversely affect our public disclosures regarding our business, prospects, financial condition or results of operations. In addition, management’s assessment of internal controls over financial reporting may identify weaknesses and conditions that need to be addressed in our internal controls over financial reporting or other matters that may raise concerns for investors. Any actual or perceived weaknesses and conditions that need to be addressed in our internal control over financial reporting or disclosure of management’s assessment of our internal controls over financial reporting may have an adverse impact on the price of our common stock.

 

Our share price could be volatile, and our trading volume may fluctuate substantially.

 

The price of our common shares has been and may in the future continue to be extremely volatile, with the sale price fluctuating from a low of $0.0001 to a high of $200.00 since trading began in 2016. Many factors could have a significant impact on the future price of our common shares, including:

 

  ● our inability to raise additional capital to fund our operations;
     
  ● our failure to successfully implement our business objectives and strategic growth plans;
     
  ● compliance with ongoing regulatory requirements;
     
  ● market acceptance of our product;
     
  ● changes in government regulations;
     
  ● general economic conditions and other external factors; and
     
  ● actual or anticipated fluctuations in our quarterly financial and operating results; and the degree of trading liquidity in our common shares.

 

Our annual and quarterly results may fluctuate, which may cause substantial fluctuations in our common stock price.

 

Our annual and quarterly operating results may in the future fluctuate significantly depending on factors including the timing of purchase orders, new product releases by us and other companies, gain or loss of significant customers, price discounting of our product, the timing of expenditures, product delivery requirements and economic conditions. Revenues related to our product are required to be recognized upon satisfaction of all applicable revenue recognition criteria. The recognition of revenues from our product is dependent on several factors, including, but not limited to, the terms of any license agreement and the timing of implementation of our products by our customers.

 

Any unfavorable change in these or other factors could have a material adverse effect on our operating results for a particular quarter or year, which may cause downward pressure on our Common stock price. We expect quarterly and annual fluctuations to continue for the foreseeable future.

 

 9 

 

 

We are subject to compliance with securities law, which exposes us to potential liabilities, including potential rescission rights.

 

We have offered and sold our common stock to investors pursuant to certain exemptions from the registration requirements of the Securities Act of 1933, as well as those of various state securities laws. The basis for relying on such exemptions is factual; that is, the applicability of such exemptions depends upon our conduct and that of those persons contacting prospective investors and making the offering. We have not received a legal opinion to the effect that any of our prior offerings were exempt from registration under any federal or state law. Instead, we have relied upon the operative facts as the basis for such exemptions, including information provided by investors themselves.

 

If any prior offering did not qualify for such exemption, an investor would have the right to rescind its purchase of the securities if it so desired. It is possible that if an investor should seek rescission, such investor would succeed. A comparable situation prevails under state law in those states where the securities may be offered without registration in reliance on the partial pre-emption from the registration or qualification provisions of such state statutes. If investors were successful in seeking rescission, we would face severe financial demands that could adversely affect our business and operations. Additionally, if we did not in fact qualify for the exemptions upon which it has relied, we may become subject to significant fines and penalties imposed by the SEC and state securities agencies.

 

The availability of a large number of authorized but unissued shares of common stock may, upon their issuance, lead to dilution of existing stockholders.

 

As of February 20, 2020, we are authorized to issue 20,000,000,000 shares of common stock, $0.001 par value per share. As of March 31, 2022 there were 18,507,683,627 shares of common stock issued and outstanding. Additional shares may be issued by our board of directors without further stockholder approval. The issuance of large numbers of shares, possibly at below market prices, is likely to result in substantial dilution to the interests of other stockholders. In addition, issuances of large numbers of shares may adversely affect the market price of our Common stock.

 

We are authorized to issue 20,000,000 shares of Series A preferred stock, $0.001 par value per share. As of December 31, 2021, there were 696,667 shares of Series A preferred stock issued and outstanding. We are authorized to issue 1,000,000 shares of Series C preferred stock, $.0001 par value per share. As of December 31, 2021, there were 920,000 shares of Series C preferred stock issued and outstanding. We are authorized to issue 200,000 shares of Series D preferred stock, $.0001 par value per share. As of December 31, 2021, there were 200,000 shares of Series D preferred stock issued and outstanding. We are authorized to issue 2,500,000 shares of Series E convertible preferred stock, $.0001 par value. As of December 31, 2021, there were 1,465,680 shares of Series E convertible preferred stock issued and outstanding. The Board of Directors is authorized to provide for the issuance of unissued shares of preferred stock in one or more series and to fix the number of shares and to determine the rights, preferences and privileges thereof. Accordingly, the Board of Directors may issue preferred stock which may convert into large numbers of shares of common stock and consequently lead to further dilution of other shareholders.

 

We have never paid cash dividends and do not anticipate doing so in the foreseeable future.

 

We have never declared or paid cash dividends on our common shares. We currently plan to retain any earnings to finance the growth of our business rather than to pay cash dividends. Payments of any cash dividends in the future will depend on our financial condition, results of operations and capital requirements, as well as other factors deemed relevant by our board of directors.

 

The Nevada Revised Statute contains provisions that could discourage, delay or prevent a change in control of our company, prevent attempts to replace or remove current management and reduce the market price of our stock.

 

Provisions in our articles of incorporation and bylaws may discourage, delay or prevent a merger or acquisition that our stockholders may consider favorable. For example, our certificate of incorporation authorizes our board of directors to issue up to ten million shares of “blank check” preferred stock. As a result, without further stockholder approval, the board of directors has the authority to attach special rights, including voting and dividend rights, to this preferred stock. With these rights, preferred stockholders could make it more difficult for a third party to acquire us.

 

 10 

 

 

We are also subject to the anti-takeover provisions of the NRS. Depending on the number of residents in the state of Nevada who own our shares, we could be subject to the provisions of Sections 78.378 et seq. of the Nevada Revised Statutes which, unless otherwise provided in the Company’s articles of incorporation or by-laws, restricts the ability of an acquiring person to obtain a controlling interest of 20% or more of our voting shares. Our articles of incorporation and by-laws do not contain any provision which would currently keep the change of control restrictions of Section 78.378 from applying to us.

 

We are subject to the provisions of Sections 78.411 et seq. of the Nevada Revised Statutes. In general, this statute prohibits a publicly held Nevada corporation from engaging in a “combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the combination or the transaction by which the person became an interested stockholder is approved by the corporation’s board of directors before the person becomes an interested stockholder. After the expiration of the three-year period, the corporation may engage in a combination with an interested stockholder under certain circumstances, including if the combination is approved by the board of directors and/or stockholders in a prescribed manner, or if specified requirements are met regarding consideration. The term “combination” includes mergers, asset sales and other transactions resulting in a financial benefit to the interested stockholder. Subject to certain exceptions, an “interested stockholder” is a person who, together with affiliates and associates, owns, or within three years did own, 10% or more of the corporation’s voting stock. A Nevada corporation may “opt out” from the application of Section 78.411 et seq. through a provision in its articles of incorporation or by-laws. We have not “opted out” from the application of this section.

 

Our stock price and ability to finance may be adversely affected by our outstanding convertible securities and warrants.

 

Sales of the shares of our common stock issuable upon exercise of warrants and upon conversion of our convertible securities, would likely have a depressive effect on the market price of our common stock. Further, the existence of, and/or potential exercise or conversion of all or a portion of these securities, create a negative and potentially depressive effect on our stock price because investors recognize that they overhang the market currently. As a result, the terms on which we may obtain additional financing during the period any of these warrants or convertible securities remain outstanding may be adversely affected by the existence of such warrants and convertible securities.

 

Our publicly filed reports are subject to review by the SEC, and any significant changes or amendments required as a result of any such review may result in material liability to us and may have a material adverse impact on the trading price of the Company’s common stock.

 

The reports of publicly traded companies are subject to review by the SEC from time to time for the purpose of assisting companies in complying with applicable disclosure requirements, and the SEC is required to undertake a comprehensive review of a company’s reports at least once every three years under the Sarbanes-Oxley Act of 2002. SEC reviews may be initiated at any time. We could be required to modify, amend or reformulate information contained in prior filings as a result of an SEC review. Any modification, amendment or reformulation of information contained in such reports could be significant and result in material liability to us and have a material adverse impact on the trading price of the Company’s common stock.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

None

 

ITEM 2. PROPERTIES

 

The corporate office is in Ft. Lauderdale, Florida.

 

ITEM 3. LEGAL PROCEEDINGS

 

The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business. On August 12, 2020, a former consultant filed suit in the Superior Court of the State of California for Breach of Contract and non-payment of fees per said contract. At the time of the suit, the Company owed to the vendor for contractual fees the total of $24,339. On March 14, 2022, the Company accepted a Stipulation and Proposed Order for the payment of $38,000 to the former consultant with the first payment of $5,000 being due immediately and additional $5,000 payments to be paid every 60 days thereafter until the total of $38,000 is paid.

 

 11 

 

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Market Information

 

On March 1, 2016, our common stock became subject to quotation on the OTCQB Market under the symbol “EWLL”, an inter-dealer automated quotation system for equity securities not included on The Nasdaq Stock Market. Quotation of the Company’s securities on the OTCQB Market limits the liquidity and price of the Company’s common stock more than if the Company’s shares of common stock were listed on The Nasdaq Stock Market or a national exchange. For the periods indicated, the following table sets forth the high and low bid prices per share of common stock. The below prices represent inter-dealer quotations without retail markup, markdown, or commission and may not necessarily represent actual transactions. On March 9, 2020, because of the bid price deficiency, the Company’s common stock was moved from the OTCQB market to the pink sheets. As of February 12, 2020, FINRA approved the 1:50 reverse split and the OTCQB Market symbol was changed to “EWLLD”.

 

   Price Range 
Period  High   Low 
Year Ended December 31, 2021:        
First Quarter  $.0049   $.0002 
Second Quarter  $.0017   $.0007 
Third Quarter  $.0007   $.0003 
Fourth Quarter  $.0007   $.0003 
Year Ending December 31, 2022:          
First Quarter  $

.0004

   $.0002 

 

The transfer agent of our common stock is VStock Transfer LLC, 18 Lafayette Place, Woodmere, NY 11598, (212) 828-8436.

 

Record Holders. As of March 31, 2022, we had 18,507,683,627 shares of $0.001 par value common stock issued and outstanding held by 128 shareholders of record.

 

As of March 31, 2022, there are no outstanding options and/or warrants to purchase common equity of the Company.

 

Dividend Policy. We have neither declared nor paid any cash dividends on either preferred or common stock. For the foreseeable future, we intend to retain any earnings to finance the development and expansion of our business and do not anticipate paying any cash dividends on our preferred or common stock. Any future determination to pay dividends will be at the discretion of the Board of Directors and will be dependent upon then existing conditions, including its financial condition, results of operations, capital requirements, contractual restrictions, business prospects, and other factors that the Board of Directors considers relevant.

 

Securities Authorized for Issuance under Equity Compensation Plans.

 

Recent Sales of Unregistered Securities

 

Information regarding any equity securities we have sold during the period covered by this Report that were not registered under the Securities Act of 1933, as amended, is set forth below. Each such transaction was exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) of the Securities Act or Rule 506 of Regulation D promulgated by the SEC, unless otherwise noted. Unless stated otherwise: (i) the securities were offered and sold only to accredited investors; (ii) there was no general solicitation or general advertising related to the offerings; (iii) each of the persons who received these unregistered securities had knowledge and experience in financial and business matters which allowed them to evaluate the merits and risk of the receipt of these securities, and that they were knowledgeable about our operations and financial condition; (iv) no underwriter participated in, nor did we pay any commissions or fees to any underwriter in connection with the transactions; and, (v) each certificate issued for these unregistered securities contained a legend stating that the securities have not been registered under the Securities Act and setting forth the restrictions on the transferability and the sale of the securities.

 

 12 

 

 

On February 12, 2020, FINRA approved a 50:1 reverse split for the Company’s common stock.

 

Sales of Unregistered Securities in 2020:

 

On January 30, 2020, the Company executed a 12-month advisory services agreement. The Company is to issue 20,000 shares of common stock monthly. The Company issued 80,000 shares of common stock with a value of $104. The remaining 160,000 shares of common stock with a value of $30 has been recorded in Shares to be Issued. In addition, the Company is to also pay the advisor a monthly fee of $2,500.

 

During the year ended December 31, 2020, the Company issued a total of 16,849,013,669 shares of common stock per debt conversion of various convertible notes. The total of the debt conversion was for $1,607,317 of principal, $145,167 of accrued interest and $95,933 of financing costs.

 

During the year ended December 31, 2020, the Company issued 588,332 shares of common stock for consultant services valued at $1,604.

 

Sales of Unregistered Securities in 2021:

 

During the year ended December 31, 2021, the Company issued 2,001,666 shares of common stock for consultant services valued at $750.

 

During the year ended December 31, 2021, the Company issued 1,643,200,000 shares of common stock for conversion of 164,320 shares of preferred series E shares.

 

The securities issued have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

 

The Registrant’s issuance of the above restricted securities was in reliance upon the exemption from registration pursuant to Section 4(2) and Regulation S promulgated by the SEC under the Act. Unless stated otherwise: (i) the securities were offered and sold only to accredited investors; (ii) there was no general solicitation or general advertising related to the offerings; (iii) each of the persons who received these unregistered securities had knowledge and experience in financial and business matters which allowed them to evaluate the merits and risk of the receipt of these securities, and that they were knowledgeable about our operations and financial condition; (iv) no underwriter participated in, nor did we pay any commissions or fees to any underwriter in connection with the transactions; and, (v) each certificate issued for these unregistered securities contained a legend stating that the securities have not been registered under the Securities Act and setting forth the restrictions on the transferability and the sale of the securities.

 

ITEM 6. SELECTED FINANCIAL DATA

 

Smaller reporting companies are not required to provide this disclosure.

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT OF OPERATIONS

 

The following discussion and analysis of our financial condition and result of operations contains forward-looking statements and involves numerous risks and uncertainties, including, but not limited to, those described in the “Risk Factors” section of the other reports we file with the Securities and Exchange Commission. Actual results may differ materially from those contained in any forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of such terms or other comparable terminology. These statements are only predictions.

 

 13 

 

 

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. We are under no obligation to update any of the forward-looking statements after the filing of this Annual Report to conform such statements to actual results or to changes in our expectations.

 

The following discussion and analysis of financial condition and results of operations relates to the operations and financial condition reported in the financial statements of eWellness Healthcare Corporation for the years ended December 31, 2021 and 2020 and should be read in conjunction with such financial statements and related notes included in this report.

 

Overview

 

Results of Operations of eWellness for the Twelve-month Periods Ended December 31, 2021 vs. 2020

 

REVENUES: Total net revenues from operations for the years ended December 31, 2021 and December 31, 2020, were $0 and $255,346, respectively.

 

OPERATING EXPENSES: Total operating expenses increased to $2,671,027 for the year ended December 31, 2021 from $2,647,662 for the year ended December 31, 2020 reflecting an increase of $23,365. The increase resulted from an increase in number of shares of preferred stock issued to consultants offset by a decrease in financing fees for conversion of convertible debt and decrease of executive compensation.

 

NET LOSS: The Company incurred a net loss of $451,707 for the year ended December 31, 2021, compared with a net loss of $8,771,527 for the year ended December 31, 2020, which reflects a decrease of $8,319,820. The decrease is primarily because of a decrease of general and administrative expenses, executive compensation and financing fees offset by an increase in professional fees (outlined above) of $23,365, decrease in interest expense of $692,826 and increase in gain on derivative liability of $7,919,238.

 

Liquidity and Capital Resources

 

As of December 31, 2021, we had negative working capital of $4,360,124 compared to negative working capital of $6,660,570 as of December 31, 2020. The main portion of the negative working capital decrease is because of a decrease in accounts payable – related party and a decrease in derivative liability. Cash used in operations was $341,594 and $284,613 for the years ended December 31, 2021 and 2020, respectively. This is primarily due to an increase in shares issued to officers, directors and consultants offset by a decrease in the net loss, decrease in amortization of debt discount and prepaids offset and an increase in gain on derivative liability. Cash flows provided by financing activities were $351,662 and $45,000 for the years ended December 31, 2021 and December 31, 2020, respectively. The increase in cash flows from financing activities was from issuance of convertible preferred shares for cash. The cash balance as of December 31, 2021 was $11,177.

 

We do not have sufficient cash on hand to operate. Our ability to meet our obligations and continue to operate as a going concern is highly dependent on our ability to obtain additional financing. We cannot predict whether this additional financing will be in the form of equity or debt or be in another form. We may not be able to obtain the necessary additional capital on a timely basis, on acceptable terms, or at all. In any of these events, we may be unable to implement our current plans which circumstances would have a material adverse effect on our business, prospects, financial conditions and results of operations.

 

Contingencies

 

The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business.

 

Off-Balance Sheet Arrangements

 

There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

 

 14 

 

 

Contractual Obligations and Commitments

 

In March 2020, the Company executed a 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $52,800. The note, which is due on January 15, 2021, has an original issue discount of $4,800 and transaction costs of $3,000. After 180 days, the convertible note converts into common stock of the Company at a conversion price that shall be equal to 70% of the average of the two lowest per share trading prices for the ten (10) trading days prior to the conversion date. As of December 31, 2020, this note was fully converted and during the year ended December 31, 2020 the Company accrued interest of $2,880.

 

From time to time the Company may become a party to litigation matters involving claims against the Company. On August 12, 2020, a former consultant filed suit in the Superior Court of the State of California for Breach of Contract and non-payment of fees per said contract. At the time of the suit, the Company owed to the vendor for contractual fees the total of $24,339. On March 14, 2022, the Company accepted a Stipulation and Proposed Order for the payment of $38,000 to the former consultant with the first payment of $5,000 being due immediately and additional $5,000 payments to be paid every 60 days thereafter until the total of $38,000 is paid.

 

CRITICAL ACCOUNTING POLICIES

 

Our significant accounting policies are disclosed in Note 2 of our Financial Statements included elsewhere in this Report.

 

ITEM 7A: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Smaller reporting companies are not required to provide this disclosure.

 

ITEM 8: CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

See Index to Financial Statements and Financial Statement Schedules appearing on pages F-1 – F-17 of this Form 10-K.

 

 15 

 

 

eWELLNESS HEALTHCARE CORPORATION

INDEX TO FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2021AND DECEMBER 31, 2020

 

  PAGES
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB ID: 457) F-2
BALANCE SHEETS F-4
STATEMENTS OF OPERATIONS F-5
STATEMENTS OF STOCKHOLDERS DEFICIT F-6
STATEMENTS OF CASH FLOWS F-7
NOTES TO FINANCIAL STATEMENTS F-8

 

F-1
 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and

Stockholders of eWellness Healthcare Corporation

 

Opinion on the Financial Statements

 

We have audited the accompanying balance sheets of eWellness Healthcare Corporation (the Company) as of December 31, 2021 and 2020, and the related statements of operations, stockholders’ deficit, and cash flows for each of the years in the two-year period ended December 31, 2021, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.

 

Consideration of the Company’s Ability to Continue as a Going Concern

 

The accompanying financial statements have been prepared assuming that Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has yet to earn significant revenue, has a deficit in stockholders’ equity, and has sustained recurring losses from operations. This raises substantial doubt about the Company’s ability to continue as a going concern. Management’s plans regarding these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

F-2
 

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

Valuation of Derivative Liabilities

 

Description of the Matter:

 

As discussed in Note 11 to the financial statements, the Company has issued convertible notes that require derivative accounting primarily due to the variable conversion features. Management evaluates convertible debentures and associated warrants in accordance with ASC Topic 815, “Derivatives and Hedging,” and uses the Black Scholes Model to value the derivatives. This model requires management to make assumptions, use judgment, and can be complex.

 

Auditing managements assessments and valuations can be complex, involves judgment, and requires a thorough understanding of the convertible note terms.

 

How We Addressed the Matter in Our Audit:

 

We reviewed all contracts to obtain a thorough understanding of the terms. We tested the inputs and assumptions management used in the Black Scholes Model. We performed independent valuations of the derivatives to test management’s valuations. Lastly, we obtained confirmations directly from the note holders to test the note balances and note terms.

 

Haynie & Company

Salt Lake City, Utah

March 31, 2022

 

We have served as the Company’s auditor since 2016.

 

F-3
 

 

eWELLNESS HEALTHCARE CORPORATION

CONSOLIDATED BALANCE SHEETS

 

   December 31, 2021   December 31, 2020 
         
ASSETS          
           
CURRENT ASSETS          
Cash  $11,177   $1,109 
Prepaid expenses   -    3,235 
           
Total current assets   11,177    4,344 
           
Property & equipment, net   2,387    3,788 
           
TOTAL ASSETS  $13,564   $8,132 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
           
CURRENT LIABILITIES          
Accounts payable and accrued expenses  $1,223,278   $892,164 
Accrued expenses - related party   144,471    292,762 
Accrued compensation   200,000    200,000 
Loan payable   1,662    - 
Convertible debt, net of discount   1,354,882    1,354,882 
Derivative liability   1,447,008    3,925,106 
           
Total current liabilities   4,371,301    6,664,914 
           
Total Liabilities   4,371,301    6,664,914 
           
COMMITMENTS AND CONTINGENCIES   -    - 
           
STOCKHOLDERS’ DEFICIT          
Preferred stock Series A , authorized, 20,000,000 shares, $.001 par value, 696,667 and 696,667 shares issued and outstanding, respectively   697    697 
Preferred stock Series C, authorized, 1,000,000 shares, $.0001 par value, 920,000 and 0 shares issued and outstanding, respectively   92    - 
Preferred stock Series D, authorized, 200,000 shares, $.0001 par value, 200,000 and 0 shares issued and outstanding, respectively   20    - 
Preferred stock Series E Convertible , authorized, 2,500,000 shares, $.0001 par value, par value, 1,465,680 and 0 shares issued and outstanding, respectively   147    - 
Common stock, authorized 20,000,000,000 shares, $.001 par value, 18,507,683,627 and 16,862,481,961 issued and outstanding, respectively    18,507,684    16,862,482 
Shares to be issued   -    263 
Additional paid in capital   17,203,420    16,097,866 
Accumulated deficit   (40,069,797)   (39,618,090)
           
Total Stockholders’ Deficit   (4,357,737)   (6,656,782)
           
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT  $13,564   $8,132 

 

The accompanying notes are an integral part of these consolidated financial statements

 

F-4
 

 

eWELLNESS HEALTHCARE CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

 

   December 31, 2021   December 31, 2020 
   Year Ended 
   December 31, 2021   December 31, 2020 
         
REVENUE          
Revenue  $-   $266,570 
Cost of revenue   -    11,224 
           
Net Revenue   -    255,346 
           
OPERATING EXPENSES          
Executive compensation   260,000    767,639 
General and administrative   280,177    699,440 
Professional fees   2,130,850    1,180,583 
           
Total Operating Expenses   2,671,027    2,647,662 
           
Loss from Operations   (2,671,027)   (2,392,316)
           
OTHER INCOME (EXPENSE)          
Interest income   -    1 
Gain on extinguishment of debt   -    24,738 
Gain (loss) on derivative liability   2,478,098    (5,441,140)
Loss on disposal of asset   -    (8,205)
Interest expense   (258,778)   (954,605)
           
Net Income (Loss) before Income Taxes   (451,707)   (8,771,527)
           
Income tax expense   -    - 
           
Net Income (Loss)  $(451,707)  $(8,771,527)
           
Basic and diluted (loss) per common share  $(0.00)  $(0.00)
           
Weighted average basic and diluted shares outstanding   17,579,528,194    7,849,264,946 

 

The accompanying notes are an integral part of these consolidated financial statements

 

F-5
 

 

eWELLNESS HEALTHCARE CORPORATION

RECONCILIATION OF STOCKHOLDERS’ DEFICIT

 

                                                         
   Preferred Shares - Series A   Preferred Shares - Series C   Preferred Shares - Series D   Preferred Shares - Series E   Common Shares   Shares to be   Additional Paid in   Accumulated  

Total

Stockholders’

 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Issued   Capital   Deficit   Deficit 
                                                         
Balance at January 1, 2020   250,000   $250    -   $-    -   $-    -   $-    12,752,084   $12,752   $150   $23,927,374   $(30,846,563)  $      (6,906,037)
                                                                       
Contributed services   -    -    -    -    -    -    -    -    -    -    -    153,518    -    153,518 
                                                                       
Shares issued to officers, directors and consultants   446,667    447    -    -    -    -    -    -    -    -    -    1,339,553    -    1,340,000 
                                                                       
Shares issued for debt conversion   -    -    -    -    -    -    -    -    16,849,013,669    16,849,014    -    (15,000,597)   -    1,848,417 
                                                                       
Shares issued for services   -    -    -    -    -    -    -    -    668,332    668    113    956    -    1,737 
                                                                       
Shares issued for rounding - 50:1 split   -    -    -    -    -    -    -    -    47,876    48    -    (48)   -    - 
                                                                       
Discontinued operations   -    -    -    -    -    -    -    -    -    -    -    688,595    -    688,595 
                                                                       
Derivative liability   -    -    -    -    -    -    -    -    -    -    -    4,988,515    -    4,988,515 
                                                                       
Net loss   -    -    -    -    -    -    -    -    -    -    -    -    (8,771,527)   (8,771,527)
                                                                       
Balance at December 31, 2020   696,667   $697    -   $-    -   $-    -   $-    16,862,481,961   $16,862,482   $263   $16,097,866   $(39,618,090)  $(6,656,782)
                                                                       
Shares issued to officers, directors and consultants   -    -    920,000    92    200,000    20    1,280,000    128    -    -    -    2,399,760    -    2,400,000 
                                                                       
Shares issued for cash   -    -    -    -    -    -    350,000    35    -    -    -    349,965    -    350,000 
                                                                       
Shares issued for conversion   -    -    -    -    -    -    (164,320)   (16)   1,643,200,000    1,643,200    -    (1,643,183)   -    - 
                                                                       
Shares issued for services   -    -    -    -    -    -    -    -    2,001,666    2,002    (263)   (988)   -    750 
                                                                       
Net loss                                                               (451,707)   (451,707)
                                                                       
Balance at December 31, 2021   696,667   $697    920,000   $92    200,000   $20    1,465,680   $147    18,507,683,627   $18,507,684   $-  $17,203,420   $(40,069,797)  $(4,357,737)

 

The accompanying notes are an integral part of these consolidated financial statements

 

F-6
 

 

eWELLNESS HEALTHCARE CORPORATION

CONSOLIDATED STATEMENT OF CASH FLOWS

 

   December 31, 2021   December 31, 2020 
   Year Ended 
   December 31, 2021   December 31, 2020 
         
Cash flows from operating activities          
Net income (loss)  $(451,707)  $(8,771,527)
Adjustments to reconcile net income (loss) to net cash used in
operating activities:		          
Depreciation and amortization   1,402    6,869 
Contributed services   -    153,518 
Shares issued to officers, directors and consultants   1,120,000    503,588 
Shares issued for consulting services   1,280,750    1,737 
Shares issued for financing costs   -    95,933 
Gain on extinguishment of debt   -    (1,556)
Amortization of debt discount and prepaids   -    795,591 
(Gain) loss on derivative liability   (2,478,098)   5,441,140 
Loss on disposal of asset   -    8,205 
Changes in operating assets and liabilities          
Prepaid expense   3,235    (21,887)
Accounts receivable   -    (66,848)
Accounts payable and accrued expenses   331,115    919,981 
Accounts payable - related party   -    160,460 
Accrued expenses - related party   (148,291)   29,995 
Accrued compensation   -    460,188 
           
Net cash used in operating activities   (341,594)   (284,613)
           
Cash flows from financing activities          
Proceeds from issuance of convertible debt   -    52,800 
Original issue discount and debt issuance costs   -    (7,800)
Loan payable   1,662    - 
Proceeds from issuance of preferred series E   350,000    - 
           
Net cash provided by financing activities   351,662    45,000 
           
Net increase (decrease) in cash   10,068    (239,613)
           
Cash, beginning of period   1,109    240,722 
           
Cash, end of period  $11,177   $1,109 
           
Supplemental Information:          
Cash paid for:          
Taxes  $-   $- 
Interest Expense  $-   $- 
Non-cash items:          
Shares issued for debt conversion  $-   $1,848,417 

 

The accompanying notes are an integral part of these consolidated financial statements

 

F-7
 

 

eWELLNESS HEALTHCARE CORPORATION

Notes to Financial Statements

 

Note 1. The Company

 

The Company, Background and Nature of Business

 

eWellness Healthcare Corporation (the “eWellness”, “Company”, “we”, “us”, “our”) was incorporated in the State of Nevada on April 7, 2011.

 

eWellness Healthcare Corporation is the first physical therapy telehealth company to offer real-time distance monitored assessments and treatments. On September 15, 2020, the Company and Bistromatics signed an agreement that transferred all worldwide marketing and Intellectual Property Rights or claims to the Company’s Phzio, Phzio TeleRehab and MSK 360 platforms to Bistromatics in return for a 15% ownership in Bistromatics. This agreement eliminated all past due professional fees of $748,832. The transfer of rights was completed on December 31, 2020.

 

During the last quarter of 2020 and the first quarter of 2021, the Company’s Board of Directors and management determined that while it would continue its efforts and resources involving physical therapy and telemedicine, it would also pursue other health-related business opportunities. With the Company’s announced plan to diversify its health-related business beyond its telemedicine operations, which telemedicine operations will continue, the Company on May 18, 2021, entered into an Agreement and Plan of Merger by and between the Company, EWLL Acquisition (a new wholly owned subsidiary of the Company) and a recently formed private Nevada company controlled by a third party, American Health Protection, Inc.(“AMHP”). pursuant to which AMHP merged with EWLL Acquisition, with AMHP being the surviving entity and becoming a wholly owned subsidiary of the Company. On July 14, 2021, the Company filed the requisite Articles of Merger with the State of Nevada and, as a result, AMHP became a wholly owned subsidiary of the Company and EWLL Acquisition ceased to exist.

 

On April 19, 2021, the Company filed a DEF 14C to disclose to the stockholders the ratification and approval by Joint Written Consent, based upon the unanimous approval by our Board of Directors and the consent of the Majority Consenting Stockholders, of the corporate actions to file an amendment to its Amended and Restated Articles of Incorporation to: (i) change the name of the Company from eWellness Healthcare Corporation to American Health Protection Corp. (“Name Change”); (ii) change the par value of the Company’s common stock and preferred stock from $0.001 per share to $0.0001 per share (“Par Value Change”); and (iii) implement the 1:2,000 reverse split of our Common Stock and the shares underlying conversion of the Company’s securities convertible into Common Stock together with the shares reserved for such conversions, on a one for two thousand (1:2,000) basis (“Reverse Split”). The Name Change, Par Value Change and Reverse Split are sometimes referred to as the “Corporate Actions”, which Corporate Actions must be approved by FINRA. The application for approval of these actions to FINRA has not yet been filed.

 

As stated in the DEF 14C, the Name Change from eWellness Healthcare Corporation to American Health Protection Corp. was to reflect the Company’s plan to diversify its business operations from the telemedicine business and the proprietary PHZIO System to include other health related services to its primary target market focused on small and mid-sized corporate clients. The Par Value Change of the Company’s Common Stock and Preferred Stock from $0.001 per share to $0.0001 per share was the result that for more than the past six months (preceding the filing of the DEF 14C), the price of its Common Stock on the OTC Markets had been less than the $0.001 par value of its Common Stock. As a result, the Company had not been able to raise capital by the issuance of shares of Common Stock at less than the $0.001 par value and, in addition, the Company could not raise capital through the issuance of shares of convertible Preferred Stock having a conversion price of less than the $0.001 par value of the Common Stock. Lastly, the rationale for the Reverse Split of the outstanding shares of Common Stock on a one for two thousand (1:2,000) basis was needed because the outstanding shares and shares reserved for convertible debt conversion resulted in no shares being available for capital raise purposes.

 

F-8
 

 

Note 2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying financial statements have been prepared to reflect the financial position, results of operations and cash flows of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.

 

Going Concern

 

For the year ended December 31, 2021, the Company had no revenues. The Company has an accumulated deficit of $40,069,797 and a working capital deficit of $4,360,124. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Fair Value of Financial Instruments

 

The Company complies with the accounting guidance under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820-10, Fair Value Measurements, as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance.

 

The guidance also establishes a fair value hierarchy for measurements of fair value as follows:

 

Level 1 – quoted market prices in active markets for identical assets or liabilities.

 

Level 2 – inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

F-9
 

 

As of December 31, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

   Total   Level 1   Level 2   Level 3 
Derivative Liability  $1,447,008   $-   $-   $1,447,008 
Total Liabilities measured at fair value  $1,447,008   $-   $-   $1,447,008 

 

As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

   Total   Level 1   Level 2   Level 3 
Derivative Liability  $3,925,106   $-   $-   $3,925,106 
Total Liabilities measured at fair value  $3,925,106   $-   $-   $3,925,106 

 

Revenue Recognition

 

The Company recognizes revenue per ASC 606. Revenue is recognized when services have been completed.

 

Property and Equipment

 

Property and equipment are recorded at historical cost. Minor additions and renewals are expensed in the year incurred. Major additions and renewals are capitalized and depreciated over their estimated useful lives. Depreciation is recorded over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The estimated useful lives for significant property and equipment categories are as follows:

 

Furniture and Fixtures   5-7 Years
Computer Equipment   5-7 Years
Software   3 Years

 

The Company regularly evaluates whether events or circumstances have occurred that indicate the carrying value of long-lived assets may not be recoverable. If factors indicate the asset may not be recoverable, we compare the related undiscounted future net cash flows to the carrying value of the asset to determine if impairment exists. If the expected future net cash flows are less than the carrying value, an impairment charge is recognized based on the fair value of the asset. For the years ended December 31, 2021 and 2020, there was no impairment recognized.

 

Intangible Assets

 

The Company accounts for assets that are not physical in nature as intangible assets. Intangible assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are amortized on a straight-line basis over their economic or legal life, whichever is shorter. Intangible assets with indefinite useful lives are reassessed each year for impairment. If an impairment has occurred, then a loss is recognized. An impairment loss is determined by subtracting the asset’s fair value from the asset’s book/carrying value. For the years ended December 31, 2021 and 2020, there were no intangible assets.

 

Income Taxes

 

The Company accounts for income taxes under FASB ASC 740-10-30. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component or all the benefits of deferred tax assets will not be realized.

 

F-10
 

 

Debt Issuance Costs

 

The Company accounts for debt issuance costs in accordance with ASU 2015-03. This guidance requires direct and incremental costs associated with the issuance of debt instruments such as legal fees, printing costs and underwriters’ fees, among others, paid to parties other than creditors, are reported and presented as a reduction of debt on the consolidated balance sheets.

 

Debt issuance costs and premiums or discounts are amortized over the term of the respective financing arrangement using the effective interest method. Amortization of these amounts is included as a component of interest expense net, in the consolidated statements of operations.

 

Derivative Financial Instruments

 

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and then is revalued at each reporting date, with changes in fair value reported in the statement of operations. For stock based derivative financial instruments, Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.

 

Once determined, derivative liabilities are adjusted to reflect fair value at the end of each reporting period. Any increase or decrease in the fair value from inception is made quarterly and appears in results of operations as a change in fair market value of derivative liabilities.”

 

Cash and Cash Equivalents

 

Cash and cash equivalents include all cash deposits and highly liquid financial instruments with an original maturity to the Company of three months or less. The Company maintains cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents.

 

Loss per Common Share

 

The Company follows ASC Topic 260 to account for the loss per share. Basic loss per common share calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share calculations are determined by dividing net loss by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. As the Company has incurred losses for the periods ended December 31, 2021 and 2020, no dilutive shares are added into the loss per share calculations. While currently antidilutive, the following instruments could potentially dilute EPS in the future resulting in the following common stock equivalents:

   2021   2020 
         
Options   -    27,000 
Warrants   -    26,015 
Convertible Notes   12,357,170,485    24,728,206,940 
 Total   12,357,170,485    27,728,259,955 

 

Recent Accounting Pronouncements

 

The Company has reviewed all other recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.

 

Reclassifications

 

Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.

 

Note 3. Property and Equipment

 

Property and equipment consist of computer equipment that is stated at cost $6,976 and $6,976 less accumulated depreciation of $4,589 and $3,188 for the years ended December 31, 2021 and 2020, respectively. During the year ended December 31, 2020, the Company disposed of computers with a cost value of $11,498 and transferred computers and equipment valued at $9,208 per the Bistromatics agreement dated September 15, 2020. (Footnote 1). Depreciation expense was $1,402 and $4,869 for the years ended December 31, 2021 and 2020, respectively.

 

Note 4. Intangible Assets

 

The Company recognizes the cost of a software license and a license for use of a programming code as intangible assets. The stated cost of these assets and accumulated amortization were transferred per the Bistromatics agreement dated September 15, 2020 (Footnote 1). For the years ended December 31, 2021 and 2020, the amortization expense recorded was $0 and $2,000, respectively.

 

F-11
 

 

Note 5. Income Taxes

 

Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

 

Net deferred tax liabilities consist of the following components as of December 31, 2021 and 2020:

   2021   2020 
         
Deferred tax assets:          
NOL carryover  $4,027,300   $4,133,200 
Accrued payroll   42,000    42,000 
Deferred tax liabilities          
Depreciation   400    300 
Valuation allowance   (4,069,700)   (4,175,500)
Net deferred tax asset  $-   $- 

 

The income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate to pre-tax income from continuing operations for the years ended December 31, 2021 and 2020 due to the following:

 

   2020   2019 
         
Book loss  $(94,900)  $(1,842,000)
Depreciation   -    700 
Contributed services   504,000    32,200 
Meals & entertainment   2,600    2,400 
Stock for prepaids   700    36,900 
Stock for consulting   200    400 
Amortization of debt discount   -    130,200 
Accrued payroll   -    (69,900)
Gain on debt extinguishment   -    (5,200)
Related party accruals   -    (123,100)
Loss on disposal   -    1,700 
Derivative (Gain)/Loss   (520,400)   114,260 
Valuation allowance   107,800    693,100 
Income tax expense benefit  $-   $- 

 

As of December 31, 2021, the Company had net operating loss carry forwards of approximately $19,177,000 that may be offset against future taxable income from the year 2022 through 2041. No tax benefit has been reported in the December 31, 2020 financial statements since the potential tax benefit is offset by a valuation allowance of the same amount.

 

Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards for federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years.

 

The Company’s policy is to recognize potential interest and penalties accrued related to unrecognized tax benefits within income tax expense. For the years ended December 31, 2021 and 2020, the Company did not recognize any interest or penalties, nor did we have any interest or penalties accrued related to unrecognized benefits.

 

The tax years ended December 31, 2021, 2020 and 2019 are open for examination for federal income tax purposes and by other major taxing jurisdictions to which we are subject.

 

F-12
 

 

Note 6. Related Party Transactions

 

Throughout the year ended December 31, 2021, the officers and directors of the Company incurred business expenses on behalf of the Company. The amounts payable to the officers as of the years ended December 31, 2021 and 2020 were $33,701 and $11,655, respectively. There were no expenses due to the board members, but the Company has accrued directors’ fees of $221,107 and $221,107 as of the years ended December 31, 2021 and 2020, respectively. Two of the independent directors resigned on May 22, 2020 so no further directors’ fees were accrued for them. On February 26, 2021, the remaining independent director signed a Settlement and Compromise Agreement which eliminated all previously accrued directors’ fees as of September 30, 2020 for a flat fee of $100,000. Since the effective date of the agreement was October 1, 2020, the adjustment was recorded as of December 31, 2020. Because the Company is not yet profitable the officers had agreed to defer compensation. On February 26, 2021, the officers signed Settlement and Compromise Agreements which eliminated all previously accrued compensation accrued as of September 30, 2020 for $100,000 each. Since the effective date of these agreements is October 1, 2020, the adjustment was recorded as of December 31, 2020. The Company had accrued executive compensation of $200,000 and $200,000 as of December 31, 2021 and 2020, respectively.

 

Note 7. Convertible Notes Payable

 

Year Ended December 31, 2021

 

During the year ended December 31, 2021, there were no new convertible notes executed. During the year ended December 31, 2021, the Company accrued interest payable of $258,778 on previously executed convertible notes payable.

 

Year Ended December 31, 2020

 

In March 2020, the Company executed a 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $52,800. The note, which is due on January 15, 2021, has an original issue discount of $4,800 and transaction costs of $3,000. After 180 days, the convertible note converts into common stock of the Company at a conversion price that shall be equal to 70% of the average of the two lowest per share trading prices for the ten (10) trading days prior to the conversion date. As of December 31, 2020, this note was fully converted and during the year ended December 31, 2020 the Company accrued interest of $2,880.

 

During the year ended December 31, 2020, the Company accrued interest of $330,871 for the 2019 convertible notes that were still outstanding throughout the year.

 

Note 8. Equity Transactions

 

Preferred Stock

 

The total number of shares of Series A Preferred Stock which the Company shall have authority to issue is 20,000,000 shares with a par value of $0.001 per share. During the year ended December 31, 2019, the Company authorized the issuance of 1,000,000 shares of preferred stock to officers, directors and consultants as deferred compensation and/or expense. The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of 40 shares per preferred share at the common share value on the date of issuance. The deferred compensation value of the shares will vest monthly at 1/24th of the calculated value of $3,000,000 and requisite expense or reduction of accrued compensation and/or accrued directors fees will be recorded. At the recording of the requisite vested share value, the corresponding number of preferred shares will be recorded as being issued. On May 22, 2020, two independent directors resigned and three officers/directors/consultant resigned. Therefore, the vesting of their preferred shares ceased on those dates per the authorization documents. As part of the Settlement and Compromise agreements signed by current officers, director and consultant on February 26, 2021, with effective date October 1, 2020, the shares issued became fully vested at the year ended December 31, 2020.

 

In April 2021, the Board of Directors issued a Certificate of Designations, Preferences, Rights and Limitations of Series C Convertible Preferred Stock. The Board authorized that the Company shall have the authority to issue 1,000,000 shares with a par value of $.0001 per share to be issued to persons designated by the Board. The Series C Preferred Stock has no stated maturity and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Holder decides to convert the shares of Series C Preferred Stock.

 

F-13
 

 

In April 2021, the Board of Directors issued a Certificate of Designations, Preferences and Rights Limitations of Series D Preferred Stock. The Board authorized that the Company shall have the authority to issue 200,000 shares with a par value of $.0001 per share to be issued to persons designated by the Board. The Series D Preferred Stock has no stated maturity and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Holder decides to convert the shares of Series D Preferred Stock.

 

In April 2021, the Board of Directors issued a Certificate of Designations, Preferences and Rights of Series E Convertible Preferred Stock. The Board authorized that the Company shall have authority to issue 2,500,000 shares with a par value of $.0001 per share. The Board of Directors may determine to : (i) issue a number of Series Preferred in a private placement at an offering price of $1.00 per share; (ii) issue the Series E Preferred in consideration for the cancellation of shares of the Company’s Series A Preferred held by the Corporation’s officers, directors and key personnel based on terms and conditions that the Board of Directors may determine; and (iii) issue the shares of Series E Preferred for such other purposes as the Board of Directors may determine.

 

The Series C, Series D and Series E Preferred Stock will rank, with respect to rights to the payment of dividends and the distribution of assets in the event of any liquidation, dissolution or winding up of the Corporation, (i) senior to all classes or series of the Corporation’s Common Stock, par value $0.001 per share (“Common Stock”), and to all other equity securities issued by the Corporation ; and (ii) effectively junior to all existing and future indebtedness (including indebtedness convertible into our Common Stock or Preferred Stock) of the Corporation and to any indebtedness and other liabilities of (as well as any preferred equity interest held by others) existing subsidiaries of the Corporation. The term “equity securities” shall not include convertible debt securities. The Holders of the Series D Preferred Stock have the right, on all matters subject to the vote of the capital stock of the Corporation, to have the collective vote equal to 70% of the total of all voting capital stock of the Corporation, notwithstanding the number of shares of voting capital stock, including shares of common stock, that may be outstanding from time to time. Upon liquidation, Preferred Stockholders will receive the liquidation preference plus an amount equal to any accumulated and unpaid dividends up to the date of payment before any distribution of assets is made.

 

On May 4, 2021, the Board of Directors issued 350,000 shares of Series E Convertible Preferred Stock for the subscription agreements dated March 1, 2021 at the value of $1.00 per share.

 

On May 12, 2021, the Board of Directors authorized the issuance of 200,000 shares of Series D Voting Preferred Stock with a value of $200,000.

 

On May 20, 2021, the Board of Directors authorized the issuance of 920,000 shares of Series C Convertible Preferred Stock with a value of $920,000.

 

On July 1, 2021, the Board of Directors authorized the issuance of 1,280,000 shares of Series E Convertible Preferred Stock with a value of $1,280,000. These shares were issued on July 14, 2021.

 

Common Stock

 

On February 12, 2020, FINRA approved a 1:50 reverse split of the Company’s common stock. As noted throughout this document, all common shares are stated as if the 1:50 reverse split had been completed as of the beginning of the year ended December 31, 2019. Following the approval, the Company’s stock began trading under the symbol “EWLLD”. Due to rounding issues for the reverse split, the Company issued 47,876 additional shares of common stock.

 

On February 14, 2020, the Company filed a Definitive Information Statement on Schedule 14C for the purpose of authorizing the increase in the number of authorized shares of Common Stock from one billion nine hundred million (1,900,000,000) shares of Common Stock to twenty billion (20,000,000,000) shares of Common Stock.

 

Debt Conversion Shares

 

2021

 

During the year ended December 31, 2021, there were no shares of common stock issued for debt conversion.

 

F-14
 

 

2020

 

During the year ended December 31, 2020, the Company issued a total of 16,849,013,669 shares of common stock per debt conversion of various convertible notes. The total of the debt conversion was for $1,607,317 of principal, $145,167 of accrued interest and $95,933 financing costs.

 

Consultant Issued Shares

 

2021

 

During the year ended December 31, 2021, the Company issued 2,001,666 shares of common stock for marketing and consulting services valued at $750.

 

2020

 

On January 30, 2020, the Company executed a 12-month advisory services agreement. The Company is to issue 20,000 shares of common stock monthly. The Company issued 80,000 shares of common stock with a value of $103. The remaining 160,000 shares of common stock with a value of $30 has been recorded in Shares to be Issued. In addition, the Company is to also pay the advisor a monthly fee of $2,500.

 

During the year ended December 31, 2020, the Company issued 588,332 shares of common stock for marketing and consulting services valued at $1,604.

 

Preferred Series E Conversion

 

2021

 

During the year ended December 31, 2021, the Company issued 1,643,200,000 shares of common stock for conversion of 164,320 shares of Preferred Series E for a value of $164,320.

 

2020

 

None

 

Stock Options

 

The following is a summary of the status of all Company’s stock options as of December 31, 2021 and changes during the periods ended on December 31, 2021 and 2020, respectively:

Summary of Stock Options Activity 

   Number   Weighted         
   of Stock   Average   Remaining   Intrinsic 
   Options   Exercise Price   Life (yrs.)   Value 
Outstanding on January 1, 2020   57,000   $40.00    1.1   $- 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Expired/cancelled   (30,000)   40.00    .14    - 
Outstanding on December 31, 2020   27,000   $40.00    .14   $- 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Expired/cancelled   (27,000)   -    -    - 
Outstanding on December 31, 2021   -    -    -   $- 
Options exercisable on December 31, 2021   -   $-    -   $- 

 

F-15
 

 

Warrants

 

The following is a summary of the status of the Company’s warrants as of December 31, 2021 and changes during the periods ended on December 31, 2021 and 2020, respectively:

Summary of Warrants Activity 

       Weighted         
   Number of   Average
Exercise		   Remaining   Intrinsic 
   Warrants   Price   Life (yrs.)   Value 
Outstanding on January 1, 2020   42,015   $12.00    1.9   $0.037 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Cancelled   (16,000)   11.04    -    - 
Outstanding on December 31, 2020   26,015   $12.50    1.2   $- 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Cancelled   (26,015)   -    -    - 
Outstanding on December 31, 2021   -   $-    -   $- 
Warrants exercisable on December 31, 2021   -   $-    -   $- 

 

Note 9. Commitments, Contingencies

 

The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business. On August 12, 2020, a former consultant filed suit in the Superior Court of the State of California for Breach of Contract and non-payment of fees per said contract. At the time of the suit, the Company owed to the vendor for contractual fees the total of $24,339. On March 14, 2022, the Company accepted a Stipulation and Proposed Order for the payment of $38,000 to the former consultant with the first payment of $5,000 being due immediately and additional $5,000 payments to be paid every 60 days thereafter until the total of $38,000 is paid

 

Note 10. Revenue Recognition

 

Under ASC Topic 606, the Company recognizes revenue when the services have been completed. During the years ended December 31, 2021 and 2020, the Company recognized net revenue of $0 and $255,346, respectively.

 

Note 11. Derivative Valuation

 

The Company evaluated the convertible debentures and associated warrants in accordance with ASC Topic 815, “Derivatives and Hedging,” and determined that the conversion feature of the convertible promissory notes was not afforded the exemption for conventional convertible instruments due to their variable conversion rates. The notes have no explicit limit on the number of shares issuable, so they did not meet the conditions set forth in current accounting standards for equity classification. In addition, the warrants have a Most Favoured Nations clause resulting in the exercise price of the warrants also not being fixed. Therefore, these have been characterized as derivative instruments. We elected to recognize the notes under ASU paragraph 815-15-25-4, whereby there would be a separation into a host contract and derivative instrument. We elected to initially and subsequently measure the notes and warrants in their entirety at fair value, with changes in fair value recognized in earnings.

 

The debt discount is amortized over the life of the note and recognized as interest expense. For the years ended December 31, 2021 and 2020, the Company amortized the debt discount of $0 and $619,799, respectively, to interest expense.

 

F-16
 

 

During the years ended December 31, 2021 and 2020, the Company had the following activity in the derivative liability account:

Schedule of Derivative Liability 

   Notes   Warrants   Total 
Derivative liability at January 1, 2020  $3,529,967   $7   $3,529,974 
Addition of new conversion   47,620    -    47,620 
Conversion of note derivatives   (5,094,792)   -    (5,094,792)
Change in fair value   5,442,306    (2)   5,442,304 
Derivative liability at December 31, 2020  $3,925,101   $5   $3,925,106 
Change in fair value   (2,478,093)   (5)   (2,478,098)
Derivative liability at December 31, 2020  $1,447,008   $-   $1,447,008 

 

For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follow:

Schedule of Assumptions Used Black Scholes Valuation of Derivative 

Stock price at valuation date  $.0002 
Risk free interest rate   .06%
Stock volatility factor   350.10%
Years to Maturity   .08 
Expected dividend yield   None 

 

Note 12. Supplemental Cash Flow Information

 

During the year ended December 31, 2021, the Company had the following cash and non-cash investing and financing activities:

 

  ●

Issued 350,000 shares of preferred series E convertible stock for $350,000 cash received.

 

  ● Issued 1,643,200,000 shares of common stock for conversion of 163,400 shares preferred series E convertible stock valued at $163,400
     
  ● Issued 2,001,666 shares of common stock valued at $750 for services

 

During the year ended December 31, 2020, the Company had the following non-cash investing and financing activities:

 

  ● Issued 16,849,013,669 shares of common stock for settlement of debt of $1,607,317, accrued interest of $145,167 and $95,933 of financing costs
     
  ● Issued 668,332 shares of common stock valued at $1,737 for services

 

Note 13. Subsequent Events

 

On March 14, 2022, the Company accepted a Stipulation and Proposed Order for the payment of $38,000 to the former consultant who had filed a lawsuit on August 12, 2020 in the Superior Court of the State of California for Breach of Contract and non-payment of fees per said contract. See Footnote 9

 

F-17
 

 

ITEM 9: CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

During the past two years, there was no disagreement of the type described in paragraph (a)(1)(iv) or any reportable event as described in paragraph (a)(1)(v) of Item 304 of Regulation S-K that is required to be disclosed under this Item 9.

 

ITEM 9A: CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures designed to provide reasonable assurance that material information required to be disclosed by us in the reports we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that the information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

 

We performed an evaluation (“Evaluation”), under the supervision and with the participation of our management including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operation of our disclosure controls and procedures (“Disclosure Controls”) as of the end of the period covered by this Report pursuant to Rule 13a-15 of the Exchange Act. Based on this evaluation and the existence of the material weaknesses discussed below in “Management’s Report on Internal Control Over Financial Reporting,” our management, including our CEO and CFO, concluded that our disclosure controls and procedures were not effective at the reasonable assurance level as of the end of the period covered by this report.

 

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

Management’s Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our Board, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

 

● pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;
   
● provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of our management and directors; and
   
● provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements.

 

 16 

 

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Additionally, projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2021. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013). Based on this assessment, management concluded that our internal control over financial reporting was not effective as of December 31, 2021, due to the existence of the material weaknesses discussed below. A material weakness is a control deficiency (within the meaning of the Public Company Accounting Oversight Board (“PCAOB”) Auditing Standard No. 5), or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected.

 

Management identified the following material weaknesses that have caused management to conclude that as of December 31, 2021, our internal control over financial reporting was not effective:

 

  ● Our size has prevented us from being able to employ sufficient resources to enable us to have an adequate level of supervision and segregation of duties within our internal control system. Specifically, there is limited review of financial reporting and policies and procedures have not yet been implemented to analyze, document, monitor and report on non-routine and complex transactions that require management estimation or judgment.
     
  ● The Company does not have adequate controls and procedures or an internal audit function to detect errors in accounting for certain of its financing transactions.
     
  ● The lack of sufficient controls in place to ensure that all disclosures required were addressed in our financial statements, which may result in ineffective oversight in the establishment and monitoring of required internal controls and procedures.
     
  ● Management determined that the Company does not have a sufficient complement of personnel with appropriate training and experience in U.S. generally accepted accounting principles (“GAAP”) and lacks certain subject matter expertise related to accounting for income taxes, complex debt and equity transactions, and disclosures.

 

This Annual Report on Form 10-K does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting due to permanent exemptions for smaller reporting companies. Management’s report was not subject to such attestation pursuant to rules of the Securities and Exchange Commission that permits us to provide only management’s report in this Annual Report.

 

Remediation Plan for Material Weaknesses

 

While management believes that the Company’s financial statements previously filed in the Company’s SEC reports have been properly recorded and disclosed in accordance with GAAP, based on the control deficiencies identified above, we have begun taking steps and plan to take additional measures to remediate the underlying causes of the material weakness, primarily through the development and implementation of formal policies, improved processes and documented procedures, as well as the hiring of additional finance personnel. Management believes that the appointment of additional management personnel will lead to increased oversight over the accounting and reporting function. As soon as we can raise sufficient capital or our operations generate sufficient cash flow, we will hire additional personnel to handle our accounting and reporting functions. We also plan to supply enhanced training and education on principles related to accounting for financing transactions, when funds allow.

 

Management has reviewed the financial statements and underlying information included herein in detail and believes the procedures performed are adequate to fairly present our financial position, results of operations and cash flows for the periods presented in all material respects.

 

 17 

 

 

Changes in Internal Control Over Financial Reporting

 

Other than as described above, there have been no changes in our internal control over financial reporting during the year ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting

 

ITEM 9B: OTHER INFORMATION

 

None.

 

Part III

 

ITEM 10: DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE

 

Our directors were elected to serve until the next annual meeting of shareholders and until his respective successors will have been elected and will have qualified. The following table sets forth the name, age and position held with respect to our present executive officers and directors:

 

Name   Age   Position(s)
David Markowski   61   Chief Financial Officer and Member of the Board of Directors
Douglas MacLellan   66   Chief Executive Officer, Chairman and Secretary
Douglas Cole   66   Member of the Board of Directors

 

David Markowski, Chief Financial Officer & Director. Mr. Markowski has been CFO and a Director of eWellness Healthcare Corporation since May 2013. From October 1997 to October 2002, he was CEO and Co-Founder of GFNN, Inc. From 2002 to 2013 Mr. Markowski has maintained various active roles within GFNN’s subsidiaries including Founder, Director and CEO positions. From October 2009 to December 2011, he was the Director of Corporate Development for Visualant, Inc. From June 2003 to 2010 he was President of Angel Systems, Inc. an independent consulting firm with competencies in strategic marketing and business development. From January 1998 to October 1998, Mr. Markowski served as the Vice President of Finance for Medcom USA, a NASDAQ listed company. Prior to that, he had a decade of investment banking experience on Wall Street involved in financing start-ups and public offerings. He is a business development specialist with accolades in INC Magazine and others. Mr. Markowski obtained a BA degree in Marketing from Florida State University in 1982.

 

Douglas MacLellan, Chief Executive Officer and Chairman of the Board. Mr. MacLellan currently serves as Chief Executive Officer and Chairman of the Board of eWellness Healthcare Corporation. Mr. MacLellan has served as Chairman since May 2013 and was appointed by the Board to serve as Chief Executive Officer upon the resignation of Darwin Fogt, former CEO and Director effective on May 22, 2020. Mr. MacLellan is also an independent member of the board of directors of American Battery Metals Corporation (OTCQB: ABML), an early-stage battery metals recycling, extraction and resource production company, since October 2017 to the present. From November 2009 to December 2017, Mr. MacLellan was an independent director of ChinaNet Online Holdings, Inc. (NASDAQ: CNET) a media development, advertising and communications company. From June 2011 to the present, Mr. MacLellan has been Chairman of Innovare Products, Inc., a privately held company that develops innovative consumer products. From September 1992 through April 2014, Mr. MacLellan was Chairman and chief executive officer at Radient Pharmaceuticals Corporation. (OTCQB: RXPC.PK), a vertically integrated specialty pharmaceutical company. He formally served as president and chief executive officer for the MacLellan Group, an international financial advisory firm from 1992 to 2017. From August 2005 to May 2009, Mr. MacLellan was co-founder and vice chairman at Ocean Smart, Inc., a Canadian based aquaculture company. Mr. MacLellan was educated at the University of Southern California in economics and international relations.

 

Douglas Cole, Director. Mr. Cole has been a Director of the Company since May 2014. Mr. Cole is currently the Chairman and CEO of American Battery Metals Corporation (OTCQB: ABML), an early-stage battery metals recycling, extraction and resource production company headquartered in Nevada. Mr. Cole has also been a Partner with Objective Equity LLC since 2005, a boutique investment bank focused on the high technology, data analytics and the mining sector. Since 1977, Mr. Cole has held various executive roles, including Chairman, Executive Vice Chairman, Chief Executive Officer and President of multiple public corporations. From May 2000 to September 2005, he was also the Director of Lair of the Bear, The University of California Family Camp located in Pinecrest, California. During the period between 1991 and 1996 he was the CEO of HealthSoft, and he also founded and operated Great Bear Technology, which acquired Sony Image Soft and Starpress, then went public and eventually sold to Graphix Zone. In 1995 Mr. Cole was honored by NEA, a leading venture capital firm, as CEO of the year. In 1997, Mr. Cole became CEO of NetAmerica until merging in 1999. Since 1982 he has been very active with the University of California, Berkeley mentoring early-stage technology companies. Mr. Cole has extensive experience in global M&A and global distributions. He obtained his BA in Social Sciences from UC Berkeley in 1978.

 

 18 

 

 

Director Qualifications

 

We seek directors with established strong professional reputations and experience in areas relevant to the strategy and operations of our businesses. We also seek directors who possess the qualities of integrity and candour, who have strong analytical skills and who are willing to engage management and each other in a constructive and collaborative fashion, in addition to the ability and commitment to devote time and energy to service on the Board and its committees, as necessary. We believe that all our directors meet the foregoing qualifications.

 

The Board believes that the leadership skills and other experience of the Board members described below, in addition to each person’s experience set forth above in their respective biographies, provide the Company with a range of perspectives and judgment necessary to guide our strategies and monitor our executives’ business execution.

 

Douglas MacLellan. Mr. MacLellan is a co-founder of the Company and has been serving as an officer and/or director of various advance technology and high growth companies over the past 20 years. Mr. MacLellan has contributed to the Board’s strong leadership and vision for the development of the Company’s innovative business model.

 

David Markowski. Mr. Markowski is a co-founder of the Company and has been serving in senior management positions in various companies over the past 20 years, with an emphasis on corporate finance, accounting, audit, financial modelling and marketing. He holds a wealth of experience in company management skills.

 

Doug Cole. Mr. Cole is an international business executive with over 20 years of active management and board roles in various software, educational and technology public and private companies.

 

Involvement in Certain Legal Proceedings

 

To the best of the Company’s knowledge, none of the following events occurred during the past ten years that are material to an evaluation of the ability or integrity of any of our executive officers, directors or promoters:

 

(1) A petition under the Federal bankruptcy laws or any state insolvency law was filed by or against, or a receiver, fiscal agent or similar officer was appointed by a court for the business or property of such person, or any partnership in which he was a general partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive officer at or within two years before the time of such filing;

 

(2) Convicted in a criminal proceeding or is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses);

 

 

(3) Subject of any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from, or otherwise limiting, the following activities:

 

(i) Acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, any other person regulated by the Commodity Futures Trading Commission, or an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice in connection with such activity;

 

(ii) Engaging in any type of business practice; or

 

(iii) Engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of Federal or State securities laws or Federal commodities laws;

 

 19 

 

 

(4) Subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any Federal or State authority barring, suspending or otherwise limiting for more than 60 days the right of such person to engage in any activity described in paragraph (3)(i) above, or to be associated with persons engaged in any such activity;

 

(5) Found by a court of competent jurisdiction in a civil action or by the Commission to have violated any Federal or State securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended, or vacated;

 

(6) Found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any Federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated;

 

(7) Subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of:

 

(i) Any Federal or State securities or commodities law or regulation; or

 

(ii) Any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or

 

(iii) Any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or

 

(8) Subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization, any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

 

Corporate Governance and Director Independence

 

Presently, we are not currently listed on a national securities exchange or in an inter-dealer quotation system and therefore are not required to comply with the director independence requirements of any securities exchange. In determining whether our directors are independent, however, we intend to comply with the rules of NASDAQ. The board of directors will also consult with counsel to ensure that the boards of director’s determinations are consistent with those rules and all relevant securities and other laws and regulations regarding the independence of directors, including those adopted under the Sarbanes-Oxley Act of 2002 with respect to the independence of audit committee members. Nasdaq Listing Rule 5605(a)(2) defines an “independent director” generally as a person other than an Executive Officer or employee of the Company or any other individual having a relationship which, in the opinion of the Company’s board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Our Board of Directors has determined that Douglas Cole, Mr. Rowberry and Ms. Pleskow would qualify as “independent” as that term is defined by Nasdaq Listing Rule 5605(a)(2). Further, Mr. Cole qualifies as “independent” under Nasdaq Listing Rules applicable to board committees.

 

Due to our lack of operations and size prior to the Share Exchange, we did not have an Audit Committee. For these same reasons, we did not have any other separate committees prior to the Share Exchange; all functions of a nominating committee, audit committee and compensation committee were performed by our sole director. Although, as stated above, we are not the subject of any listing requirements, in connection with the Share Exchange, our Board of Directors established several committees to assist it in carrying out its duties. In particular, committees shall work on key issues in greater detail than would be practical at a meeting of all the members of the Board of Directors; each committee reviews the results of its deliberations with the full Board of Directors.

 

The standing committees of the Board of Directors currently consist of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee. Current copies of the charters for the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee, as well as our Corporate Governance Guidelines, Code of Ethics and Business Conduct, may be found on our website at www.ewellnesshealth.com, under the heading “Corporate Information—Governance Documents.” Printed versions also are available to any stockholder who requests them by writing to our corporate Secretary at our corporate address. Our Board of Directors may, from time to time, establish certain other committees to facilitate our management.

 

 20 

 

 

The Board will consider appointing members to each of the Committees when enough independent directors are appointed to the Board or as otherwise determined by the Board. Until such time, the full board of directors will undertake the duties of the audit committee, compensation committee and nominating committee.

 

Compliance with Section 16(a) of the Securities Exchange Act of 1934

 

Section 16(a) of the Exchange Act, as amended, requires that our directors, executive officers and persons who own more than 10% of a class of our equity securities that are registered under the Exchange Act to file with the SEC initial reports of ownership and reports of changes of ownership of such registered securities.

 

Based solely upon a review of information furnished to the Company, to the Company’s knowledge, during the fiscal year ended December 31, 2020, all such forms were filed.

 

ITEM 11: EXECUTIVE COMPENSATION

 

For the fiscal years ended December 31, 2021 and 2020, we did not pay any compensation to our executive officers, nor did any other person receive a total annual salary and bonus exceeding $150,000.

 

On February 12, 2021, each of the two officers signed a Settlement and Compromise Agreement within which they agreed to eliminate any previously accrued compensation as of September 30, 2020 for $100,000 each. Since the effective date of this agreement was October 1, 2020, this transaction was recorded at the year ended December 31, 2020. This Settlement and Compromise Agreement eliminated any previous compensation agreements established with the Share Purchase Agreement in 2014.

 

Director’s Compensation

 

There is no formal or informal arrangements or agreements to compensate employee directors for service provided as a director; however, compensation for new non-employee directors is determined on an ad hoc basis by the existing members of the board of directors at the time a director is elected. They are entitled to receive reimbursement of out-of-pocket expenses.

 

On February 12, 2021, the independent director signed a Settlement and Compromise Agreement within which they agreed to eliminate any previously accrued directors’ fees for this director as of September 30, 2020 for $100,000. Since the effective date of this agreement was October 1, 2020, this transaction was recorded at the year ended December 31, 2020. This Settlement and Compromise Agreement eliminates the future need to accrue monthly directors’ fees.

 

Compensation Policies and Practices as They Relate to the Company’s Risk Management

 

We believe that our compensation policies and practices for all employees, including executive officers, do not create risks that are reasonably likely to have a material adverse effect on us.

 

Employment Contracts

 

We do not have any formal employment agreement with any of the officers. Any future compensation will be determined by the Board of Directors, and, as appropriate, an employment agreement will be executed.

 

Outstanding Equity Awards

 

There were no equity awards outstanding as of the end the year ended December 31, 2021.

 

Option Grants

 

During the year ended December 31, 2021, there were no options granted.

 

 21 

 

 

Aggregated Option Exercises and Fiscal Year-End Option Value

 

There were no stock options exercised during the year ending December 31, 2021 and 2020 by our executive officers.

 

Long-Term Incentive Plan (“LTIP”) Awards

 

There were no awards made to any named executive officers in the last completed fiscal year under any LTIP.

 

ITEM 12: SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

The following table sets forth certain information regarding beneficial ownership of our common stock as of March 31, 2022 by (i) each person (or group of affiliated persons) who is known by us to own more than five percent (5%) of the outstanding shares of our common stock, (ii) each director, executive officer and director nominee, and (iii) all of our directors, executive officers and director nominees as a group.

 

Beneficial ownership is determined in accordance with SEC rules and generally includes voting or investment power with respect to securities. For purposes of this table, a person or group of persons is deemed to have “beneficial ownership” of any shares of common stock that such person has the right to acquire within 60 days of the date of the respective table. For purposes of computing the percentage of outstanding shares of our common stock held by each person or group of persons named above, any shares that such person or persons has the right to acquire within 60 days of the date of the respective table is deemed to be outstanding for such person but is not deemed to be outstanding for the purpose of computing the percentage ownership of any other person. The inclusion herein of any shares listed as beneficially owned does not constitute an admission of beneficial ownership.

 

Except as otherwise indicated, the persons listed below have sole voting and investment power with respect to all shares of our common stock owned by them, except to the extent that power may be shared with a spouse.

 

As of March 31, 2022, we had 18,507,683,627 shares of common stock issued and outstanding.

 

   Amount and     
   Nature of     
   Beneficial   Percent of 
Name of Beneficial Owner  Ownership   Class 
         
Douglas MacLellan   155,000    .00%
David Markowski   62,000    .00%
Doug Cole   16,000    .00%

 

ITEM 13: CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

 

Certain Related Party Transactions

 

Other than the relationships and transactions discussed below, we are not a party to, nor are we proposed to be a party, to any transaction during the last fiscal year involving an amount exceeding $120,000 and in which a related person, as such term is defined by Item 404 of Regulation S-K, had or will have a direct or indirect material interest.

 

 22 

 

 

Indebtedness of Management

 

No officer, director or security holder known to us beneficially owns more than 5% of our Common stock or any member of the immediate family or sharing the household (other than a tenant or employee) of any of the foregoing persons is indebted to us in the years 2021 and 2020.

 

 

Review, Approval and Ratification of Related Party Transactions

 

Our Board of Directors conducts an appropriate review of and oversees all related-party transactions. We have not yet adopted formal standards in respect of the review and approval or ratification of related-party transactions; however, our board has conformed to the following standards: (i) all related-party transactions must be fair and reasonable to us and on terms comparable to those reasonably expected to be agreed to with independent third parties for the same goods and/or services at the time authorized by the board; and (ii) all related-party transactions must be authorized, approved or ratified by the affirmative vote of a majority of the directors who have no interest, either directly or indirectly, in any such related party transaction.

 

ITEM 14: PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

The following table shows the fees that were billed for the audit and other services provided by Haynie & Company, our independent registered public accounting firm, for the fiscal years ended December 31, 2021 and 2020.

 

   2021   2020 
Audit Fees  $71,500   $79,500 
Audit-Related Fees   -    9,100 
Tax Fees   -    - 
All Other Fees   -    - 
Total  $71,500   $88,600 

 

Audit Fees — This category includes the audit of our annual financial statements, review of financial statements included in our Annual Reports on Form 10-K and services that are normally provided by the independent registered public accounting firm in connection with engagements for those fiscal years. This category also includes advice on audit and accounting matters that arose during, or because of, the audit or the review of interim financial statements.

 

Audit-Related Fees — This category consists of assurance and related services by the independent registered public accounting firm that are reasonably related to the performance of the audit or review of our financial statements and are not reported above under “Audit Fees.” The services for the fees disclosed under this category include consultation regarding our correspondence with the Securities and Exchange Commission and other accounting consulting.

 

Tax Fees — This category consists of professional services rendered by our independent registered public accounting firm for tax compliance and tax advice. The services for the fees disclosed under this category include tax return preparation and technical tax advice.

 

All Other Fees — This category consists of fees for other miscellaneous items.

 

Preapproval Policy

 

Our Board of Directors reviews and approves audit and permissible non-audit services performed by its independent accountants, as well as the fees charged for such services. In its review of non-audit service fees and its appointment of Haynie & Company as our independent accountants, the Board of Directors considered whether the provision of such services is compatible with maintaining independence.

 

 23 

 

 

Part IV

 

ITEM 15: EXHIBITS, CONSOLIDATED FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULES

 

(a)

 

  1. The financial statements listed in the “Index to Financial Statements” at page F-1 are filed as part of this report.
     
  2. Financial statement schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.
     
  3. Exhibits included or incorporated herein: See index to Exhibits.

 

(b) Exhibits

 

Exhibit No.   Description
3.1(a)   Articles of Amendment to the Amended and Restated Articles of Incorporation, dated February 14, 2020 filed in the Company’s 10K for the period ended December 31, 2019.
3.2   Bylaws (Incorporated by reference to Exhibit 3(b) to the Registration Statement on Form S-1 filed on May 15, 2012)
10.30   Agreement between the Company and Bistromatics, Inc. Dated September 15, 2020 transferring Intellectual Property Rights to the Company’s Phzio, Phzio TeleRehab and MSK 360 platforms in Exchange for debt forgiveness and 15% of Bistromatics, Inc. (Incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed on September 24, 2020)
10.31   Agreement and Plan of Merger dated May 18, 2021 between EWLL Acquisition Corp. and American Health Protection, Inc., filed with the Company’s Form 10Q for June 30, 2021 filed on August 23, 2021.
31.1   Certification of CEO pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2   Certification of CFO pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1   Certification of CEO pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2   Certification of CFO pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS **   XBRL Instance Document
     
101.SCH **   XBRL Taxonomy Extension Schema Document
     
101.CAL **   XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF **   XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB **   XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE **   XBRL Taxonomy Extension Presentation Linkbase Document

 

** Filed herewith.

 

 24 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

eWellness Healthcare Corporation  
(Registrant)  

 

By: /s/ Douglas MacLellan   Date: March 31, 2022
  Douglas MacLellan    
  President, CEO, Chairman of the Board    

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

 

Signature   Title   Date
         
/s/ Douglas MacLellan   Chief Executive Officer and Director   March 31, 2022
Douglas MacLellan   (Principal Executive Officer)    
         
/s/ David Markowski   Chief Financial Officer and Director   March 31, 2022
David Markowski   (Principal Financial and Accounting Officer)    
         
/s/ Douglas Cole   Director   March 31, 2022
Douglas Cole        

 

 25 

 

 EX-31.1 2 ex31-1.htm

 

EXHIBIT 31.1

 

Exhibit 31.1 Certification of the Chief Executive Officer of eWellness Healthcare Corporation., pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Douglas MacLellan, certify that:

 

1. I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2021 of eWellness Healthcare Corporation (the “registrant”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made considering the circumstances made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the Audit Committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 31, 2022  
   
/s/ Douglas MacLellan  
Douglas MacLellan  
Chief Executive Officer (Principal Executive Officer)  

 

 

 

 EX-31.2 3 ex31-2.htm

 

EXHIBIT 31.2

 

Exhibit 31.2 Certification of the Chief Financial Officer of eWellness Healthcare Corporation, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, David Markowski, certify that:

 

1. I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2021 of eWellness Healthcare Corporation (the “registrant”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the Audit Committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 31, 2022  
   
/s/ David Markowski  
David Markowski,  
Chief Financial Officer  
(Principal Financial and Accounting Officer)  

 

 

 

 EX-32.1 4 ex32-1.htm

 

EXHIBIT 32.1

 

Exhibit 32.1 Certification of the Chief Executive Officer of eWellness Healthcare Corporation pursuant to Section 906 of the Sarbanes Oxley Act of 2002

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report on Form 10-K of eWellness Healthcare Corporation (the “Company”) for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission (the “Report”), the undersigned Darwin Fogt, Chief Executive Officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  eWellness Healthcare Corporation.
     
Date: March 31, 2022 By: /s/ Douglas MacLellan
    Douglas MacLellan, Director and Chief Executive Officer
    (Principal Executive Officer)

 

This certification accompanies this Annual Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

 

 

 

 EX-32.2 5 ex32-2.htm

 

EXHIBIT 32.2

 

Exhibit 32.2 Certification of the Chief Financial Officer of eWellness Healthcare Corporation pursuant to Section 906 of the Sarbanes Oxley Act of 2002

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report on Form 10-K of eWellness Healthcare Corporation (the “Company”) for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission (the “Report”), the undersigned David Markowski, Chief Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  eWellness Healthcare Corporation
   
Date: March 31, 2022 /s/ David Markowski
  David Markowski, Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

This certification accompanies this Annual Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

 

 

 

 

 GRAPHIC 6 form10-k_001.jpg begin 644 form10-k_001.jpg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end EX-101.SCH 7 ewll-20211231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Reconciliation of Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statement of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - The Company link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Convertible Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Equity Transactions link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Commitments, Contingencies link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Derivative Valuation link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Supplemental Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Equity Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Derivative Valuation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - The Company (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Summary of Assets and Liabilities Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Schedule of Estimated Useful Lives for Significant Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Schedule of Deferred Tax Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Schedule of Pre-tax from Continuing Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Convertible Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Summary of Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Summary of Warrants Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Equity Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Commitments, Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Revenue Recognition (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Schedule of Derivative Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Derivative Valuation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Supplemental Cash Flow Information (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 ewll-20211231_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 ewll-20211231_def.xml XBRL DEFINITION FILE EX-101.LAB 10 ewll-20211231_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A Preferred Stock [Member] Series C Preferred Stock [Member] Series D Preferred Stock [Member] Series E Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Shares to be Issued [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Services Agreement [Member] Legal Entity [Axis] Bistromatics Inc. [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Long-Lived Tangible Asset [Axis] Furniture and Fixtures [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Computer Equipment [Member] Software Development [Member] Antidilutive Securities [Axis] Share-based Payment Arrangement, Option [Member] Warrant [Member] Convertible Debt Securities [Member] Title of Individual [Axis] Officers and Directors [Member] Settlement and compromise agreement [Member] Debt Instrument [Axis] Convertible Notes Payable [Member] 12% Convertible Promissory Note [Member] 2019 Convertible Notes [Member] Officers, Directors and Consultants [Member] Board of Directors [Member] Series E Convertible Preferred Stock [Member] Series D Voting Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Convertible Notes [Member] 12- month Advisory Services Agreement [Member] Consultant [Member] Preferred Series E Conversion [Member] Customer [Axis] Vendor [Member] Former Consultant [Member] Subsequent Event Type [Axis] Subsequent Event [Member] First Payment [Member] Every Sixty Days Thereafter [Member] Award Type [Axis] Derivative Liability [Member] Derivative Instrument [Axis] Notes [Member] Warrants Derivative [Member] Measurement Input Type [Axis] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Price Volatility [Member] Measurement Input, Expected Dividend Rate [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents incorporated by reference Auditor Firm ID Auditor Name Auditor Location Statement [Table] Statement [Line Items] ASSETS CURRENT ASSETS Cash Prepaid expenses Total current assets Property & equipment, net TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ DEFICIT CURRENT LIABILITIES Accounts payable and accrued expenses Accrued expenses - related party Accrued compensation Loan payable Convertible debt, net of discount Derivative liability Total current liabilities Total Liabilities COMMITMENTS AND CONTINGENCIES STOCKHOLDERS’ DEFICIT Preferred Stock Value Common stock, authorized 20,000,000,000 shares, $.001 par value, 18,507,683,627 and 16,862,481,961 issued and outstanding, respectively Shares to be issued Additional paid in capital Accumulated deficit Total Stockholders’ Deficit TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT Preferred stock, shares authorized Preferred stock, par value Preferred stock, shares issued Preferred stock, shares outstanding Common stock, shares authorized Common stock, par value Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] REVENUE Revenue Cost of revenue Net Revenue OPERATING EXPENSES Executive compensation General and administrative Professional fees Total Operating Expenses Loss from Operations OTHER INCOME (EXPENSE) Interest income Gain on extinguishment of debt Gain (loss) on derivative liability Loss on disposal of asset Interest expense Net Income (Loss) before Income Taxes Income tax expense Net Income (Loss) Basic and diluted (loss) per common share Weighted average basic and diluted shares outstanding Balance Balance, shares Contributed services Shares issued to officers, directors and consultants Shares issued to officers, directors and consultants, shares Shares issued to officers, directors and consultants, shares Shares issued for debt conversion Shares issued for debt conversion, shares Shares issued for services Shares issued for services, shares Shares issued for rounding - 50:1 split Shares issued for rounding - 50:1 split, shares Discontinued operations Derivative liability Net loss Shares issued for cash Shares issued for cash, shares Shares issued for conversion Shares issued for conversion, shares Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities Net income (loss) Adjustments to reconcile net income (loss) to net cash used in operating activities: Depreciation and amortization Contributed services Shares issued to officers, directors and consultants Shares issued for consulting services Shares issued for financing costs Gain on extinguishment of debt Amortization of debt discount and prepaids (Gain) loss on derivative liability Loss on disposal of asset Changes in operating assets and liabilities Prepaid expense Accounts receivable Accounts payable and accrued expenses Accounts payable - related party Accrued expenses - related party Accrued compensation Net cash used in operating activities Cash flows from financing activities Proceeds from issuance of convertible debt Original issue discount and debt issuance costs Loan payable Proceeds from issuance of preferred series E Net cash provided by financing activities Net increase (decrease) in cash Cash, beginning of period Cash, end of period Supplemental Information: Cash paid for: Taxes Interest Expense Non-cash items: Shares issued for debt conversion Organization, Consolidation and Presentation of Financial Statements [Abstract] The Company Accounting Policies [Abstract] Summary of Significant Accounting Policies Property, Plant and Equipment [Abstract] Property and Equipment Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Income Tax Disclosure [Abstract] Income Taxes Related Party Transactions [Abstract] Related Party Transactions Debt Disclosure [Abstract] Convertible Notes Payable Equity [Abstract] Equity Transactions Commitments and Contingencies Disclosure [Abstract] Commitments, Contingencies Revenue from Contract with Customer [Abstract] Revenue Recognition Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Valuation Supplemental Cash Flow Elements [Abstract] Supplemental Cash Flow Information Subsequent Events [Abstract] Subsequent Events Basis of Presentation Use of Estimates Going Concern Fair Value of Financial Instruments Revenue Recognition Property and Equipment Intangible Assets Income Taxes Debt Issuance Costs Derivative Financial Instruments Cash and Cash Equivalents Loss per Common Share Recent Accounting Pronouncements Reclassifications Summary of Assets and Liabilities Fair Value on Recurring Basis Schedule of Estimated Useful Lives for Significant Property and Equipment Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Deferred Tax Liabilities Schedule of Pre-tax from Continuing Operations Summary of Stock Options Activity Summary of Warrants Activity Schedule of Derivative Liability Schedule of Assumptions Used Black Scholes Valuation of Derivative Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Equity Method Investment, Ownership Percentage Professional Fees Common stock par value Preferred stock par value Reverse Stock Split Description of change in par value Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Derivative Liability Total Liabilities measured at fair value Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Useful Life Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive potential earnings per share, amount Accumulated loss Working capital deficit Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Impairment of Long-Lived Assets to be Disposed of Transferred computers and equipment Depreciation Amortization of Intangible Assets NOL carryover Accrued payroll Depreciation Valuation allowance Net deferred tax asset Book loss Depreciation Contributed services Meals & entertainment Stock for prepaids Stock for consulting Amortization of debt discount Accrued payroll Gain on debt extinguishment Related party accruals Loss on disposal Derivative (Gain)/Loss Valuation allowance Income tax expense benefit Operating Loss Carryforwards Income taxable description Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] Due to related parties, current Accrued director's fees Accrued executive compensation Schedule of Short-term Debt [Table] Short-term Debt [Line Items] Accrued interest Debt interest stated rate Debt Instrument, principal amount Debt instrument maturity date Original issue discount Transaction costs Convertible debt percentage Number of trading days Accrued interest Number of Stock Options Outstanding, Beginning Balance Weighted Average Exercise Price Outstanding, Beginning Balance Remaining Life (yrs) Outstanding, Beginning Balance Intrinsic Value Outstanding, Beginning Balance Number of Stock Options Outstanding, Granted Weighted Average Exercise Price, Granted Number of Stock Options Outstanding, Exercised Weighted Average Exercise Price, Exercised Number of Stock Options Outstanding, Cancelled Weighted Average Exercise Price Outstanding,Ending Balance Remaining Life (yrs) expired/ cancelled Number of Warrants, Outstanding, Ending Balance Remaining Life (yrs) Outstanding, Ending Balance Intrinsic Value Options exercisable, Ending Balance Number of Stock Options exercisable, Ending Balance Weighted Average Exercise Price Options exercisable, Ending Balance Remaining Life (yrs) Outstanding, Ending Balance Intrinsic Value Options exercisable, Ending Balance Number of Warrants, Outstanding, Beginning Balance Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance Remaining Life (yrs.) Warrants Outstanding, Beginning Balance Intrinsic Value, Warrants Outstanding, Beginning Balance Number of Warrants, Granted Number of Warrants, Exercised Number of Warrants, Cancelled Weighted Average Exercise Price, Cancelled Weighted Average Exercise Price, Warrants Outstanding, Ending Balance Remaining Life (yrs.) Warrants Outstanding, Ending Balance Intrinsic Value, Warrants Outstanding, Ending Balance Number of Warrants, exercisable, Ending balance Weighted Average Exercise Price Exercisable, Ending Balance Remaining Life (yrs.) Warrants Exercisable, Ending Balance Intrinsic Value, Warrants Outstanding, Exercisable Schedule of Stock by Class [Table] Class of Stock [Line Items] Conversion of stock, description Deferred compensation Offering price per share Preferred Stock, Voting Rights Shares issued during period shares Preferred stock value Shares issued date Reverse stock split, description Shares issued for debt conversion,shares Principal amount Accrued interest Financing cost Shares issued during period for services,shares Shares issued during period for services, value Stock issued during the period, value Number of sharesto be issued Number of sharesto be issued, value Monthly base fee Conversion of Stock, Shares Converted Shares issued during period for conversion, value Contractual Fees Payment of plaintiffs Revenue Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative liability, beginning balance Addition of new conversion Conversion of note derivatives Change in fair value Derivative liability, ending balance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock price at valuation date Derivative liability, fair value measurement input, percentage Derivative liability, term Amortized of debt discount Dividends Payable [Table] Dividends Payable [Line Items] [custom:StockIssuedDuringPeriodSharesNewIssue] [custom:StockIssuedDuringPeriodValueNewIssue] Conversion of stock, shares converted [custom:ConversionOfStockShareConverted1] [custom:ConversionsOfStockAmountConverted1] Shares issued during period for services, shares Shares issued during period for services, value Stock issued during the period for settlement of debt, shares Stock issued during the period for settlement of debt,value Financing costs Subsequent Event [Table] Subsequent Event [Line Items] Accrued liabilities related parties current. Shares to be issued. Shares to be Issued [Member] Shares issued to officers, directors and cosultants. Shares issued for debt conversion. Shares issued for services. Stock issued during period value reverse stock splits. Adjustments to additional paid in capital contributed services. Derivative liability. Stock issued during period value discontinued operations. Stock issued during period shares officers and directors Shares issued for debt conversion, shares. Shares issued for preferred share conversions of share Contributed services. Shares issued to officers directors and consultants. Shares issued for consulting services. Shares issued for financing costs. Increase (decrease) in prepaid expenses. Increase decrease in accrued receivables net Increase decrease in accrued liabilities related parties. Shares issued for debt conversion. Gain on extinguishment of debt. Services Agreement [Member] Bistromatics Inc. [Member] Going Concern [Policy Text Block] Officers and Directors [Member] Transferred computers and equipment. Depreciation. Income Tax Reconciliation Nondeductible Expense Book Income. Income tax reconciliation nondeductible expense stock for prepaids. Income tax reconciliation nondeductible expense stock for consulting. Income tax reconciliation nondeductible expense gain on debt extinguishment. Income tax reconciliation nondeductible expense related party accruals Income tax reconciliation nondeductible expense loss on disposal Operating loss carry forward loss expiration Term. Settlement and compromise agreement [Member] 12% Convertible Promissory Note [Member] 2019 Convertible Notes [Member] Officers, Directors and Consultants [Member] Board of Directors [Member] Series E Convertible Preferred Stock [Member] Series D Voting Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Convertible Notes [Member] 12- month Advisory Services Agreement [Member] Consultant [Member] Remaining Life (yrs), Ending. Number of Warrants, exercisable, Ending balance. Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Weighted Average Number Of Share. Share Based Compensation Arrangement By Share Based Payment Award Non Option Grand In Period Weighted Average Exercise Price. Share Based Compensation Arrangement By Share Based Payment Award Non Option Exercised In Period Weighted Average Exercise Price. Share Based Compensation Arrangement By Share Based Payment Award Non Option Forfeited Or Expired In Period Weighted Average Exercise Price. Weighted Average Exercise Price, Exercisable Ending. Remaining Life (yrs), Beginning. Remaining Life (yrs.) Warrants Outstanding, Granted Remaining Life (yrs), Ending. Remaining Life (yrs), Exercisable Ending. Intrinsic Value, Warrants Outstanding. Intrinsic Value, Warrants Outstanding, Granted Intrinsic Value, Warrants Outstanding, Exercised Intrinsic Value, Warrants Outstanding, Cancelled Weighted Average Exercise Price, Warrants Exercisable Weighted Average Exercise Price Payment of plaintiffs. Vendor [Member] First Payment [Member] Every Sixty Days Thereafter [Member] Contractual fees. Derivative Liability [Member] Notes [Member] Addition of new conversion option derivatives. Conversion of note derivatives. Warrants Derivative [Member] Intrinsic Value, Warrants Outstanding, Cancelled Interest payable current and Noncurrent. 2019 Convertible Note [Member] Former Consultant [Member] Common Stock [Member] Description of changes in par value. Working capital deficit. Income tax expense benefit continuing operations. Stock issued during period shares to be issued. Stock issued during period shares value to be issued. Preferred Series E Conversion [Member] Number of new stock issued during the period. Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Interest Expense, Other Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shares, Outstanding StockIssuedDuringPeriodSharesOfficersAndDirectors DerivativeLiability ContributedServices SharesIssuedToOfficersDirectorsAndConsultants GainOnExtinguishmentOfDebt Increase (Decrease) in Accounts Payable and Accrued Liabilities IncreaseDecreaseInAccruedLiabilitiesRelatedParties Increase (Decrease) in Employee Related Liabilities Net Cash Provided by (Used in) Operating Activities Payments of Debt Issuance Costs Proceeds from Construction Loans Payable Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations SharesIssuedForDebtConversion Revenue from Contract with Customer [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Intangible Assets, Finite-Lived, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Working capital deficit Depreciation [Default Label] Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation, Amount Effective Income Tax Rate Reconciliation, Nondeductible Expense, Charitable Contributions, Amount Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount InterestPayableNoncurrent Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare ShareBasedCompensationArrangementByShareBasedPaymentWarrantBeginningInPeriodGrantDateIntrinsic Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures Interest Payable, Current Revenues Derivative Liability [Default Label] EX-101.PRE 11 ewll-20211231_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2021
Mar. 31, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2021    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2021    
Current Fiscal Year End Date --12-31    
Entity File Number 000-55203    
Entity Registrant Name eWELLNESS HEALTHCARE CORPORATION    
Entity Central Index Key 0001550020    
Entity Tax Identification Number 90-1073143    
Entity Incorporation, State or Country Code NV    
Entity Address, Address Line One 1125 S Federal Hwy #464    
Entity Address, City or Town Fort Lauderdale    
Entity Address, State or Province FL    
Entity Address, Postal Zip Code 33316    
City Area Code (855)    
Local Phone Number 470-1700    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 10,624,610
Entity Common Stock, Shares Outstanding   18,507,683,627  
Documents incorporated by reference None    
Auditor Firm ID 457    
Auditor Name Haynie & Company    
Auditor Location Salt Lake City, Utah    

XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2021
Dec. 31, 2020
CURRENT ASSETS    
Cash $ 11,177 $ 1,109
Prepaid expenses 3,235
Total current assets 11,177 4,344
Property & equipment, net 2,387 3,788
TOTAL ASSETS 13,564 8,132
CURRENT LIABILITIES    
Accounts payable and accrued expenses 1,223,278 892,164
Accrued expenses - related party 144,471 292,762
Accrued compensation 200,000 200,000
Loan payable 1,662
Convertible debt, net of discount 1,354,882 1,354,882
Derivative liability 1,447,008 3,925,106
Total current liabilities 4,371,301 6,664,914
Total Liabilities 4,371,301 6,664,914
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ DEFICIT    
Common stock, authorized 20,000,000,000 shares, $.001 par value, 18,507,683,627 and 16,862,481,961 issued and outstanding, respectively 18,507,684 16,862,482
Shares to be issued 263
Additional paid in capital 17,203,420 16,097,866
Accumulated deficit (40,069,797) (39,618,090)
Total Stockholders’ Deficit (4,357,737) (6,656,782)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT 13,564 8,132
Series A Preferred Stock [Member]    
STOCKHOLDERS’ DEFICIT    
Preferred Stock Value 697 697
Series C Preferred Stock [Member]    
STOCKHOLDERS’ DEFICIT    
Preferred Stock Value 92
Series D Preferred Stock [Member]    
STOCKHOLDERS’ DEFICIT    
Preferred Stock Value 20
Series E Preferred Stock [Member]    
STOCKHOLDERS’ DEFICIT    
Preferred Stock Value $ 147
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2021
Dec. 31, 2020
Common stock, shares authorized 20,000,000,000 20,000,000,000
Common stock, par value $ 0.001 $ 0.001
Common stock, shares issued 18,507,683,627 16,862,481,961
Common stock, shares outstanding 18,507,683,627 16,862,481,961
Series A Preferred Stock [Member]    
Preferred stock, shares authorized 20,000,000 20,000,000
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares issued 696,667 696,667
Preferred stock, shares outstanding 696,667 696,667
Series C Preferred Stock [Member]    
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares issued 920,000 0
Preferred stock, shares outstanding 920,000 0
Series D Preferred Stock [Member]    
Preferred stock, shares authorized 200,000 200,000
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares issued 200,000 0
Preferred stock, shares outstanding 200,000 0
Series E Preferred Stock [Member]    
Preferred stock, shares authorized 2,500,000 2,500,000
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares issued 1,465,680 0
Preferred stock, shares outstanding 1,465,680 0
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
REVENUE    
Revenue $ 266,570
Cost of revenue 11,224
Net Revenue 255,346
OPERATING EXPENSES    
Executive compensation 260,000 767,639
General and administrative 280,177 699,440
Professional fees 2,130,850 1,180,583
Total Operating Expenses 2,671,027 2,647,662
Loss from Operations (2,671,027) (2,392,316)
OTHER INCOME (EXPENSE)    
Interest income 1
Gain on extinguishment of debt 24,738
Gain (loss) on derivative liability 2,478,098 (5,441,140)
Loss on disposal of asset (8,205)
Interest expense (258,778) (954,605)
Net Income (Loss) before Income Taxes (451,707) (8,771,527)
Income tax expense
Net Income (Loss) $ (451,707) $ (8,771,527)
Basic and diluted (loss) per common share $ (0.00) $ (0.00)
Weighted average basic and diluted shares outstanding 17,579,528,194 7,849,264,946
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Reconciliation of Stockholders' Deficit - USD ($)
Preferred Stock [Member]
Series A Preferred Stock [Member]
Preferred Stock [Member]
Series C Preferred Stock [Member]
Preferred Stock [Member]
Series D Preferred Stock [Member]
Preferred Stock [Member]
Series E Preferred Stock [Member]
Common Stock [Member]
Shares to be Issued [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2019 $ 250 $ 12,752 $ 150 $ 23,927,374 $ (30,846,563) $ (6,906,037)
Balance, shares at Dec. 31, 2019 250,000 12,752,084        
Contributed services 153,518 153,518
Shares issued to officers, directors and consultants $ 447 1,339,553 1,340,000
Shares issued to officers, directors and consultants, shares 446,667                
Shares issued to officers, directors and consultants, shares                
Shares issued for debt conversion $ 16,849,014 (15,000,597) 1,848,417
Shares issued for debt conversion, shares         16,849,013,669        
Shares issued for services $ 668 $ 113 $ 956 $ 1,737
Shares issued for services, shares         668,332        
Shares issued for rounding - 50:1 split 48 (48)
Shares issued for rounding - 50:1 split, shares         47,876        
Discontinued operations $ 688,595 $ 688,595
Derivative liability 4,988,515 4,988,515
Net loss (8,771,527) (8,771,527)
Balance at Dec. 31, 2020 $ 697 $ 16,862,482 263 16,097,866 (39,618,090) (6,656,782)
Balance, shares at Dec. 31, 2020 696,667 16,862,481,961        
Shares issued to officers, directors and consultants $ 92 $ 20 $ 128 2,399,760 2,400,000
Shares issued to officers, directors and consultants, shares   920,000 200,000 1,280,000          
Shares issued for services $ 2,002 (263) (988) $ 750
Shares issued for services, shares         2,001,666       2,001,666
Net loss               (451,707) $ (451,707)
Shares issued for cash $ 35 349,965 350,000
Shares issued for cash, shares       350,000          
Shares issued for conversion $ (16) $ 1,643,200 (1,643,183)
Shares issued for conversion, shares       (164,320) 1,643,200,000        
Balance at Dec. 31, 2021 $ 697 $ 92 $ 20 $ 147 $ 18,507,684 $ 17,203,420 $ (40,069,797) $ (4,357,737)
Balance, shares at Dec. 31, 2021 696,667 920,000 200,000 1,465,680 18,507,683,627        
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statement of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities    
Net income (loss) $ (451,707) $ (8,771,527)
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Depreciation and amortization 1,402 6,869
Contributed services 153,518
Shares issued to officers, directors and consultants 1,120,000 503,588
Shares issued for consulting services 1,280,750 1,737
Shares issued for financing costs 95,933
Gain on extinguishment of debt (1,556)
Amortization of debt discount and prepaids 795,591
(Gain) loss on derivative liability (2,478,098) 5,441,140
Loss on disposal of asset 8,205
Changes in operating assets and liabilities    
Prepaid expense 3,235 (21,887)
Accounts receivable (66,848)
Accounts payable and accrued expenses 331,115 919,981
Accounts payable - related party 160,460
Accrued expenses - related party (148,291) 29,995
Accrued compensation 460,188
Net cash used in operating activities (341,594) (284,613)
Cash flows from financing activities    
Proceeds from issuance of convertible debt 52,800
Original issue discount and debt issuance costs (7,800)
Loan payable 1,662
Proceeds from issuance of preferred series E 350,000
Net cash provided by financing activities 351,662 45,000
Net increase (decrease) in cash 10,068 (239,613)
Cash, beginning of period 1,109 240,722
Cash, end of period 11,177 1,109
Cash paid for:    
Taxes
Interest Expense
Non-cash items:    
Shares issued for debt conversion $ 1,848,417
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.1
The Company
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
The Company

Note 1. The Company

 

The Company, Background and Nature of Business

 

eWellness Healthcare Corporation (the “eWellness”, “Company”, “we”, “us”, “our”) was incorporated in the State of Nevada on April 7, 2011.

 

eWellness Healthcare Corporation is the first physical therapy telehealth company to offer real-time distance monitored assessments and treatments. On September 15, 2020, the Company and Bistromatics signed an agreement that transferred all worldwide marketing and Intellectual Property Rights or claims to the Company’s Phzio, Phzio TeleRehab and MSK 360 platforms to Bistromatics in return for a 15% ownership in Bistromatics. This agreement eliminated all past due professional fees of $748,832. The transfer of rights was completed on December 31, 2020.

 

During the last quarter of 2020 and the first quarter of 2021, the Company’s Board of Directors and management determined that while it would continue its efforts and resources involving physical therapy and telemedicine, it would also pursue other health-related business opportunities. With the Company’s announced plan to diversify its health-related business beyond its telemedicine operations, which telemedicine operations will continue, the Company on May 18, 2021, entered into an Agreement and Plan of Merger by and between the Company, EWLL Acquisition (a new wholly owned subsidiary of the Company) and a recently formed private Nevada company controlled by a third party, American Health Protection, Inc.(“AMHP”). pursuant to which AMHP merged with EWLL Acquisition, with AMHP being the surviving entity and becoming a wholly owned subsidiary of the Company. On July 14, 2021, the Company filed the requisite Articles of Merger with the State of Nevada and, as a result, AMHP became a wholly owned subsidiary of the Company and EWLL Acquisition ceased to exist.

 

On April 19, 2021, the Company filed a DEF 14C to disclose to the stockholders the ratification and approval by Joint Written Consent, based upon the unanimous approval by our Board of Directors and the consent of the Majority Consenting Stockholders, of the corporate actions to file an amendment to its Amended and Restated Articles of Incorporation to: (i) change the name of the Company from eWellness Healthcare Corporation to American Health Protection Corp. (“Name Change”); (ii) change the par value of the Company’s common stock and preferred stock from $0.001 per share to $0.0001 per share (“Par Value Change”); and (iii) implement the 1:2,000 reverse split of our Common Stock and the shares underlying conversion of the Company’s securities convertible into Common Stock together with the shares reserved for such conversions, on a one for two thousand (1:2,000) basis (“Reverse Split”). The Name Change, Par Value Change and Reverse Split are sometimes referred to as the “Corporate Actions”, which Corporate Actions must be approved by FINRA. The application for approval of these actions to FINRA has not yet been filed.

 

As stated in the DEF 14C, the Name Change from eWellness Healthcare Corporation to American Health Protection Corp. was to reflect the Company’s plan to diversify its business operations from the telemedicine business and the proprietary PHZIO System to include other health related services to its primary target market focused on small and mid-sized corporate clients. The Par Value Change of the Company’s Common Stock and Preferred Stock from $0.001 per share to $0.0001 per share was the result that for more than the past six months (preceding the filing of the DEF 14C), the price of its Common Stock on the OTC Markets had been less than the $0.001 par value of its Common Stock. As a result, the Company had not been able to raise capital by the issuance of shares of Common Stock at less than the $0.001 par value and, in addition, the Company could not raise capital through the issuance of shares of convertible Preferred Stock having a conversion price of less than the $0.001 par value of the Common Stock. Lastly, the rationale for the Reverse Split of the outstanding shares of Common Stock on a one for two thousand (1:2,000) basis was needed because the outstanding shares and shares reserved for convertible debt conversion resulted in no shares being available for capital raise purposes.

 

 
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying financial statements have been prepared to reflect the financial position, results of operations and cash flows of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.

 

Going Concern

 

For the year ended December 31, 2021, the Company had no revenues. The Company has an accumulated deficit of $40,069,797 and a working capital deficit of $4,360,124. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Fair Value of Financial Instruments

 

The Company complies with the accounting guidance under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820-10, Fair Value Measurements, as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance.

 

The guidance also establishes a fair value hierarchy for measurements of fair value as follows:

 

Level 1 – quoted market prices in active markets for identical assets or liabilities.

 

Level 2 – inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

 

As of December 31, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

   Total   Level 1   Level 2   Level 3 
Derivative Liability  $1,447,008   $-   $-   $1,447,008 
Total Liabilities measured at fair value  $1,447,008   $-   $-   $1,447,008 

 

As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

   Total   Level 1   Level 2   Level 3 
Derivative Liability  $3,925,106   $-   $-   $3,925,106 
Total Liabilities measured at fair value  $3,925,106   $-   $-   $3,925,106 

 

Revenue Recognition

 

The Company recognizes revenue per ASC 606. Revenue is recognized when services have been completed.

 

Property and Equipment

 

Property and equipment are recorded at historical cost. Minor additions and renewals are expensed in the year incurred. Major additions and renewals are capitalized and depreciated over their estimated useful lives. Depreciation is recorded over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The estimated useful lives for significant property and equipment categories are as follows:

 

Furniture and Fixtures   5-7 Years
Computer Equipment   5-7 Years
Software   3 Years

 

The Company regularly evaluates whether events or circumstances have occurred that indicate the carrying value of long-lived assets may not be recoverable. If factors indicate the asset may not be recoverable, we compare the related undiscounted future net cash flows to the carrying value of the asset to determine if impairment exists. If the expected future net cash flows are less than the carrying value, an impairment charge is recognized based on the fair value of the asset. For the years ended December 31, 2021 and 2020, there was no impairment recognized.

 

Intangible Assets

 

The Company accounts for assets that are not physical in nature as intangible assets. Intangible assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are amortized on a straight-line basis over their economic or legal life, whichever is shorter. Intangible assets with indefinite useful lives are reassessed each year for impairment. If an impairment has occurred, then a loss is recognized. An impairment loss is determined by subtracting the asset’s fair value from the asset’s book/carrying value. For the years ended December 31, 2021 and 2020, there were no intangible assets.

 

Income Taxes

 

The Company accounts for income taxes under FASB ASC 740-10-30. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component or all the benefits of deferred tax assets will not be realized.

 

 

Debt Issuance Costs

 

The Company accounts for debt issuance costs in accordance with ASU 2015-03. This guidance requires direct and incremental costs associated with the issuance of debt instruments such as legal fees, printing costs and underwriters’ fees, among others, paid to parties other than creditors, are reported and presented as a reduction of debt on the consolidated balance sheets.

 

Debt issuance costs and premiums or discounts are amortized over the term of the respective financing arrangement using the effective interest method. Amortization of these amounts is included as a component of interest expense net, in the consolidated statements of operations.

 

Derivative Financial Instruments

 

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and then is revalued at each reporting date, with changes in fair value reported in the statement of operations. For stock based derivative financial instruments, Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.

 

Once determined, derivative liabilities are adjusted to reflect fair value at the end of each reporting period. Any increase or decrease in the fair value from inception is made quarterly and appears in results of operations as a change in fair market value of derivative liabilities.”

 

Cash and Cash Equivalents

 

Cash and cash equivalents include all cash deposits and highly liquid financial instruments with an original maturity to the Company of three months or less. The Company maintains cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents.

 

Loss per Common Share

 

The Company follows ASC Topic 260 to account for the loss per share. Basic loss per common share calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share calculations are determined by dividing net loss by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. As the Company has incurred losses for the periods ended December 31, 2021 and 2020, no dilutive shares are added into the loss per share calculations. While currently antidilutive, the following instruments could potentially dilute EPS in the future resulting in the following common stock equivalents:

   2021   2020 
         
Options   -    27,000 
Warrants   -    26,015 
Convertible Notes   12,357,170,485    24,728,206,940 
 Total   12,357,170,485    27,728,259,955 

 

Recent Accounting Pronouncements

 

The Company has reviewed all other recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.

 

Reclassifications

 

Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.

 
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment
 12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
Property and Equipment

Note 3. Property and Equipment

 

Property and equipment consist of computer equipment that is stated at cost $6,976 and $6,976 less accumulated depreciation of $4,589 and $3,188 for the years ended December 31, 2021 and 2020, respectively. During the year ended December 31, 2020, the Company disposed of computers with a cost value of $11,498 and transferred computers and equipment valued at $9,208 per the Bistromatics agreement dated September 15, 2020. (Footnote 1). Depreciation expense was $1,402 and $4,869 for the years ended December 31, 2021 and 2020, respectively.

 
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Intangible Assets
 12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

Note 4. Intangible Assets

 

The Company recognizes the cost of a software license and a license for use of a programming code as intangible assets. The stated cost of these assets and accumulated amortization were transferred per the Bistromatics agreement dated September 15, 2020 (Footnote 1). For the years ended December 31, 2021 and 2020, the amortization expense recorded was $0 and $2,000, respectively.

 

 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes

Note 5. Income Taxes

 

Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

 

Net deferred tax liabilities consist of the following components as of December 31, 2021 and 2020:

   2021   2020 
         
Deferred tax assets:          
NOL carryover  $4,027,300   $4,133,200 
Accrued payroll   42,000    42,000 
Deferred tax liabilities          
Depreciation   400    300 
Valuation allowance   (4,069,700)   (4,175,500)
Net deferred tax asset  $-   $- 

 

The income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate to pre-tax income from continuing operations for the years ended December 31, 2021 and 2020 due to the following:

 

   2020   2019 
         
Book loss  $(94,900)  $(1,842,000)
Depreciation   -    700 
Contributed services   504,000    32,200 
Meals & entertainment   2,600    2,400 
Stock for prepaids   700    36,900 
Stock for consulting   200    400 
Amortization of debt discount   -    130,200 
Accrued payroll   -    (69,900)
Gain on debt extinguishment   -    (5,200)
Related party accruals   -    (123,100)
Loss on disposal   -    1,700 
Derivative (Gain)/Loss   (520,400)   114,260 
Valuation allowance   107,800    693,100 
Income tax expense benefit  $-   $- 

 

As of December 31, 2021, the Company had net operating loss carry forwards of approximately $19,177,000 that may be offset against future taxable income from the year 2022 through 2041. No tax benefit has been reported in the December 31, 2020 financial statements since the potential tax benefit is offset by a valuation allowance of the same amount.

 

Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards for federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years.

 

The Company’s policy is to recognize potential interest and penalties accrued related to unrecognized tax benefits within income tax expense. For the years ended December 31, 2021 and 2020, the Company did not recognize any interest or penalties, nor did we have any interest or penalties accrued related to unrecognized benefits.

 

The tax years ended December 31, 2021, 2020 and 2019 are open for examination for federal income tax purposes and by other major taxing jurisdictions to which we are subject.

 

 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions
 12 Months Ended
Dec. 31, 2021
Related Party Transactions [Abstract]  
Related Party Transactions

Note 6. Related Party Transactions

 

Throughout the year ended December 31, 2021, the officers and directors of the Company incurred business expenses on behalf of the Company. The amounts payable to the officers as of the years ended December 31, 2021 and 2020 were $33,701 and $11,655, respectively. There were no expenses due to the board members, but the Company has accrued directors’ fees of $221,107 and $221,107 as of the years ended December 31, 2021 and 2020, respectively. Two of the independent directors resigned on May 22, 2020 so no further directors’ fees were accrued for them. On February 26, 2021, the remaining independent director signed a Settlement and Compromise Agreement which eliminated all previously accrued directors’ fees as of September 30, 2020 for a flat fee of $100,000. Since the effective date of the agreement was October 1, 2020, the adjustment was recorded as of December 31, 2020. Because the Company is not yet profitable the officers had agreed to defer compensation. On February 26, 2021, the officers signed Settlement and Compromise Agreements which eliminated all previously accrued compensation accrued as of September 30, 2020 for $100,000 each. Since the effective date of these agreements is October 1, 2020, the adjustment was recorded as of December 31, 2020. The Company had accrued executive compensation of $200,000 and $200,000 as of December 31, 2021 and 2020, respectively.

 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Convertible Notes Payable
 12 Months Ended
Dec. 31, 2021
Debt Disclosure [Abstract]  
Convertible Notes Payable

Note 7. Convertible Notes Payable

 

Year Ended December 31, 2021

 

During the year ended December 31, 2021, there were no new convertible notes executed. During the year ended December 31, 2021, the Company accrued interest payable of $258,778 on previously executed convertible notes payable.

 

Year Ended December 31, 2020

 

In March 2020, the Company executed a 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $52,800. The note, which is due on January 15, 2021, has an original issue discount of $4,800 and transaction costs of $3,000. After 180 days, the convertible note converts into common stock of the Company at a conversion price that shall be equal to 70% of the average of the two lowest per share trading prices for the ten (10) trading days prior to the conversion date. As of December 31, 2020, this note was fully converted and during the year ended December 31, 2020 the Company accrued interest of $2,880.

 

During the year ended December 31, 2020, the Company accrued interest of $330,871 for the 2019 convertible notes that were still outstanding throughout the year.

 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Equity Transactions
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Equity Transactions

Note 8. Equity Transactions

 

Preferred Stock

 

The total number of shares of Series A Preferred Stock which the Company shall have authority to issue is 20,000,000 shares with a par value of $0.001 per share. During the year ended December 31, 2019, the Company authorized the issuance of 1,000,000 shares of preferred stock to officers, directors and consultants as deferred compensation and/or expense. The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of 40 shares per preferred share at the common share value on the date of issuance. The deferred compensation value of the shares will vest monthly at 1/24th of the calculated value of $3,000,000 and requisite expense or reduction of accrued compensation and/or accrued directors fees will be recorded. At the recording of the requisite vested share value, the corresponding number of preferred shares will be recorded as being issued. On May 22, 2020, two independent directors resigned and three officers/directors/consultant resigned. Therefore, the vesting of their preferred shares ceased on those dates per the authorization documents. As part of the Settlement and Compromise agreements signed by current officers, director and consultant on February 26, 2021, with effective date October 1, 2020, the shares issued became fully vested at the year ended December 31, 2020.

 

In April 2021, the Board of Directors issued a Certificate of Designations, Preferences, Rights and Limitations of Series C Convertible Preferred Stock. The Board authorized that the Company shall have the authority to issue 1,000,000 shares with a par value of $.0001 per share to be issued to persons designated by the Board. The Series C Preferred Stock has no stated maturity and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Holder decides to convert the shares of Series C Preferred Stock.

 

 

In April 2021, the Board of Directors issued a Certificate of Designations, Preferences and Rights Limitations of Series D Preferred Stock. The Board authorized that the Company shall have the authority to issue 200,000 shares with a par value of $.0001 per share to be issued to persons designated by the Board. The Series D Preferred Stock has no stated maturity and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Holder decides to convert the shares of Series D Preferred Stock.

 

In April 2021, the Board of Directors issued a Certificate of Designations, Preferences and Rights of Series E Convertible Preferred Stock. The Board authorized that the Company shall have authority to issue 2,500,000 shares with a par value of $.0001 per share. The Board of Directors may determine to : (i) issue a number of Series Preferred in a private placement at an offering price of $1.00 per share; (ii) issue the Series E Preferred in consideration for the cancellation of shares of the Company’s Series A Preferred held by the Corporation’s officers, directors and key personnel based on terms and conditions that the Board of Directors may determine; and (iii) issue the shares of Series E Preferred for such other purposes as the Board of Directors may determine.

 

The Series C, Series D and Series E Preferred Stock will rank, with respect to rights to the payment of dividends and the distribution of assets in the event of any liquidation, dissolution or winding up of the Corporation, (i) senior to all classes or series of the Corporation’s Common Stock, par value $0.001 per share (“Common Stock”), and to all other equity securities issued by the Corporation ; and (ii) effectively junior to all existing and future indebtedness (including indebtedness convertible into our Common Stock or Preferred Stock) of the Corporation and to any indebtedness and other liabilities of (as well as any preferred equity interest held by others) existing subsidiaries of the Corporation. The term “equity securities” shall not include convertible debt securities. The Holders of the Series D Preferred Stock have the right, on all matters subject to the vote of the capital stock of the Corporation, to have the collective vote equal to 70% of the total of all voting capital stock of the Corporation, notwithstanding the number of shares of voting capital stock, including shares of common stock, that may be outstanding from time to time. Upon liquidation, Preferred Stockholders will receive the liquidation preference plus an amount equal to any accumulated and unpaid dividends up to the date of payment before any distribution of assets is made.

 

On May 4, 2021, the Board of Directors issued 350,000 shares of Series E Convertible Preferred Stock for the subscription agreements dated March 1, 2021 at the value of $1.00 per share.

 

On May 12, 2021, the Board of Directors authorized the issuance of 200,000 shares of Series D Voting Preferred Stock with a value of $200,000.

 

On May 20, 2021, the Board of Directors authorized the issuance of 920,000 shares of Series C Convertible Preferred Stock with a value of $920,000.

 

On July 1, 2021, the Board of Directors authorized the issuance of 1,280,000 shares of Series E Convertible Preferred Stock with a value of $1,280,000. These shares were issued on July 14, 2021.

 

Common Stock

 

On February 12, 2020, FINRA approved a 1:50 reverse split of the Company’s common stock. As noted throughout this document, all common shares are stated as if the 1:50 reverse split had been completed as of the beginning of the year ended December 31, 2019. Following the approval, the Company’s stock began trading under the symbol “EWLLD”. Due to rounding issues for the reverse split, the Company issued 47,876 additional shares of common stock.

 

On February 14, 2020, the Company filed a Definitive Information Statement on Schedule 14C for the purpose of authorizing the increase in the number of authorized shares of Common Stock from one billion nine hundred million (1,900,000,000) shares of Common Stock to twenty billion (20,000,000,000) shares of Common Stock.

 

Debt Conversion Shares

 

2021

 

During the year ended December 31, 2021, there were no shares of common stock issued for debt conversion.

 

 

2020

 

During the year ended December 31, 2020, the Company issued a total of 16,849,013,669 shares of common stock per debt conversion of various convertible notes. The total of the debt conversion was for $1,607,317 of principal, $145,167 of accrued interest and $95,933 financing costs.

 

Consultant Issued Shares

 

2021

 

During the year ended December 31, 2021, the Company issued 2,001,666 shares of common stock for marketing and consulting services valued at $750.

 

2020

 

On January 30, 2020, the Company executed a 12-month advisory services agreement. The Company is to issue 20,000 shares of common stock monthly. The Company issued 80,000 shares of common stock with a value of $103. The remaining 160,000 shares of common stock with a value of $30 has been recorded in Shares to be Issued. In addition, the Company is to also pay the advisor a monthly fee of $2,500.

 

During the year ended December 31, 2020, the Company issued 588,332 shares of common stock for marketing and consulting services valued at $1,604.

 

Preferred Series E Conversion

 

2021

 

During the year ended December 31, 2021, the Company issued 1,643,200,000 shares of common stock for conversion of 164,320 shares of Preferred Series E for a value of $164,320.

 

2020

 

None

 

Stock Options

 

The following is a summary of the status of all Company’s stock options as of December 31, 2021 and changes during the periods ended on December 31, 2021 and 2020, respectively:

Summary of Stock Options Activity 

   Number   Weighted         
   of Stock   Average   Remaining   Intrinsic 
   Options   Exercise Price   Life (yrs.)   Value 
Outstanding on January 1, 2020   57,000   $40.00    1.1   $- 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Expired/cancelled   (30,000)   40.00    .14    - 
Outstanding on December 31, 2020   27,000   $40.00    .14   $- 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Expired/cancelled   (27,000)   -    -    - 
Outstanding on December 31, 2021   -    -    -   $- 
Options exercisable on December 31, 2021   -   $-    -   $- 

 

 

Warrants

 

The following is a summary of the status of the Company’s warrants as of December 31, 2021 and changes during the periods ended on December 31, 2021 and 2020, respectively:

Summary of Warrants Activity 

       Weighted         
   Number of   Average
Exercise		   Remaining   Intrinsic 
   Warrants   Price   Life (yrs.)   Value 
Outstanding on January 1, 2020   42,015   $12.00    1.9   $0.037 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Cancelled   (16,000)   11.04    -    - 
Outstanding on December 31, 2020   26,015   $12.50    1.2   $- 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Cancelled   (26,015)   -    -    - 
Outstanding on December 31, 2021   -   $-    -   $- 
Warrants exercisable on December 31, 2021   -   $-    -   $- 

 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments, Contingencies
 12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments, Contingencies

Note 9. Commitments, Contingencies

 

The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business. On August 12, 2020, a former consultant filed suit in the Superior Court of the State of California for Breach of Contract and non-payment of fees per said contract. At the time of the suit, the Company owed to the vendor for contractual fees the total of $24,339. On March 14, 2022, the Company accepted a Stipulation and Proposed Order for the payment of $38,000 to the former consultant with the first payment of $5,000 being due immediately and additional $5,000 payments to be paid every 60 days thereafter until the total of $38,000 is paid

 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue Recognition
 12 Months Ended
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]  
Revenue Recognition

Note 10. Revenue Recognition

 

Under ASC Topic 606, the Company recognizes revenue when the services have been completed. During the years ended December 31, 2021 and 2020, the Company recognized net revenue of $0 and $255,346, respectively.

 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Derivative Valuation
 12 Months Ended
Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Valuation

Note 11. Derivative Valuation

 

The Company evaluated the convertible debentures and associated warrants in accordance with ASC Topic 815, “Derivatives and Hedging,” and determined that the conversion feature of the convertible promissory notes was not afforded the exemption for conventional convertible instruments due to their variable conversion rates. The notes have no explicit limit on the number of shares issuable, so they did not meet the conditions set forth in current accounting standards for equity classification. In addition, the warrants have a Most Favoured Nations clause resulting in the exercise price of the warrants also not being fixed. Therefore, these have been characterized as derivative instruments. We elected to recognize the notes under ASU paragraph 815-15-25-4, whereby there would be a separation into a host contract and derivative instrument. We elected to initially and subsequently measure the notes and warrants in their entirety at fair value, with changes in fair value recognized in earnings.

 

The debt discount is amortized over the life of the note and recognized as interest expense. For the years ended December 31, 2021 and 2020, the Company amortized the debt discount of $0 and $619,799, respectively, to interest expense.

 

 

During the years ended December 31, 2021 and 2020, the Company had the following activity in the derivative liability account:

Schedule of Derivative Liability 

   Notes   Warrants   Total 
Derivative liability at January 1, 2020  $3,529,967   $7   $3,529,974 
Addition of new conversion   47,620    -    47,620 
Conversion of note derivatives   (5,094,792)   -    (5,094,792)
Change in fair value   5,442,306    (2)   5,442,304 
Derivative liability at December 31, 2020  $3,925,101   $5   $3,925,106 
Change in fair value   (2,478,093)   (5)   (2,478,098)
Derivative liability at December 31, 2020  $1,447,008   $-   $1,447,008 

 

For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follow:

Schedule of Assumptions Used Black Scholes Valuation of Derivative 

Stock price at valuation date  $.0002 
Risk free interest rate   .06%
Stock volatility factor   350.10%
Years to Maturity   .08 
Expected dividend yield   None 

 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Supplemental Cash Flow Information
 12 Months Ended
Dec. 31, 2021
Supplemental Cash Flow Elements [Abstract]  
Supplemental Cash Flow Information

Note 12. Supplemental Cash Flow Information

 

During the year ended December 31, 2021, the Company had the following cash and non-cash investing and financing activities:

 

  ●

Issued 350,000 shares of preferred series E convertible stock for $350,000 cash received.

 

  ● Issued 1,643,200,000 shares of common stock for conversion of 163,400 shares preferred series E convertible stock valued at $163,400
     
  ● Issued 2,001,666 shares of common stock valued at $750 for services

 

During the year ended December 31, 2020, the Company had the following non-cash investing and financing activities:

 

  ● Issued 16,849,013,669 shares of common stock for settlement of debt of $1,607,317, accrued interest of $145,167 and $95,933 of financing costs
     
  ● Issued 668,332 shares of common stock valued at $1,737 for services

 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Events
 12 Months Ended
Dec. 31, 2021
Subsequent Events [Abstract]  
Subsequent Events

Note 13. Subsequent Events

 

On March 14, 2022, the Company accepted a Stipulation and Proposed Order for the payment of $38,000 to the former consultant who had filed a lawsuit on August 12, 2020 in the Superior Court of the State of California for Breach of Contract and non-payment of fees per said contract. See Footnote 9
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying financial statements have been prepared to reflect the financial position, results of operations and cash flows of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.

 
Going Concern

Going Concern

 

For the year ended December 31, 2021, the Company had no revenues. The Company has an accumulated deficit of $40,069,797 and a working capital deficit of $4,360,124. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company complies with the accounting guidance under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820-10, Fair Value Measurements, as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance.

 

The guidance also establishes a fair value hierarchy for measurements of fair value as follows:

 

Level 1 – quoted market prices in active markets for identical assets or liabilities.

 

Level 2 – inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

 

As of December 31, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

   Total   Level 1   Level 2   Level 3 
Derivative Liability  $1,447,008   $-   $-   $1,447,008 
Total Liabilities measured at fair value  $1,447,008   $-   $-   $1,447,008 

 

As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

   Total   Level 1   Level 2   Level 3 
Derivative Liability  $3,925,106   $-   $-   $3,925,106 
Total Liabilities measured at fair value  $3,925,106   $-   $-   $3,925,106 

 
Revenue Recognition

Revenue Recognition

 

The Company recognizes revenue per ASC 606. Revenue is recognized when services have been completed.

 
Property and Equipment

Property and Equipment

 

Property and equipment are recorded at historical cost. Minor additions and renewals are expensed in the year incurred. Major additions and renewals are capitalized and depreciated over their estimated useful lives. Depreciation is recorded over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The estimated useful lives for significant property and equipment categories are as follows:

 

Furniture and Fixtures   5-7 Years
Computer Equipment   5-7 Years
Software   3 Years

 

The Company regularly evaluates whether events or circumstances have occurred that indicate the carrying value of long-lived assets may not be recoverable. If factors indicate the asset may not be recoverable, we compare the related undiscounted future net cash flows to the carrying value of the asset to determine if impairment exists. If the expected future net cash flows are less than the carrying value, an impairment charge is recognized based on the fair value of the asset. For the years ended December 31, 2021 and 2020, there was no impairment recognized.

 
Intangible Assets

Intangible Assets

 

The Company accounts for assets that are not physical in nature as intangible assets. Intangible assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are amortized on a straight-line basis over their economic or legal life, whichever is shorter. Intangible assets with indefinite useful lives are reassessed each year for impairment. If an impairment has occurred, then a loss is recognized. An impairment loss is determined by subtracting the asset’s fair value from the asset’s book/carrying value. For the years ended December 31, 2021 and 2020, there were no intangible assets.

 
Income Taxes

Income Taxes

 

The Company accounts for income taxes under FASB ASC 740-10-30. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component or all the benefits of deferred tax assets will not be realized.

 

 
Debt Issuance Costs

Debt Issuance Costs

 

The Company accounts for debt issuance costs in accordance with ASU 2015-03. This guidance requires direct and incremental costs associated with the issuance of debt instruments such as legal fees, printing costs and underwriters’ fees, among others, paid to parties other than creditors, are reported and presented as a reduction of debt on the consolidated balance sheets.

 

Debt issuance costs and premiums or discounts are amortized over the term of the respective financing arrangement using the effective interest method. Amortization of these amounts is included as a component of interest expense net, in the consolidated statements of operations.

 
Derivative Financial Instruments

Derivative Financial Instruments

 

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and then is revalued at each reporting date, with changes in fair value reported in the statement of operations. For stock based derivative financial instruments, Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.

 

Once determined, derivative liabilities are adjusted to reflect fair value at the end of each reporting period. Any increase or decrease in the fair value from inception is made quarterly and appears in results of operations as a change in fair market value of derivative liabilities.”

 
Cash and Cash Equivalents

Cash and Cash Equivalents

 

Cash and cash equivalents include all cash deposits and highly liquid financial instruments with an original maturity to the Company of three months or less. The Company maintains cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents.

 
Loss per Common Share

Loss per Common Share

 

The Company follows ASC Topic 260 to account for the loss per share. Basic loss per common share calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share calculations are determined by dividing net loss by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. As the Company has incurred losses for the periods ended December 31, 2021 and 2020, no dilutive shares are added into the loss per share calculations. While currently antidilutive, the following instruments could potentially dilute EPS in the future resulting in the following common stock equivalents:

   2021   2020 
         
Options   -    27,000 
Warrants   -    26,015 
Convertible Notes   12,357,170,485    24,728,206,940 
 Total   12,357,170,485    27,728,259,955 

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

The Company has reviewed all other recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.

 
Reclassifications

Reclassifications

 

Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Summary of Assets and Liabilities Fair Value on Recurring Basis

As of December 31, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

   Total   Level 1   Level 2   Level 3 
Derivative Liability  $1,447,008   $-   $-   $1,447,008 
Total Liabilities measured at fair value  $1,447,008   $-   $-   $1,447,008 

 

As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

   Total   Level 1   Level 2   Level 3 
Derivative Liability  $3,925,106   $-   $-   $3,925,106 
Total Liabilities measured at fair value  $3,925,106   $-   $-   $3,925,106 
Schedule of Estimated Useful Lives for Significant Property and Equipment

Property and equipment are recorded at historical cost. Minor additions and renewals are expensed in the year incurred. Major additions and renewals are capitalized and depreciated over their estimated useful lives. Depreciation is recorded over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The estimated useful lives for significant property and equipment categories are as follows:

 

Furniture and Fixtures   5-7 Years
Computer Equipment   5-7 Years
Software   3 Years
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

   2021   2020 
         
Options   -    27,000 
Warrants   -    26,015 
Convertible Notes   12,357,170,485    24,728,206,940 
 Total   12,357,170,485    27,728,259,955 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Schedule of Deferred Tax Liabilities

Net deferred tax liabilities consist of the following components as of December 31, 2021 and 2020:

   2021   2020 
         
Deferred tax assets:          
NOL carryover  $4,027,300   $4,133,200 
Accrued payroll   42,000    42,000 
Deferred tax liabilities          
Depreciation   400    300 
Valuation allowance   (4,069,700)   (4,175,500)
Net deferred tax asset  $-   $- 
Schedule of Pre-tax from Continuing Operations

The income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate to pre-tax income from continuing operations for the years ended December 31, 2021 and 2020 due to the following:

 

   2020   2019 
         
Book loss  $(94,900)  $(1,842,000)
Depreciation   -    700 
Contributed services   504,000    32,200 
Meals & entertainment   2,600    2,400 
Stock for prepaids   700    36,900 
Stock for consulting   200    400 
Amortization of debt discount   -    130,200 
Accrued payroll   -    (69,900)
Gain on debt extinguishment   -    (5,200)
Related party accruals   -    (123,100)
Loss on disposal   -    1,700 
Derivative (Gain)/Loss   (520,400)   114,260 
Valuation allowance   107,800    693,100 
Income tax expense benefit  $-   $- 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Equity Transactions (Tables)
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Summary of Stock Options Activity

The following is a summary of the status of all Company’s stock options as of December 31, 2021 and changes during the periods ended on December 31, 2021 and 2020, respectively:

Summary of Stock Options Activity 

   Number   Weighted         
   of Stock   Average   Remaining   Intrinsic 
   Options   Exercise Price   Life (yrs.)   Value 
Outstanding on January 1, 2020   57,000   $40.00    1.1   $- 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Expired/cancelled   (30,000)   40.00    .14    - 
Outstanding on December 31, 2020   27,000   $40.00    .14   $- 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Expired/cancelled   (27,000)   -    -    - 
Outstanding on December 31, 2021   -    -    -   $- 
Options exercisable on December 31, 2021   -   $-    -   $- 
Summary of Warrants Activity

The following is a summary of the status of the Company’s warrants as of December 31, 2021 and changes during the periods ended on December 31, 2021 and 2020, respectively:

Summary of Warrants Activity 

       Weighted         
   Number of   Average
Exercise		   Remaining   Intrinsic 
   Warrants   Price   Life (yrs.)   Value 
Outstanding on January 1, 2020   42,015   $12.00    1.9   $0.037 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Cancelled   (16,000)   11.04    -    - 
Outstanding on December 31, 2020   26,015   $12.50    1.2   $- 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Cancelled   (26,015)   -    -    - 
Outstanding on December 31, 2021   -   $-    -   $- 
Warrants exercisable on December 31, 2021   -   $-    -   $- 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Derivative Valuation (Tables)
 12 Months Ended
Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Derivative Liability

During the years ended December 31, 2021 and 2020, the Company had the following activity in the derivative liability account:

Schedule of Derivative Liability 

   Notes   Warrants   Total 
Derivative liability at January 1, 2020  $3,529,967   $7   $3,529,974 
Addition of new conversion   47,620    -    47,620 
Conversion of note derivatives   (5,094,792)   -    (5,094,792)
Change in fair value   5,442,306    (2)   5,442,304 
Derivative liability at December 31, 2020  $3,925,101   $5   $3,925,106 
Change in fair value   (2,478,093)   (5)   (2,478,098)
Derivative liability at December 31, 2020  $1,447,008   $-   $1,447,008 
Schedule of Assumptions Used Black Scholes Valuation of Derivative

For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follow:

Schedule of Assumptions Used Black Scholes Valuation of Derivative 

Stock price at valuation date  $.0002 
Risk free interest rate   .06%
Stock volatility factor   350.10%
Years to Maturity   .08 
Expected dividend yield   None 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.1
The Company (Details Narrative) - USD ($)
 12 Months Ended
Apr. 19, 2021
Sep. 15, 2020
Dec. 31, 2021
Dec. 31, 2020
Apr. 18, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Professional Fees     $ 2,130,850 $ 1,180,583  
Common stock par value $ 0.0001   $ 0.001 $ 0.001 $ 0.001
Preferred stock par value $ 0.0001       $ 0.001
Reverse Stock Split     implement the 1:2,000 reverse split of our Common Stock and the shares underlying conversion of the Company’s securities convertible into Common Stock together with the shares reserved for such conversions, on a one for two thousand (1:2,000) basis (“Reverse Split”). The Name Change, Par Value Change and Reverse Split are sometimes referred to as the “Corporate Actions”, which Corporate Actions must be approved by FINRA. The application for approval of these actions to FINRA has not yet been filed    
Description of change in par value Common Stock on the OTC Markets had been less than the $0.001 par value of its Common Stock. As a result, the Company had not been able to raise capital by the issuance of shares of Common Stock at less than the $0.001 par value and, in addition, the Company could not raise capital through the issuance of shares of convertible Preferred Stock having a conversion price of less than the $0.001 par value of the Common Stock.        
Services Agreement [Member] | Bistromatics Inc. [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Equity Method Investment, Ownership Percentage   15.00%      
Professional Fees   $ 748,832      
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Assets and Liabilities Fair Value on Recurring Basis (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]    
Derivative Liability $ 1,447,008 $ 3,925,106
Total Liabilities measured at fair value 1,447,008 3,925,106
Fair Value, Inputs, Level 1 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Derivative Liability
Total Liabilities measured at fair value
Fair Value, Inputs, Level 2 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Derivative Liability
Total Liabilities measured at fair value
Fair Value, Inputs, Level 3 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Derivative Liability 1,447,008 3,925,106
Total Liabilities measured at fair value $ 1,447,008 $ 3,925,106
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Estimated Useful Lives for Significant Property and Equipment (Details)
 12 Months Ended
Dec. 31, 2021
Furniture and Fixtures [Member] | Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 5 years
Furniture and Fixtures [Member] | Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 7 years
Computer Equipment [Member] | Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 5 years
Computer Equipment [Member] | Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 7 years
Software Development [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 3 years
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive potential earnings per share, amount 12,357,170,485 27,728,259,955
Share-based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive potential earnings per share, amount 27,000
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive potential earnings per share, amount 26,015
Convertible Debt Securities [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive potential earnings per share, amount 12,357,170,485 24,728,206,940
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Accounting Policies [Abstract]    
Accumulated loss $ 40,069,797 $ 39,618,090
Working capital deficit $ 4,360,124  
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Abstract]    
Property, Plant and Equipment, Gross $ 6,976 $ 6,976
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment 4,589 3,188
Impairment of Long-Lived Assets to be Disposed of   11,498
Transferred computers and equipment   9,208
Depreciation $ 1,402 $ 4,869
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Intangible Assets (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization of Intangible Assets $ 0 $ 2,000
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Deferred Tax Liabilities (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
NOL carryover $ 4,027,300 $ 4,133,200
Accrued payroll 42,000 42,000
Depreciation 400 300
Valuation allowance (4,069,700) (4,175,500)
Net deferred tax asset
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Pre-tax from Continuing Operations (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Book loss $ (94,900) $ (1,842,000)
Depreciation 700
Contributed services 504,000 32,200
Meals & entertainment 2,600 2,400
Stock for prepaids 700 36,900
Stock for consulting 200 400
Amortization of debt discount 130,200
Accrued payroll (69,900)
Gain on debt extinguishment (5,200)
Related party accruals (123,100)
Loss on disposal 1,700
Derivative (Gain)/Loss (520,400) 114,260
Valuation allowance 107,800 693,100
Income tax expense benefit
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Details Narrative)
 12 Months Ended
Dec. 31, 2021
USD ($)
Income Tax Disclosure [Abstract]  
Operating Loss Carryforwards $ 19,177,000
Income taxable description 2022 through 2041
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions (Details Narrative) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]      
Accrued director's fees $ 221,107 $ 221,107  
Accrued executive compensation 200,000 200,000  
Settlement and compromise agreement [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]      
Accrued director's fees     $ 100,000
Officers and Directors [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]      
Due to related parties, current $ 33,701 $ 11,655  
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Convertible Notes Payable (Details Narrative)
 1 Months Ended
Mar. 31, 2020
USD ($)
Trading
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Short-term Debt [Line Items]      
Accrued interest     $ 145,167
Convertible Notes Payable [Member]      
Short-term Debt [Line Items]      
Accrued interest   $ 258,778  
12% Convertible Promissory Note [Member]      
Short-term Debt [Line Items]      
Accrued interest     2,880
Debt interest stated rate 12.00%    
Debt Instrument, principal amount $ 52,800    
Debt instrument maturity date Jan. 15, 2021    
Original issue discount $ 4,800    
Transaction costs $ 3,000    
Convertible debt percentage 70.00%    
Number of trading days | Trading 10    
2019 Convertible Notes [Member]      
Short-term Debt [Line Items]      
Accrued interest     $ 330,871
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Stock Options Activity (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Equity [Abstract]    
Number of Stock Options Outstanding, Beginning Balance 27,000 57,000
Weighted Average Exercise Price Outstanding, Beginning Balance $ 40.00 $ 40.00
Remaining Life (yrs) Outstanding, Beginning Balance 1 month 20 days 1 year 1 month 6 days
Intrinsic Value Outstanding, Beginning Balance
Number of Stock Options Outstanding, Granted
Weighted Average Exercise Price, Granted
Number of Stock Options Outstanding, Exercised
Weighted Average Exercise Price, Exercised
Number of Stock Options Outstanding, Cancelled (27,000) (30,000)
Weighted Average Exercise Price Outstanding,Ending Balance $ 40.00
Remaining Life (yrs) expired/ cancelled   1 month 20 days
Number of Warrants, Outstanding, Ending Balance 26,015
Remaining Life (yrs) Outstanding, Ending Balance  
Intrinsic Value Options exercisable, Ending Balance
Number of Stock Options exercisable, Ending Balance  
Weighted Average Exercise Price Options exercisable, Ending Balance  
Remaining Life (yrs) Outstanding, Ending Balance  
Intrinsic Value Options exercisable, Ending Balance  
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Warrants Activity (Details) - $ / shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Equity [Abstract]    
Number of Warrants, Outstanding, Beginning Balance 26,015 42,015
Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance $ 12.50 $ 12.00
Remaining Life (yrs.) Warrants Outstanding, Beginning Balance 1 year 2 months 12 days 1 year 10 months 24 days
Intrinsic Value, Warrants Outstanding, Beginning Balance $ 0.037
Number of Warrants, Granted
Weighted Average Exercise Price, Granted
Number of Warrants, Exercised
Weighted Average Exercise Price, Exercised
Number of Warrants, Cancelled (26,015) (16,000)
Weighted Average Exercise Price, Cancelled $ 11.04
Number of Warrants, Outstanding, Ending Balance 26,015
Weighted Average Exercise Price, Warrants Outstanding, Ending Balance $ 12.50
Remaining Life (yrs.) Warrants Outstanding, Ending Balance  
Intrinsic Value, Warrants Outstanding, Ending Balance
Number of Warrants, exercisable, Ending balance  
Weighted Average Exercise Price Exercisable, Ending Balance  
Remaining Life (yrs.) Warrants Exercisable, Ending Balance  
Intrinsic Value, Warrants Outstanding, Exercisable  
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Equity Transactions (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
May 04, 2021
Feb. 12, 2020
Jan. 30, 2020
Jan. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Jul. 01, 2021
May 20, 2021
May 12, 2021
Apr. 30, 2021
Apr. 19, 2021
Apr. 18, 2021
Feb. 14, 2020
Class of Stock [Line Items]                            
Preferred stock par value                       $ 0.0001 $ 0.001  
Deferred compensation         $ 3,000,000                  
Preferred Stock, Voting Rights         The term “equity securities” shall not include convertible debt securities. The Holders of the Series D Preferred Stock have the right, on all matters subject to the vote of the capital stock of the Corporation, to have the collective vote equal to 70% of the total of all voting capital stock of the Corporation, notwithstanding the number of shares of voting capital stock, including shares of common stock, that may be outstanding from time to time                  
Shares issued during period shares     20,000                      
Reverse stock split, description         implement the 1:2,000 reverse split of our Common Stock and the shares underlying conversion of the Company’s securities convertible into Common Stock together with the shares reserved for such conversions, on a one for two thousand (1:2,000) basis (“Reverse Split”). The Name Change, Par Value Change and Reverse Split are sometimes referred to as the “Corporate Actions”, which Corporate Actions must be approved by FINRA. The application for approval of these actions to FINRA has not yet been filed                  
Common stock, shares authorized         20,000,000,000 20,000,000,000                
Shares issued for debt conversion,shares           16,849,013,669                
Financing cost           $ 95,933                
Shares issued during period for services,shares         2,001,666                  
Shares issued during period for services, value         $ 750 1,737                
Stock issued during the period, value         350,000                  
Monthly base fee           $ 2,500                
Shares issued during period for conversion, value                          
12- month Advisory Services Agreement [Member]                            
Class of Stock [Line Items]                            
Shares issued during period shares       80,000                    
Stock issued during the period, value       $ 103                    
Number of sharesto be issued           160,000                
Number of sharesto be issued, value           30                
Convertible Notes [Member]                            
Class of Stock [Line Items]                            
Shares issued for debt conversion,shares           16,849,013,669                
Principal amount           $ 1,607,317                
Accrued interest           145,167                
Financing cost           $ 95,933                
Preferred Stock [Member]                            
Class of Stock [Line Items]                            
Conversion of stock, description         The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of 40 shares per preferred share at the common share value on the date of issuance                  
Common Stock [Member]                            
Class of Stock [Line Items]                            
Common stock, shares authorized         20,000,000,000                 1,900,000,000
Shares issued during period for services,shares         2,001,666 668,332                
Shares issued during period for services, value         $ 2,002 $ 668                
Stock issued during the period, value                          
Conversion of Stock, Shares Converted         1,643,200,000                  
Shares issued during period for conversion, value         $ 1,643,200                  
Officers, Directors and Consultants [Member]                            
Class of Stock [Line Items]                            
Preferred stock, shares authorized             1,000,000              
Board of Directors [Member] | Common Stock [Member]                            
Class of Stock [Line Items]                            
Shares issued during period shares             47,876              
Reverse stock split, description   1:50 reverse split         1:50 reverse split              
Consultant [Member]                            
Class of Stock [Line Items]                            
Shares issued during period for services,shares           588,332                
Shares issued during period for services, value           $ 1,604                
Series A Preferred Stock [Member]                            
Class of Stock [Line Items]                            
Preferred stock, shares authorized         20,000,000 20,000,000                
Preferred stock par value         $ 0.001 $ 0.001                
Preferred stock value         $ 697 $ 697                
Series A Preferred Stock [Member] | Preferred Stock [Member]                            
Class of Stock [Line Items]                            
Shares issued during period for services, value                        
Stock issued during the period, value                          
Shares issued during period for conversion, value                          
Series C Preferred Stock [Member]                            
Class of Stock [Line Items]                            
Preferred stock, shares authorized         1,000,000 1,000,000                
Preferred stock par value         $ 0.0001 $ 0.0001                
Preferred stock value         $ 92                
Series C Preferred Stock [Member] | Preferred Stock [Member]                            
Class of Stock [Line Items]                            
Shares issued during period for services, value                        
Stock issued during the period, value                          
Shares issued during period for conversion, value                          
Series C Preferred Stock [Member] | Board of Directors [Member]                            
Class of Stock [Line Items]                            
Preferred stock, shares authorized                     1,000,000      
Preferred stock par value                     $ 0.0001      
Series D Preferred Stock [Member]                            
Class of Stock [Line Items]                            
Preferred stock, shares authorized         200,000 200,000                
Preferred stock par value         $ 0.0001 $ 0.0001                
Preferred stock value         $ 20                
Series D Preferred Stock [Member] | Preferred Stock [Member]                            
Class of Stock [Line Items]                            
Shares issued during period for services, value                        
Stock issued during the period, value                          
Shares issued during period for conversion, value                          
Series D Preferred Stock [Member] | Board of Directors [Member]                            
Class of Stock [Line Items]                            
Preferred stock, shares authorized                     200,000      
Preferred stock par value                     $ 0.0001      
Series E Preferred Stock [Member]                            
Class of Stock [Line Items]                            
Preferred stock, shares authorized         2,500,000 2,500,000                
Preferred stock par value         $ 0.0001 $ 0.0001                
Preferred stock value         $ 147                
Series E Preferred Stock [Member] | Preferred Stock [Member]                            
Class of Stock [Line Items]                            
Shares issued during period shares         350,000                  
Shares issued during period for services, value                        
Stock issued during the period, value         $ 35                  
Conversion of Stock, Shares Converted         (164,320)                  
Shares issued during period for conversion, value         $ (16)                  
Series E Preferred Stock [Member] | Board of Directors [Member]                            
Class of Stock [Line Items]                            
Preferred stock, shares authorized                     2,500,000      
Preferred stock par value                     $ 0.0001      
Offering price per share                     $ 1.00      
Series E Convertible Preferred Stock [Member]                            
Class of Stock [Line Items]                            
Preferred stock, shares authorized               1,280,000            
Offering price per share $ 1.00                          
Shares issued during period shares 350,000                          
Preferred stock value               $ 1,280,000            
Shares issued date               Jul. 14, 2021            
Series D Voting Preferred Stock [Member]                            
Class of Stock [Line Items]                            
Preferred stock, shares authorized                   200,000        
Preferred stock value                   $ 200,000        
Series C Convertible Preferred Stock [Member]                            
Class of Stock [Line Items]                            
Preferred stock, shares authorized                 920,000          
Preferred stock value                 $ 920,000          
Preferred Series E Conversion [Member]                            
Class of Stock [Line Items]                            
Shares issued during period shares         1,643,200,000                  
Conversion of Stock, Shares Converted         164,320                  
Shares issued during period for conversion, value         $ 164,320                  
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments, Contingencies (Details Narrative) - USD ($)
Mar. 14, 2022
Aug. 12, 2020
Former Consultant [Member] | Subsequent Event [Member]    
Payment of plaintiffs $ 38,000  
First Payment [Member] | Subsequent Event [Member]    
Payment of plaintiffs 5,000  
Every Sixty Days Thereafter [Member] | Subsequent Event [Member]    
Payment of plaintiffs $ 5,000  
Vendor [Member]    
Contractual Fees   $ 24,339
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue Recognition (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Revenue from Contract with Customer [Abstract]    
Revenue $ 0 $ 255,346
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Derivative Liability (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Derivative Instruments, Gain (Loss) [Line Items]    
Derivative liability, beginning balance $ 3,925,106 $ 3,529,974
Addition of new conversion   47,620
Conversion of note derivatives   (5,094,792)
Change in fair value (2,478,098) 5,442,304
Derivative liability, ending balance 1,447,008 3,925,106
Notes [Member]    
Derivative Instruments, Gain (Loss) [Line Items]    
Derivative liability, beginning balance 3,925,101 3,529,967
Addition of new conversion   47,620
Conversion of note derivatives   (5,094,792)
Change in fair value (2,478,093) 5,442,306
Derivative liability, ending balance 1,447,008 3,925,101
Warrants Derivative [Member]    
Derivative Instruments, Gain (Loss) [Line Items]    
Derivative liability, beginning balance 5 7
Addition of new conversion  
Conversion of note derivatives  
Change in fair value (5) (2)
Derivative liability, ending balance $ 5
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details) - Derivative Liability [Member]
 12 Months Ended
Dec. 31, 2021
$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Stock price at valuation date $ 0.0002
Derivative liability, term 29 days
Measurement Input, Risk Free Interest Rate [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Derivative liability, fair value measurement input, percentage 0.0006
Measurement Input, Price Volatility [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Derivative liability, fair value measurement input, percentage 3.5010
Measurement Input, Expected Dividend Rate [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Derivative liability, fair value measurement input, percentage 0
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.22.1
Derivative Valuation (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Amortized of debt discount $ 795,591
Derivative Liability [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Amortized of debt discount $ 0 $ 619,799
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.22.1
Supplemental Cash Flow Information (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dividends Payable [Line Items]    
Stock issued during the period for settlement of debt, shares   16,849,013,669
Stock issued during the period for settlement of debt,value   $ 1,607,317
Accrued interest   145,167
Financing costs   $ 95,933
Common Stock [Member]    
Dividends Payable [Line Items]    
Conversion of stock, shares converted 1,643,200,000  
Shares issued during period for services, shares 2,001,666 668,332
Shares issued during period for services, value $ 750 $ 1,737
Series E Preferred Stock [Member]    
Dividends Payable [Line Items]    
[custom:StockIssuedDuringPeriodSharesNewIssue] 350,000  
[custom:StockIssuedDuringPeriodValueNewIssue] $ 350,000  
[custom:ConversionOfStockShareConverted1] 163,400  
Series E Preferred Stock [Member] | Common Stock [Member]    
Dividends Payable [Line Items]    
[custom:ConversionsOfStockAmountConverted1] $ 163,400  
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Events (Details Narrative)
Mar. 14, 2022
USD ($)
Former Consultant [Member] | Subsequent Event [Member]  
Subsequent Event [Line Items]  
Payment of plaintiffs $ 38,000
XML 58 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001550020 2021-01-01 2021-12-31 0001550020 2021-06-30 0001550020 2022-03-31 0001550020 2021-12-31 0001550020 2020-12-31 0001550020 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001550020 us-gaap:SeriesAPreferredStockMember 2020-12-31 0001550020 us-gaap:SeriesCPreferredStockMember 2021-12-31 0001550020 us-gaap:SeriesCPreferredStockMember 2020-12-31 0001550020 us-gaap:SeriesDPreferredStockMember 2021-12-31 0001550020 us-gaap:SeriesDPreferredStockMember 2020-12-31 0001550020 us-gaap:SeriesEPreferredStockMember 2021-12-31 0001550020 us-gaap:SeriesEPreferredStockMember 2020-12-31 0001550020 2020-01-01 2020-12-31 0001550020 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001550020 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001550020 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001550020 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001550020 us-gaap:CommonStockMember 2019-12-31 0001550020 EWLL:SharesToBeIssuedMember 2019-12-31 0001550020 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001550020 us-gaap:RetainedEarningsMember 2019-12-31 0001550020 2019-12-31 0001550020 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001550020 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001550020 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001550020 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001550020 us-gaap:CommonStockMember 2020-12-31 0001550020 EWLL:SharesToBeIssuedMember 2020-12-31 0001550020 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001550020 us-gaap:RetainedEarningsMember 2020-12-31 0001550020 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001550020 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001550020 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001550020 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001550020 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001550020 EWLL:SharesToBeIssuedMember 2020-01-01 2020-12-31 0001550020 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001550020 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001550020 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001550020 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001550020 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001550020 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001550020 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001550020 EWLL:SharesToBeIssuedMember 2021-01-01 2021-12-31 0001550020 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001550020 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001550020 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001550020 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001550020 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001550020 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001550020 us-gaap:CommonStockMember 2021-12-31 0001550020 EWLL:SharesToBeIssuedMember 2021-12-31 0001550020 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001550020 us-gaap:RetainedEarningsMember 2021-12-31 0001550020 EWLL:ServicesAgreementMember EWLL:BistromaticsIncMember 2020-09-15 0001550020 EWLL:ServicesAgreementMember EWLL:BistromaticsIncMember 2020-09-14 2020-09-15 0001550020 2021-04-18 0001550020 2021-04-19 0001550020 2021-04-18 2021-04-19 0001550020 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001550020 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001550020 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001550020 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001550020 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001550020 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001550020 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-12-31 0001550020 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-12-31 0001550020 srt:MinimumMember us-gaap:ComputerEquipmentMember 2021-01-01 2021-12-31 0001550020 srt:MaximumMember us-gaap:ComputerEquipmentMember 2021-01-01 2021-12-31 0001550020 us-gaap:SoftwareDevelopmentMember 2021-01-01 2021-12-31 0001550020 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001550020 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001550020 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001550020 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001550020 us-gaap:ConvertibleDebtSecuritiesMember 2021-01-01 2021-12-31 0001550020 us-gaap:ConvertibleDebtSecuritiesMember 2020-01-01 2020-12-31 0001550020 EWLL:OfficersAndDirectorsMember 2021-12-31 0001550020 EWLL:OfficersAndDirectorsMember 2020-12-31 0001550020 EWLL:SettlementAndCompromiseAgreementMember 2020-09-30 0001550020 us-gaap:ConvertibleNotesPayableMember 2021-12-31 0001550020 EWLL:TwelvePercentConvertiblePromissoryNoteMember 2020-03-31 0001550020 EWLL:TwelvePercentConvertiblePromissoryNoteMember 2020-03-01 2020-03-31 0001550020 EWLL:TwelvePercentConvertiblePromissoryNoteMember 2020-12-31 0001550020 EWLL:TwoThousandNineteenConvertibleNotesMember 2020-12-31 0001550020 EWLL:OfficersDirectorsAndConsultantsMember 2019-12-31 0001550020 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001550020 EWLL:BoardOfDirectorsMember us-gaap:SeriesCPreferredStockMember 2021-04-30 0001550020 EWLL:BoardOfDirectorsMember us-gaap:SeriesDPreferredStockMember 2021-04-30 0001550020 EWLL:BoardOfDirectorsMember us-gaap:SeriesEPreferredStockMember 2021-04-30 0001550020 EWLL:SeriesEConvertiblePreferredStockMember 2021-05-03 2021-05-04 0001550020 EWLL:SeriesEConvertiblePreferredStockMember 2021-05-04 0001550020 EWLL:SeriesDVotingPreferredStockMember 2021-05-12 0001550020 EWLL:SeriesCConvertiblePreferredStockMember 2021-05-20 0001550020 EWLL:SeriesEConvertiblePreferredStockMember 2021-07-01 0001550020 EWLL:BoardOfDirectorsMember us-gaap:CommonStockMember 2020-02-10 2020-02-12 0001550020 EWLL:BoardOfDirectorsMember us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001550020 us-gaap:CommonStockMember 2020-02-14 0001550020 EWLL:ConvertibleNotesMember 2020-01-01 2020-12-31 0001550020 EWLL:ConvertibleNotesMember 2020-12-31 0001550020 2020-01-29 2020-01-30 0001550020 EWLL:TwelveMonthAdvisoryServicesAgreementMember 2020-01-01 2020-01-31 0001550020 EWLL:TwelveMonthAdvisoryServicesAgreementMember 2020-01-01 2020-12-31 0001550020 EWLL:ConsultantMember 2020-01-01 2020-12-31 0001550020 EWLL:PreferredSeriesEConversionMember 2021-01-01 2021-12-31 0001550020 EWLL:VendorMember 2020-08-11 2020-08-12 0001550020 EWLL:FormerConsultantMember us-gaap:SubsequentEventMember 2022-03-13 2022-03-14 0001550020 EWLL:FirstPaymentMember us-gaap:SubsequentEventMember 2022-03-13 2022-03-14 0001550020 EWLL:EverySixtyDaysThereafterMember us-gaap:SubsequentEventMember 2022-03-13 2022-03-14 0001550020 EWLL:DerivativeLiabilityMember 2021-01-01 2021-12-31 0001550020 EWLL:DerivativeLiabilityMember 2020-01-01 2020-12-31 0001550020 EWLL:NotesMember 2019-12-31 0001550020 EWLL:WarrantsDerivativeMember 2019-12-31 0001550020 EWLL:NotesMember 2020-01-01 2020-12-31 0001550020 EWLL:WarrantsDerivativeMember 2020-01-01 2020-12-31 0001550020 EWLL:NotesMember 2020-12-31 0001550020 EWLL:WarrantsDerivativeMember 2020-12-31 0001550020 EWLL:NotesMember 2021-01-01 2021-12-31 0001550020 EWLL:WarrantsDerivativeMember 2021-01-01 2021-12-31 0001550020 EWLL:NotesMember 2021-12-31 0001550020 EWLL:WarrantsDerivativeMember 2021-12-31 0001550020 EWLL:DerivativeLiabilityMember 2021-12-31 0001550020 EWLL:DerivativeLiabilityMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001550020 EWLL:DerivativeLiabilityMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001550020 EWLL:DerivativeLiabilityMember us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001550020 us-gaap:SeriesEPreferredStockMember 2021-01-01 2021-12-31 0001550020 us-gaap:SeriesEPreferredStockMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 iso4217:USD shares iso4217:USD shares pure EWLL:Trading 0001550020 false FY 10-K true 2021-12-31 --12-31 2021 false 000-55203 eWELLNESS HEALTHCARE CORPORATION NV 90-1073143 1125 S Federal Hwy #464 Fort Lauderdale FL 33316 (855) 470-1700 No No Yes Yes Non-accelerated Filer true false false 10624610 18507683627 None 457 Haynie & Company Salt Lake City, Utah 11177 1109 3235 11177 4344 2387 3788 13564 8132 1223278 892164 144471 292762 200000 200000 1662 1354882 1354882 1447008 3925106 4371301 6664914 4371301 6664914 20000000 20000000 0.001 0.001 696667 696667 696667 696667 697 697 1000000 1000000 0.0001 0.0001 920000 920000 0 0 92 200000 200000 0.0001 0.0001 200000 200000 0 0 20 2500000 2500000 0.0001 0.0001 1465680 1465680 0 0 147 20000000000 20000000000 0.001 0.001 18507683627 18507683627 16862481961 16862481961 18507684 16862482 263 17203420 16097866 -40069797 -39618090 -4357737 -6656782 13564 8132 266570 11224 255346 260000 767639 280177 699440 2130850 1180583 2671027 2647662 -2671027 -2392316 1 24738 2478098 -5441140 -8205 258778 954605 -451707 -8771527 -451707 -8771527 -0.00 -0.00 17579528194 7849264946 250000 250 12752084 12752 150 23927374 -30846563 -6906037 153518 153518 446667 447 1339553 1340000 16849013669 16849014 -15000597 1848417 668332 668 113 956 1737 47876 48 -48 688595 688595 4988515 4988515 -8771527 -8771527 696667 697 16862481961 16862482 263 16097866 -39618090 -6656782 696667 697 16862481961 16862482 263 16097866 -39618090 -6656782 920000 92 200000 20 1280000 128 2399760 2400000 350000 35 349965 350000 -164320 -16 1643200000 1643200 -1643183 2001666 2002 -263 -988 750 -451707 -451707 696667 697 920000 92 200000 20 1465680 147 18507683627 18507684 17203420 -40069797 -4357737 696667 697 920000 92 200000 20 1465680 147 18507683627 18507684 17203420 -40069797 -4357737 -451707 -8771527 1402 6869 153518 1120000 503588 1280750 1737 95933 1556 795591 2478098 -5441140 -8205 3235 -21887 -66848 331115 919981 160460 -148291 29995 460188 -341594 -284613 52800 7800 1662 350000 351662 45000 10068 -239613 1109 240722 11177 1109 1848417 <p id="xdx_808_eus-gaap--NatureOfOperations_zxpY9egaBS47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1. <span id="xdx_82C_zR6SbmY7XMpf">The Company </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">The Company, Background and Nature of Business</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">eWellness Healthcare Corporation (the “eWellness”, “Company”, “we”, “us”, “our”) was incorporated in the State of Nevada on April 7, 2011.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">eWellness Healthcare Corporation is the first physical therapy telehealth company to offer real-time distance monitored assessments and treatments. On September 15, 2020, the Company and Bistromatics signed an agreement that transferred all worldwide marketing and Intellectual Property Rights or claims to the Company’s Phzio, Phzio TeleRehab and MSK 360 platforms to Bistromatics in return for a <span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20200915__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember__dei--LegalEntityAxis__custom--BistromaticsIncMember_ze5OVKnI7rsa" title="Equity Method Investment, Ownership Percentage">15</span>% ownership in Bistromatics. This agreement eliminated all past due professional fees of $<span id="xdx_90F_eus-gaap--ProfessionalFees_pp0p0_c20200914__20200915__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember__dei--LegalEntityAxis__custom--BistromaticsIncMember_z6kaG0N1aXph" title="Professional Fees">748,832</span>. The transfer of rights was completed on December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the last quarter of 2020 and the first quarter of 2021, the Company’s Board of Directors and management determined that while it would continue its efforts and resources involving physical therapy and telemedicine, it would also pursue other health-related business opportunities. With the Company’s announced plan to diversify its health-related business beyond its telemedicine operations, which telemedicine operations will continue, the Company on May 18, 2021, entered into an Agreement and Plan of Merger by and between the Company, EWLL Acquisition (a new wholly owned subsidiary of the Company) and a recently formed private Nevada company controlled by a third party, American Health Protection, Inc.(“AMHP”). pursuant to which AMHP merged with EWLL Acquisition, with AMHP being the surviving entity and becoming a wholly owned subsidiary of the Company. On July 14, 2021, the Company filed the requisite Articles of Merger with the State of Nevada and, as a result, AMHP became a wholly owned subsidiary of the Company and EWLL Acquisition ceased to exist.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 19, 2021, the Company filed a DEF 14C to disclose to the stockholders the ratification and approval by Joint Written Consent, based upon the unanimous approval by our Board of Directors and the consent of the Majority Consenting Stockholders, of the corporate actions to file an amendment to its Amended and Restated Articles of Incorporation to: (i) change the name of the Company from eWellness Healthcare Corporation to American Health Protection Corp. (“Name Change”); (ii) change the par value of the Company’s common stock and preferred stock from $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20210418_zgog05YNcuvd" title="Common stock par value"><span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210418_zVJXQKS47p4l" title="Preferred stock par value">0.001</span></span> per share to $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20210419_zEsIhdW46Szf" title="Common stock par value"><span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210419_zxhQ9R9IdApg" title="Preferred stock par value">0.0001</span></span> per share (“Par Value Change”); and (iii) <span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20210101__20211231_zH9oNbJjkkU6" title="Reverse Stock Split">implement the 1:2,000 reverse split of our Common Stock and the shares underlying conversion of the Company’s securities convertible into Common Stock together with the shares reserved for such conversions, on a one for two thousand (1:2,000) basis (“Reverse Split”). The Name Change, Par Value Change and Reverse Split are sometimes referred to as the “Corporate Actions”, which Corporate Actions must be approved by FINRA. The application for approval of these actions to FINRA has not yet been filed</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As stated in the DEF 14C, the Name Change from eWellness Healthcare Corporation to American Health Protection Corp. was to reflect the Company’s plan to diversify its business operations from the telemedicine business and the proprietary PHZIO System to include other health related services to its primary target market focused on small and mid-sized corporate clients. The Par Value Change of the Company’s Common Stock and Preferred Stock from $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20210418_z32IcWGIho81" title="Common stock par value"><span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210418_zeT77zyPKW" title="Preferred stock par value">0.001</span></span> per share to $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20210419_zTW3nUQj2qXh" title="Common stock par value"><span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210419_z3Uno1XBHsF" title="Preferred stock par value">0.0001</span></span> per share was the result that for more than the past six months (preceding the filing of the DEF 14C), the price of its <span id="xdx_903_ecustom--DescriptionOfChangesInParValue_c20210418__20210419_zwfIA2HjLHF8" title="Description of change in par value">Common Stock on the OTC Markets had been less than the $0.001 par value of its Common Stock. As a result, the Company had not been able to raise capital by the issuance of shares of Common Stock at less than the $0.001 par value and, in addition, the Company could not raise capital through the issuance of shares of convertible Preferred Stock having a conversion price of less than the $0.001 par value of the Common Stock.</span> Lastly, the rationale for the Reverse Split of the outstanding shares of Common Stock on a one for two thousand (1:2,000) basis was needed because the outstanding shares and shares reserved for convertible debt conversion resulted in no shares being available for capital raise purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.15 748832 0.001 0.001 0.0001 0.0001 implement the 1:2,000 reverse split of our Common Stock and the shares underlying conversion of the Company’s securities convertible into Common Stock together with the shares reserved for such conversions, on a one for two thousand (1:2,000) basis (“Reverse Split”). The Name Change, Par Value Change and Reverse Split are sometimes referred to as the “Corporate Actions”, which Corporate Actions must be approved by FINRA. The application for approval of these actions to FINRA has not yet been filed 0.001 0.001 0.0001 0.0001 Common Stock on the OTC Markets had been less than the $0.001 par value of its Common Stock. As a result, the Company had not been able to raise capital by the issuance of shares of Common Stock at less than the $0.001 par value and, in addition, the Company could not raise capital through the issuance of shares of convertible Preferred Stock having a conversion price of less than the $0.001 par value of the Common Stock. <p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zpRa2Q6TIvl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2. <span id="xdx_82C_z9wVbwJFtfN">Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zax85YB2A3b8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zjbFcyzPe4bd">Basis of Presentation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared to reflect the financial position, results of operations and cash flows of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--UseOfEstimates_zw6S7So4kCsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zCdV49v6wPhg">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_ecustom--GoingConcernPolicyTextBlock_zdQuqdPpWOzh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Going Concern</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2021, the Company had no revenues. The Company has an accumulated deficit of $<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20211231_zQZs71ph2FOc" title="Accumulated loss">40,069,797</span> and a working capital deficit of $<span id="xdx_900_ecustom--WorkingCapitalDeficit_iNI_pp0p0_di_c20211231_zFz5ZYa8Qpch" title="Working capital deficit">4,360,124</span>. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zILj92CGVLml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86E_zIGWsVBn1wU">Fair Value of Financial Instruments</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company complies with the accounting guidance under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820-10, <i>Fair Value Measurements,</i> as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The guidance also establishes a fair value hierarchy for measurements of fair value as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 – quoted market prices in active markets for identical assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 – inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zjRB0govCSIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zskXsggwYbh1" style="display: none">Summary of Assets and Liabilities Fair Value on Recurring Basis</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20211231_zbFxnvswtNmk" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_490_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zXqGycTiKr95" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zc7jpX175pC9" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zZTiTq2hMCdd" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Derivative Liability</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,447,008</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0679">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0680">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,447,008</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--FairValueNetAssetLiability_iI_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Liabilities measured at fair value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,447,008</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0684">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0685">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,447,008</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_497_20201231_zXS8dph2Ykeb" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zjCrmgd8dXMa" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCRdi1lQSYo5" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEHUbAb6eIh3" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_zG5JkMUBVny7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Derivative Liability</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,925,106</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0689">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0690">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,925,106</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_zqfHEftKjgH4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Liabilities measured at fair value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,925,106</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0694">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0695">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,925,106</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AE_zM6W8LbplmGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_ziKnIwE6Kdc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zZil0BDaDJni">Revenue Recognition</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue per ASC 606. Revenue is recognized when services have been completed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zTzxCGRSkW6h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86E_zjOCOwmtIPw1">Property and Equipment</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_zDiUcOij0Zhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are recorded at historical cost. Minor additions and renewals are expensed in the year incurred. Major additions and renewals are capitalized and depreciated over their estimated useful lives. Depreciation is recorded over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The estimated useful lives for significant property and equipment categories are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_8B5_zug0xFlFlZj4" style="display: none">Schedule of Estimated Useful Lives for Significant Property and Equipment</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and Fixtures</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zsJnxxVcGgfc" title="Estimated useful lives">5</span>-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zDdvGslx3Qv5" title="Estimated useful lives">7</span> Years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer Equipment</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zqZGIifO1Vv4" title="Estimated useful lives">5</span>-<span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zvY60DAfsUxd" title="Estimated useful lives">7</span> Years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareDevelopmentMember_z5D8GdqnnbJb" title="Property, Plant and Equipment, Useful Life">3</span> Years</span></td></tr> </table> <p id="xdx_8A2_zHHDi3J4F2R8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company regularly evaluates whether events or circumstances have occurred that indicate the carrying value of long-lived assets may not be recoverable. If factors indicate the asset may not be recoverable, we compare the related undiscounted future net cash flows to the carrying value of the asset to determine if impairment exists. If the expected future net cash flows are less than the carrying value, an impairment charge is recognized based on the fair value of the asset. For the years ended December 31, 2021 and 2020, there was no impairment recognized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zEra1mwupUZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zfjm50v3BAR9">Intangible Assets</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for assets that are not physical in nature as intangible assets. Intangible assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are amortized on a straight-line basis over their economic or legal life, whichever is shorter. Intangible assets with indefinite useful lives are reassessed each year for impairment. If an impairment has occurred, then a loss is recognized. An impairment loss is determined by subtracting the asset’s fair value from the asset’s book/carrying value. For the years ended December 31, 2021 and 2020, there were no intangible assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_z7gfJ5PpbhC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zYXHcMcWChPa">Income Taxes</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes under FASB ASC 740-10-30. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component or all the benefits of deferred tax assets will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_zI4PunVQTpe9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zdIWMne70cN4">Debt Issuance Costs</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for debt issuance costs in accordance with ASU 2015-03. This guidance requires direct and incremental costs associated with the issuance of debt instruments such as legal fees, printing costs and underwriters’ fees, among others, paid to parties other than creditors, are reported and presented as a reduction of debt on the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt issuance costs and premiums or discounts are amortized over the term of the respective financing arrangement using the effective interest method. Amortization of these amounts is included as a component of interest expense net, in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--DerivativesReportingOfDerivativeActivity_zK8zqxjIQ0Q9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zGHVmZvBZSf6">Derivative Financial Instruments</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and then is revalued at each reporting date, with changes in fair value reported in the statement of operations. For stock based derivative financial instruments, Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once determined, derivative liabilities are adjusted to reflect fair value at the end of each reporting period. Any increase or decrease in the fair value from inception is made quarterly and appears in results of operations as a change in fair market value of derivative liabilities.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zCvocnOrxoZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_864_zFy0sbHBUARd">Cash and Cash Equivalents</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents include all cash deposits and highly liquid financial instruments with an original maturity to the Company of three months or less. The Company maintains cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zlwWi1WnmOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_zhyT2Wn6MWx4">Loss per Common Share</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows ASC Topic 260 to account for the loss per share. Basic loss per common share calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share calculations are determined by dividing net loss by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. As the Company has incurred losses for the periods ended December 31, 2021 and 2020, no dilutive shares are added into the loss per share calculations. While currently antidilutive, the following instruments could potentially dilute EPS in the future resulting in the following common stock equivalents:</span></p> <p id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zM7ydr47aTGa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zbPICpuKGI5b" style="display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 56%"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zdo9R8sb5wJ6" style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0728">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zyZb7cI3gkYb" style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">27,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zswT6PrbO62h" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0732">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zgZv14Ha0TPi" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">26,015</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Convertible Notes</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zSUzFV9raXL8" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">12,357,170,485</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zJhrkwHAIsq1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">24,728,206,940</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> <span style="display: none; font-size: 10pt">Total</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zjEJ522HTSPf" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">12,357,170,485</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231_z82qPllGgYB3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">27,728,259,955</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A4_zUVzr1XS7Ma7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zJ5UnLsoXKHc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zDeOGioqGaof">Recent Accounting Pronouncements</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has reviewed all other recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zyFHccNdG9Gj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zmSnxUOtsA52">Reclassifications</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.</span></p> <p id="xdx_856_zO71xh7qtoie" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zax85YB2A3b8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zjbFcyzPe4bd">Basis of Presentation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared to reflect the financial position, results of operations and cash flows of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--UseOfEstimates_zw6S7So4kCsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zCdV49v6wPhg">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_ecustom--GoingConcernPolicyTextBlock_zdQuqdPpWOzh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Going Concern</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2021, the Company had no revenues. The Company has an accumulated deficit of $<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20211231_zQZs71ph2FOc" title="Accumulated loss">40,069,797</span> and a working capital deficit of $<span id="xdx_900_ecustom--WorkingCapitalDeficit_iNI_pp0p0_di_c20211231_zFz5ZYa8Qpch" title="Working capital deficit">4,360,124</span>. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -40069797 -4360124 <p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zILj92CGVLml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86E_zIGWsVBn1wU">Fair Value of Financial Instruments</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company complies with the accounting guidance under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820-10, <i>Fair Value Measurements,</i> as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The guidance also establishes a fair value hierarchy for measurements of fair value as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 – quoted market prices in active markets for identical assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 – inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zjRB0govCSIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zskXsggwYbh1" style="display: none">Summary of Assets and Liabilities Fair Value on Recurring Basis</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20211231_zbFxnvswtNmk" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_490_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zXqGycTiKr95" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zc7jpX175pC9" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zZTiTq2hMCdd" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Derivative Liability</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,447,008</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0679">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0680">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,447,008</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--FairValueNetAssetLiability_iI_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Liabilities measured at fair value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,447,008</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0684">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0685">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,447,008</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_497_20201231_zXS8dph2Ykeb" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zjCrmgd8dXMa" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCRdi1lQSYo5" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEHUbAb6eIh3" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_zG5JkMUBVny7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Derivative Liability</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,925,106</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0689">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0690">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,925,106</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_zqfHEftKjgH4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Liabilities measured at fair value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,925,106</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0694">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0695">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,925,106</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AE_zM6W8LbplmGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zjRB0govCSIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zskXsggwYbh1" style="display: none">Summary of Assets and Liabilities Fair Value on Recurring Basis</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20211231_zbFxnvswtNmk" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_490_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zXqGycTiKr95" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zc7jpX175pC9" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zZTiTq2hMCdd" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Derivative Liability</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,447,008</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0679">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0680">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,447,008</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--FairValueNetAssetLiability_iI_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Liabilities measured at fair value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,447,008</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0684">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0685">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,447,008</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_497_20201231_zXS8dph2Ykeb" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zjCrmgd8dXMa" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCRdi1lQSYo5" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEHUbAb6eIh3" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_zG5JkMUBVny7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Derivative Liability</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,925,106</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0689">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0690">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,925,106</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_zqfHEftKjgH4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Liabilities measured at fair value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,925,106</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0694">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0695">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,925,106</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 1447008 1447008 1447008 1447008 3925106 3925106 3925106 3925106 <p id="xdx_847_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_ziKnIwE6Kdc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zZil0BDaDJni">Revenue Recognition</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue per ASC 606. Revenue is recognized when services have been completed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zTzxCGRSkW6h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86E_zjOCOwmtIPw1">Property and Equipment</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_zDiUcOij0Zhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are recorded at historical cost. Minor additions and renewals are expensed in the year incurred. Major additions and renewals are capitalized and depreciated over their estimated useful lives. Depreciation is recorded over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The estimated useful lives for significant property and equipment categories are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_8B5_zug0xFlFlZj4" style="display: none">Schedule of Estimated Useful Lives for Significant Property and Equipment</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and Fixtures</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zsJnxxVcGgfc" title="Estimated useful lives">5</span>-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zDdvGslx3Qv5" title="Estimated useful lives">7</span> Years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer Equipment</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zqZGIifO1Vv4" title="Estimated useful lives">5</span>-<span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zvY60DAfsUxd" title="Estimated useful lives">7</span> Years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareDevelopmentMember_z5D8GdqnnbJb" title="Property, Plant and Equipment, Useful Life">3</span> Years</span></td></tr> </table> <p id="xdx_8A2_zHHDi3J4F2R8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company regularly evaluates whether events or circumstances have occurred that indicate the carrying value of long-lived assets may not be recoverable. If factors indicate the asset may not be recoverable, we compare the related undiscounted future net cash flows to the carrying value of the asset to determine if impairment exists. If the expected future net cash flows are less than the carrying value, an impairment charge is recognized based on the fair value of the asset. For the years ended December 31, 2021 and 2020, there was no impairment recognized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_zDiUcOij0Zhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are recorded at historical cost. Minor additions and renewals are expensed in the year incurred. Major additions and renewals are capitalized and depreciated over their estimated useful lives. Depreciation is recorded over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The estimated useful lives for significant property and equipment categories are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_8B5_zug0xFlFlZj4" style="display: none">Schedule of Estimated Useful Lives for Significant Property and Equipment</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and Fixtures</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zsJnxxVcGgfc" title="Estimated useful lives">5</span>-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zDdvGslx3Qv5" title="Estimated useful lives">7</span> Years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer Equipment</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zqZGIifO1Vv4" title="Estimated useful lives">5</span>-<span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zvY60DAfsUxd" title="Estimated useful lives">7</span> Years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareDevelopmentMember_z5D8GdqnnbJb" title="Property, Plant and Equipment, Useful Life">3</span> Years</span></td></tr> </table> P5Y P7Y P5Y P7Y P3Y <p id="xdx_843_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zEra1mwupUZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zfjm50v3BAR9">Intangible Assets</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for assets that are not physical in nature as intangible assets. Intangible assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are amortized on a straight-line basis over their economic or legal life, whichever is shorter. Intangible assets with indefinite useful lives are reassessed each year for impairment. If an impairment has occurred, then a loss is recognized. An impairment loss is determined by subtracting the asset’s fair value from the asset’s book/carrying value. For the years ended December 31, 2021 and 2020, there were no intangible assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_z7gfJ5PpbhC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zYXHcMcWChPa">Income Taxes</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes under FASB ASC 740-10-30. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component or all the benefits of deferred tax assets will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_zI4PunVQTpe9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zdIWMne70cN4">Debt Issuance Costs</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for debt issuance costs in accordance with ASU 2015-03. This guidance requires direct and incremental costs associated with the issuance of debt instruments such as legal fees, printing costs and underwriters’ fees, among others, paid to parties other than creditors, are reported and presented as a reduction of debt on the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt issuance costs and premiums or discounts are amortized over the term of the respective financing arrangement using the effective interest method. Amortization of these amounts is included as a component of interest expense net, in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--DerivativesReportingOfDerivativeActivity_zK8zqxjIQ0Q9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zGHVmZvBZSf6">Derivative Financial Instruments</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and then is revalued at each reporting date, with changes in fair value reported in the statement of operations. For stock based derivative financial instruments, Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once determined, derivative liabilities are adjusted to reflect fair value at the end of each reporting period. Any increase or decrease in the fair value from inception is made quarterly and appears in results of operations as a change in fair market value of derivative liabilities.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zCvocnOrxoZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_864_zFy0sbHBUARd">Cash and Cash Equivalents</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents include all cash deposits and highly liquid financial instruments with an original maturity to the Company of three months or less. The Company maintains cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zlwWi1WnmOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_zhyT2Wn6MWx4">Loss per Common Share</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows ASC Topic 260 to account for the loss per share. Basic loss per common share calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share calculations are determined by dividing net loss by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. As the Company has incurred losses for the periods ended December 31, 2021 and 2020, no dilutive shares are added into the loss per share calculations. While currently antidilutive, the following instruments could potentially dilute EPS in the future resulting in the following common stock equivalents:</span></p> <p id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zM7ydr47aTGa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zbPICpuKGI5b" style="display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 56%"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zdo9R8sb5wJ6" style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0728">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zyZb7cI3gkYb" style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">27,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zswT6PrbO62h" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0732">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zgZv14Ha0TPi" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">26,015</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Convertible Notes</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zSUzFV9raXL8" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">12,357,170,485</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zJhrkwHAIsq1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">24,728,206,940</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> <span style="display: none; font-size: 10pt">Total</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zjEJ522HTSPf" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">12,357,170,485</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231_z82qPllGgYB3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">27,728,259,955</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A4_zUVzr1XS7Ma7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zM7ydr47aTGa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zbPICpuKGI5b" style="display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 56%"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zdo9R8sb5wJ6" style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0728">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zyZb7cI3gkYb" style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">27,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zswT6PrbO62h" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0732">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zgZv14Ha0TPi" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">26,015</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Convertible Notes</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zSUzFV9raXL8" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">12,357,170,485</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zJhrkwHAIsq1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">24,728,206,940</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> <span style="display: none; font-size: 10pt">Total</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zjEJ522HTSPf" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">12,357,170,485</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231_z82qPllGgYB3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Antidilutive potential earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">27,728,259,955</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 27000 26015 12357170485 24728206940 12357170485 27728259955 <p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zJ5UnLsoXKHc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zDeOGioqGaof">Recent Accounting Pronouncements</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has reviewed all other recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zyFHccNdG9Gj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zmSnxUOtsA52">Reclassifications</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.</span></p> <p id="xdx_80A_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zg7Q5BtdREpl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3. <span><span id="xdx_82F_z6vWKMS5SVKk">Property and Equipment</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment consist of computer equipment that is stated at cost $<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231_zNsD6zhM67Vh">6,976 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231_zbmhNhQg2rf7">6,976 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">less accumulated depreciation of $<span id="xdx_90D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_c20211231_zfQXuziZhIm6">4,589 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_c20201231_zMxe1WJ5Qz62">3,188 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2021 and 2020, respectively. During the year ended December 31, 2020, the Company disposed of computers with a cost value of $<span id="xdx_902_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_c20200101__20201231_zomz168ek0Oe">11,498 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and transferred computers and equipment valued at $<span id="xdx_90D_ecustom--TransferredComputersAndEquipment_iI_c20201231_zeQI0nVFbR22" title="Transferred computers and equipment">9,208</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per the Bistromatics agreement dated September 15, 2020. (Footnote 1). Depreciation expense was $<span id="xdx_90B_eus-gaap--Depreciation_c20210101__20211231_ztRVgoSSN7ui">1,402 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_900_eus-gaap--Depreciation_c20200101__20201231_zWtK4R1sFVq3">4,869 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 6976 6976 4589 3188 11498 9208 1402 4869 <p id="xdx_803_eus-gaap--IntangibleAssetsDisclosureTextBlock_zE7YTxDCxNob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4. <span id="xdx_82E_zHTWGDd8Nub">Intangible Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes the cost of a software license and a license for use of a programming code as intangible assets. The stated cost of these assets and accumulated amortization were transferred per the Bistromatics agreement dated September 15, 2020 (Footnote 1). For the years ended December 31, 2021 and 2020, the amortization expense recorded was $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231_zgHRYSNmOaPk" title="Amortization of Intangible Assets">0</span> and $<span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231_zpX0y7TV3SF6" title="Amortization of Intangible Assets">2,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 2000 <p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_zwi2rH3mqRye" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5. <span id="xdx_82A_z4Q6ZHvuHI82">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zeSG43RUDsQ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax liabilities consist of the following components as of December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zlfuwrZI0d48" style="display: none">Schedule of Deferred Tax Liabilities </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_496_20211231_zFM4PiJu0rf7" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49F_20201231_zApxLJNMMjQ5" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">NOL carryover</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,027,300</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,133,200</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_iI_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued payroll</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">42,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">42,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax liabilities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_ecustom--DeferredTaxAssetsTaxDepreciation_iI_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Depreciation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">400</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">300</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_z2JH8mHLmdf2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Valuation allowance</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,069,700</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,175,500</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTIC_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net deferred tax asset</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0781">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0782">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AC_zANgTQugKAp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zoDYzO98mcU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate to pre-tax income from continuing operations for the years ended December 31, 2021 and 2020 due to the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zRdoeRMCeQM6" style="display: none">Schedule of Pre-tax from Continuing Operations</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20210101__20211231_zEdCmV0c70ng" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_498_20200101__20201231_zCuMgApxIuE7" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_ecustom--IncomeTaxReconciliationNondeductibleExpenseBookIncome_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Book loss</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(94,900</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,842,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseDepreciation_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Depreciation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0789"> </span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">700</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseCharitableContributions_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Contributed services</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">504,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,200</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Meals &amp; entertainment</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,600</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,400</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_ecustom--IncomeTaxReconciliationNondeductibleExpenseStockForPrepaids_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock for prepaids</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">700</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,900</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_ecustom--IncomeTaxReconciliationNondeductibleExpenseStockForConsulting_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock for consulting</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">400</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseAmortization_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Amortization of debt discount</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0804"> </span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">130,200</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued payroll</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0807"> </span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(69,900</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_409_ecustom--IncomeTaxReconciliationNondeductibleExpenseGainOnDebtExtinguishment_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gain on debt extinguishment</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0810"> </span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,200</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_400_ecustom--IncomeTaxReconciliationNondeductibleExpenseRelatedPartyAccruals_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Related party accruals</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0813"> </span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(123,100</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_406_ecustom--IncomeTaxReconciliationNondeductibleExpenseLossOnDisposal_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss on disposal</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0816"> </span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,700</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--GainLossOnDerivativeInstrumentsNetPretax_zvK6zh2Odd82" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Derivative (Gain)/Loss</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(520,400</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">114,260</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Valuation allowance</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">107,800</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">693,100</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_zWVYoM8qMXTk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Income tax expense benefit</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0825">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0826">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A1_z9HsijraCyTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, the Company had net operating loss carry forwards of approximately $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_c20211231_z13DFPukhyOc">19,177,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that may be offset against future taxable income from the year <span id="xdx_904_ecustom--OperatingLossCarryforwardLossExpirationTerm_c20210101__20211231_zuk705Vg3DMe" title="Income taxable description">2022 through 2041</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. No tax benefit has been reported in the December 31, 2020 financial statements since the potential tax benefit is offset by a valuation allowance of the same amount.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards for federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s policy is to recognize potential interest and penalties accrued related to unrecognized tax benefits within income tax expense. For the years ended December 31, 2021 and 2020, the Company did not recognize any interest or penalties, nor did we have any interest or penalties accrued related to unrecognized benefits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The tax years ended December 31, 2021, 2020 and 2019 are open for examination for federal income tax purposes and by other major taxing jurisdictions to which we are subject.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zeSG43RUDsQ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax liabilities consist of the following components as of December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zlfuwrZI0d48" style="display: none">Schedule of Deferred Tax Liabilities </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_496_20211231_zFM4PiJu0rf7" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49F_20201231_zApxLJNMMjQ5" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">NOL carryover</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,027,300</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,133,200</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_iI_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued payroll</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">42,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">42,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax liabilities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_ecustom--DeferredTaxAssetsTaxDepreciation_iI_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Depreciation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">400</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">300</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_z2JH8mHLmdf2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Valuation allowance</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,069,700</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,175,500</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTIC_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net deferred tax asset</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0781">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0782">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 4027300 4133200 42000 42000 400 300 4069700 4175500 <p id="xdx_890_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zoDYzO98mcU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate to pre-tax income from continuing operations for the years ended December 31, 2021 and 2020 due to the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zRdoeRMCeQM6" style="display: none">Schedule of Pre-tax from Continuing Operations</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20210101__20211231_zEdCmV0c70ng" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_498_20200101__20201231_zCuMgApxIuE7" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_ecustom--IncomeTaxReconciliationNondeductibleExpenseBookIncome_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Book loss</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(94,900</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,842,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseDepreciation_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Depreciation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0789"> </span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">700</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseCharitableContributions_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Contributed services</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">504,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,200</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Meals &amp; entertainment</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,600</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,400</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_ecustom--IncomeTaxReconciliationNondeductibleExpenseStockForPrepaids_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock for prepaids</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">700</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,900</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_ecustom--IncomeTaxReconciliationNondeductibleExpenseStockForConsulting_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock for consulting</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">400</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseAmortization_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Amortization of debt discount</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0804"> </span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">130,200</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued payroll</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0807"> </span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(69,900</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_409_ecustom--IncomeTaxReconciliationNondeductibleExpenseGainOnDebtExtinguishment_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gain on debt extinguishment</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0810"> </span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,200</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_400_ecustom--IncomeTaxReconciliationNondeductibleExpenseRelatedPartyAccruals_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Related party accruals</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0813"> </span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(123,100</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_406_ecustom--IncomeTaxReconciliationNondeductibleExpenseLossOnDisposal_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss on disposal</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0816"> </span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,700</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--GainLossOnDerivativeInstrumentsNetPretax_zvK6zh2Odd82" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Derivative (Gain)/Loss</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(520,400</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">114,260</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Valuation allowance</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">107,800</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">693,100</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_zWVYoM8qMXTk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Income tax expense benefit</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0825">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0826">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> -94900 -1842000 700 504000 32200 2600 2400 700 36900 200 400 130200 -69900 -5200 -123100 1700 -520400 114260 107800 693100 19177000 2022 through 2041 <p id="xdx_80A_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zfOiP3Jio961" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6. <span id="xdx_82C_zbNKa77Y5ZJg">Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout the year ended December 31, 2021, the officers and directors of the Company incurred business expenses on behalf of the Company. The amounts payable to the officers as of the years ended December 31, 2021 and 2020 were $<span id="xdx_90C_eus-gaap--DueToRelatedPartiesCurrent_iI_pp0p0_c20211231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_ziLkIugPW8Mg" title="Due to related parties, current">33,701</span> and $<span id="xdx_908_eus-gaap--DueToRelatedPartiesCurrent_iI_pp0p0_c20201231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zrHRsQ9BL2wa" title="Due to related parties, current">11,655</span>, respectively. There were no expenses due to the board members, but the Company has accrued directors’ fees of $<span id="xdx_908_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_pp0p0_c20211231_z3ENWqEIxe8a" title="Accrued director's fees">221,107</span> and $<span id="xdx_909_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_pp0p0_c20201231_zHp16DUi8Z1k" title="Accrued director's fees">221,107</span> as of the years ended December 31, 2021 and 2020, respectively. Two of the independent directors resigned on May 22, 2020 so no further directors’ fees were accrued for them. On February 26, 2021, the remaining independent director signed a Settlement and Compromise Agreement which eliminated all previously accrued directors’ fees as of September 30, 2020 for a flat fee of $<span id="xdx_905_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_c20200930__us-gaap--TypeOfArrangementAxis__custom--SettlementAndCompromiseAgreementMember_zgAjAEUNYB5a" title="Accrued director's fees">100,000</span>. Since the effective date of the agreement was October 1, 2020, the adjustment was recorded as of December 31, 2020. Because the Company is not yet profitable the officers had agreed to defer compensation. On February 26, 2021, the officers signed Settlement and Compromise Agreements which eliminated all previously accrued compensation accrued as of September 30, 2020 for $<span id="xdx_90A_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_c20200930__us-gaap--TypeOfArrangementAxis__custom--SettlementAndCompromiseAgreementMember_zVLskOpAgWc4" title="Accrued director's fees">100,000</span> each. Since the effective date of these agreements is October 1, 2020, the adjustment was recorded as of December 31, 2020. The Company had accrued executive compensation of $<span id="xdx_90E_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_c20211231_zFMxvW5zIh0j" title="Accrued executive compensation">200,000</span> and $<span id="xdx_903_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_c20201231_zGUsgw9rAXvc" title="Accrued executive compensation">200,000</span> as of December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 33701 11655 221107 221107 100000 100000 200000 200000 <p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_z8cMOs2puJOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7. <span id="xdx_820_zwhKI3AEmSoe">Convertible Notes Payable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Year Ended December 31, 2021</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, there were no new convertible notes executed. During the year ended December 31, 2021, the Company accrued interest payable of $<span id="xdx_90E_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_z9UHPU7dCrl5" title="Accrued interest payable">258,778</span> on previously executed convertible notes payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Year Ended December 31, 2020</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2020, the Company executed a <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20200331__us-gaap--DebtInstrumentAxis__custom--TwelvePercentConvertiblePromissoryNoteMember_zHGG8hKJc92k" title="Debt interest stated rate">12</span>% Convertible Promissory Note payable to an institutional investor in the principal amount of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200331__us-gaap--DebtInstrumentAxis__custom--TwelvePercentConvertiblePromissoryNoteMember_zgxjLRpUbive" title="Debt Instrument, principal amount">52,800</span>. The note, which is due on <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20200301__20200331__us-gaap--DebtInstrumentAxis__custom--TwelvePercentConvertiblePromissoryNoteMember_z0LfZXYvggn9" title="Debt instrument maturity date">January 15, 2021</span>, has an original issue discount of $<span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20200331__us-gaap--DebtInstrumentAxis__custom--TwelvePercentConvertiblePromissoryNoteMember_zxelfF7edob1" title="Original issue discount">4,800</span> and transaction costs of $<span id="xdx_90B_eus-gaap--DeferredFinanceCostsNet_iI_pp0p0_c20200331__us-gaap--DebtInstrumentAxis__custom--TwelvePercentConvertiblePromissoryNoteMember_z7H3DzKT7nPd" title="Transaction costs">3,000</span>. After 180 days, the convertible note converts into common stock of the Company at a conversion price that shall be equal to <span id="xdx_909_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_dp_uPure_c20200301__20200331__us-gaap--DebtInstrumentAxis__custom--TwelvePercentConvertiblePromissoryNoteMember_zyO3uUa75QQj" title="Convertible debt percentage">70</span>% of the average of the two lowest per share trading prices for the ten (<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_dtD_uTradingDays_c20200301__20200331__us-gaap--DebtInstrumentAxis__custom--TwelvePercentConvertiblePromissoryNoteMember_zGlbbLzxPO9h" title="Number of trading days">10</span>) trading days prior to the conversion date. As of December 31, 2020, this note was fully converted and during the year ended December 31, 2020 the Company accrued interest of $<span id="xdx_903_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20201231__us-gaap--DebtInstrumentAxis__custom--TwelvePercentConvertiblePromissoryNoteMember_zqojFdIMFVC7" title="Accrued interest">2,880</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company accrued interest of $<span id="xdx_905_ecustom--InterestPayableNoncurrent_iI_pp0p0_c20201231__us-gaap--DebtInstrumentAxis__custom--TwoThousandNineteenConvertibleNotesMember_z3rnxgTyO8ci" title="Accrued interest">330,871</span> for the 2019 convertible notes that were still outstanding throughout the year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 258778 0.12 52800 2021-01-15 4800 3000 0.70 10 2880 330871 <p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z0sLXYMW29Ac" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8. <span id="xdx_82A_z2IqRiz2ltB3">Equity Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Preferred Stock</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total number of shares of Series A Preferred Stock which the Company shall have authority to issue is <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1c32a7F8jHc" title="Preferred stock, shares authorized">20,000,000</span> shares with a par value of $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCdE8ILtI6nf" title="Preferred stock, par value">0.001</span> per share. During the year ended December 31, 2019, the Company authorized the issuance of <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20191231__srt--TitleOfIndividualAxis__custom--OfficersDirectorsAndConsultantsMember_zVRCDkMIgE91" title="Preferred stock, shares authorized">1,000,000</span> shares of preferred stock to officers, directors and consultants as deferred compensation and/or expense. <span id="xdx_90D_eus-gaap--ConversionOfStockDescription_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zCIAm9VPZXXk" title="Conversion of stock, description">The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of 40 shares per preferred share at the common share value on the date of issuance</span>. The deferred compensation value of the shares will vest monthly at 1/24th of the calculated value of $<span id="xdx_90E_eus-gaap--DeferredCompensationEquity_iI_pid_c20211231_zjoLZEjXkgbe" title="Deferred compensation">3,000,000</span> and requisite expense or reduction of accrued compensation and/or accrued directors fees will be recorded. At the recording of the requisite vested share value, the corresponding number of preferred shares will be recorded as being issued. On May 22, 2020, two independent directors resigned and three officers/directors/consultant resigned. Therefore, the vesting of their preferred shares ceased on those dates per the authorization documents. As part of the Settlement and Compromise agreements signed by current officers, director and consultant on February 26, 2021, with effective date October 1, 2020, the shares issued became fully vested at the year ended December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2021, the Board of Directors issued a Certificate of Designations, Preferences, Rights and Limitations of Series C Convertible Preferred Stock. The Board authorized that the Company shall have the authority to issue <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210430__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zwnScCKKwwqi" title="Preferred stock shares authorized">1,000,000</span> shares with a par value of $<span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210430__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zOgElMjNtCc5" title="Preferred stock par value">.0001</span> per share to be issued to persons designated by the Board. The Series C Preferred Stock has no stated maturity and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Holder decides to convert the shares of Series C Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2021, the Board of Directors issued a Certificate of Designations, Preferences and Rights Limitations of Series D Preferred Stock. The Board authorized that the Company shall have the authority to issue <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210430__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zufs3rGzzavb" title="Preferred stock, shares authorized">200,000</span> shares with a par value of $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210430__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_za4mBXi5JBF2" title="Preferred stock, par value">.0001</span> per share to be issued to persons designated by the Board. The Series D Preferred Stock has no stated maturity and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Holder decides to convert the shares of Series D Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2021, the Board of Directors issued a Certificate of Designations, Preferences and Rights of Series E Convertible Preferred Stock. The Board authorized that the Company shall have authority to issue <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210430__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_z30trwICG7ad" title="Preferred stock shares authorized">2,500,000</span> shares with a par value of $<span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210430__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zFasccQSLte1" title="Preferred stock par value">.0001</span> per share. The Board of Directors may determine to : (i) issue a number of Series Preferred in a private placement at an offering price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210430__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_znMAuymQvDoc" title="Offering price per share">1.00 </span>per share; (ii) issue the Series E Preferred in consideration for the cancellation of shares of the Company’s Series A Preferred held by the Corporation’s officers, directors and key personnel based on terms and conditions that the Board of Directors may determine; and (iii) issue the shares of Series E Preferred for such other purposes as the Board of Directors may determine.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series C, Series D and Series E Preferred Stock will rank, with respect to rights to the payment of dividends and the distribution of assets in the event of any liquidation, dissolution or winding up of the Corporation, (i) senior to all classes or series of the Corporation’s Common Stock, par value $0.001 per share (“Common Stock”), and to all other equity securities issued by the Corporation ; and (ii) effectively junior to all existing and future indebtedness (including indebtedness convertible into our Common Stock or Preferred Stock) of the Corporation and to any indebtedness and other liabilities of (as well as any preferred equity interest held by others) existing subsidiaries of the Corporation. <span id="xdx_903_eus-gaap--PreferredStockVotingRights_c20210101__20211231_zOg7nOptK2Gj">The term “equity securities” shall not include convertible debt securities. The Holders of the Series D Preferred Stock have the right, on all matters subject to the vote of the capital stock of the Corporation, to have the collective vote equal to 70% of the total of all voting capital stock of the Corporation, notwithstanding the number of shares of voting capital stock, including shares of common stock, that may be outstanding from time to time</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. </span>Upon liquidation, Preferred Stockholders will receive the liquidation preference plus an amount equal to any accumulated and unpaid dividends up to the date of payment before any distribution of assets is made.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 4, 2021, the Board of Directors issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210503__20210504__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zY9QrA8cLMNj" title="Shares issued for cash, shares">350,000</span> shares of Series E Convertible Preferred Stock for the subscription agreements dated March 1, 2021 at the value of $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210504__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zU54eUWH3eag" title="Offering price per share">1.00</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 12, 2021, the Board of Directors authorized the issuance of <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210512__us-gaap--StatementClassOfStockAxis__custom--SeriesDVotingPreferredStockMember_zBrfX6nWjmMf" title="Preferred stock, shares authorized">200,000</span> shares of Series D Voting Preferred Stock with a value of $<span id="xdx_905_eus-gaap--PreferredStockValue_iI_pid_c20210512__us-gaap--StatementClassOfStockAxis__custom--SeriesDVotingPreferredStockMember_zdlYutYcPlba" title="Preferred stock value">200,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 20, 2021, the Board of Directors authorized the issuance of <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210520__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_z9Bi1Ti7wwU4" title="Preferred stock, shares authorized">920,000</span> shares of Series C Convertible Preferred Stock with a value of $<span id="xdx_904_eus-gaap--PreferredStockValue_iI_pid_c20210520__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zQBwDyAwm3J4" title="Preferred stock value">920,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 1, 2021, the Board of Directors authorized the issuance of <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210701__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zGWtU5FxbhS9" title="Preferred stock, shares authorized">1,280,000</span> shares of Series E Convertible Preferred Stock with a value of $<span id="xdx_90B_eus-gaap--PreferredStockValue_iI_pid_c20210701__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zEkkdYTCNmR1" title="Preferred stock value">1,280,000</span>. These shares were issued on <span id="xdx_902_eus-gaap--PreferredStockConvertibleConversionDate_iI_pid_dd_c20210701__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zCcW1ScIEeK4" title="Shares issued date">July 14, 2021</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Common Stock</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 12, 2020, FINRA approved a <span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20200210__20200212__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zhesSwr9ukve" title="Reverse stock split, description">1:50 reverse split</span> of the Company’s common stock. As noted throughout this document, all common shares are stated as if the <span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_z97b79QfoGFg" title="Reverse stock split, description">1:50 reverse split</span> had been completed as of the beginning of the year ended December 31, 2019. Following the approval, the Company’s stock began trading under the symbol “EWLLD”. Due to rounding issues for the reverse split, the Company issued<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_z4zURMweAIH3" title="Number of shares issued, new issues"> 47,876</span> additional shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 14, 2020, the Company filed a Definitive Information Statement on Schedule 14C for the purpose of authorizing the increase in the number of authorized shares of Common Stock from one billion nine hundred million (<span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20200214__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2ZwZzZzQIOd" title="Common stock, shares authorized">1,900,000,000</span>) shares of Common Stock to twenty billion (<span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNi6tv5ZzLvf" title="Common stock, shares authorized">20,000,000,000</span>) shares of Common Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Debt Conversion Shares</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2021</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, there were no shares of common stock issued for debt conversion.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2020</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company issued a total of <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zlm0tKaJ6pgf" title="Shares issued for debt conversion,shares">16,849,013,669</span> shares of common stock per debt conversion of various convertible notes. The total of the debt conversion was for $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20201231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zUdSa47eO2Oh" title="Principal amount">1,607,317</span> of principal, $<span id="xdx_908_eus-gaap--InterestPayableCurrent_iI_c20201231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zi8DsbHAV4bi" title="Accrued interest">145,167</span> of accrued interest and $<span id="xdx_90C_eus-gaap--PaymentsOfFinancingCosts_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zLKpwsBNu354" title="Financing cost">95,933</span> financing costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Consultant Issued Shares</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20211231_zstWKEfXFWz9" title="Stock issued during period for services">2,001,666</span> shares of common stock for marketing and consulting services valued at $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210101__20211231_zSS9H2RLu8Bk" title="Stock issued during period for services">750</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2020</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 30, 2020, the Company executed a 12-month advisory services agreement. The Company is to issue <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200129__20200130_zAo6BwiMrchk">20,000</span> shares of common stock monthly. The Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--TwelveMonthAdvisoryServicesAgreementMember_ze4b7bbevwuj" title="Number of shares issued, new issues">80,000</span> shares of common stock with a value of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--TwelveMonthAdvisoryServicesAgreementMember_zrdAOyS0jUyl" title="Stock issued during the period, value">103</span>. The remaining <span id="xdx_902_ecustom--StockIssuedDuringPeriodSharesToBeIssued_pp0p0_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--TwelveMonthAdvisoryServicesAgreementMember_zYkT290ivAr8" title="Number of sharesto be issued">160,000</span> shares of common stock with a value of $<span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesValueToBeIssued_pp0p0_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--TwelveMonthAdvisoryServicesAgreementMember_znVgOfEhVaK9" title="Number of sharesto be issued, value">30</span> has been recorded in Shares to be Issued. In addition, the Company is to also pay the advisor a monthly fee of $<span id="xdx_90A_eus-gaap--LegalFees_pp0p0_c20200101__20201231_zhkQQwxg07Yk" title="Monthly base fee">2,500</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__srt--TitleOfIndividualAxis__custom--ConsultantMember_zqMKgZR3Sd53" title="Shares issued during period for services,shares">588,332</span> shares of common stock for marketing and consulting services valued at $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20200101__20201231__srt--TitleOfIndividualAxis__custom--ConsultantMember_zgnix8uzGm48" title="Shares issued during period for services, value">1,604</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred Series E Conversion</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2021</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--PreferredSeriesEConversionMember_z0xknYbfdQR7" title="Shares issued during period shares">1,643,200,000</span> shares of common stock for conversion of <span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--PreferredSeriesEConversionMember_zE5oBwf1Sud3">164,320</span> shares of Preferred Series E for a value of $<span id="xdx_902_eus-gaap--ConversionOfStockAmountConverted1_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--PreferredSeriesEConversionMember_zWIooRbF3gRg" title="Shares issued during period for conversion, value">164,320</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2020</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Stock Options</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zhqWVzapKUs7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of the status of all Company’s stock options as of December 31, 2021 and changes during the periods ended on December 31, 2021 and 2020, respectively:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><span style="display: none"><span id="xdx_8B9_zqJlCFlwUxC4">Summary of Stock Options Activity</span></span> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">of Stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise Price</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Life (yrs.)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif">Outstanding on January 1, 2020</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20200101__20201231_zPXLcpQnizbh" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of Stock Options Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">57,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200101__20201231_zExYtRERNZb" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">40.00</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_z7T8VyNmnI97" title="Remaining Life (yrs) Outstanding, Beginning Balance">1.1</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20200101__20201231_zGsAxScp3529" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Intrinsic Value Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0966">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200101__20201231_zJQrrGqEHVI5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options Outstanding, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0968">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zjHM91XjToE6" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0970">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20200101__20201231_zsqY5KFP5xpd" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options Outstanding, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0972">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zDvOCBeSUk8l" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0974">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired/cancelled</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20200101__20201231_z6aNp6l8RdDd" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options Outstanding, Cancelled"><span style="font-family: Times New Roman, Times, Serif">(30,000</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zJFkBJ6uXLZ7" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled"><span style="font-family: Times New Roman, Times, Serif">40.00</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardCancelledOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zXYdetDJClH2" title="Remaining Life (yrs) expired/ cancelled">.14</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding on December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_zCA64QHDa5pk" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">27,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zo1EP7t8QG22" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">40.00</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY0_c20210101__20211231_zSiNJPa23zU2" title="Remaining Life (yrs) Outstanding, Beginning Balance">.14</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20210101__20211231_z2rrmrd3nPQ2" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Intrinsic Value Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0988">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231_zrS1RIkq6DU5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options Outstanding, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0990">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zdrxzTylbAh4" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0992">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20210101__20211231_ztWivs2Q6rob" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options Outstanding, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0994">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zfWnnm9WvWwg" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0996">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired/cancelled</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20210101__20211231_zlsIbAWdnOcc" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options Outstanding, Cancelled"><span style="font-family: Times New Roman, Times, Serif">(27,000</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zmbQi4A0lFCf" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1000">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding on December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20210101__20211231_z9Z8xdl0R6Wj" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1002">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zh4oXOWGG0ub" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Outstanding,Ending Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1004">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingEndingWeightedAverageRemainingContractualTerm2_dtY0_c20210101__20211231_zmhYH0rwIKnj" title="Remaining Life (yrs) Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1006">-</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20210101__20211231_z0k7PcLiLJWd" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Intrinsic Value Options exercisable, Ending Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1008">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options exercisable on December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20211231_zQ5eL78CGpw5" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options exercisable, Ending Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1010">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20211231_zIexEyayZqOl" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Options exercisable, Ending Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1012">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY0_c20210101__20211231_zpwBDPi0w562" title="Remaining Life (yrs) Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1014">-</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20211231_zYDdoQBdqUi8" title="Intrinsic Value Options exercisable, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1016">-</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AF_zNVIGdAhInG4" style="display: none; margin-top: 0; margin-bottom: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Warrants</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zVyvTasPi4W5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of the status of the Company’s warrants as of December 31, 2021 and changes during the periods ended on December 31, 2021 and 2020, respectively:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><span style="display: none"><span id="xdx_8BB_zChbWZRtLOdc">Summary of Warrants Activity</span></span> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average <br/> Exercise</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Life (yrs.)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif">Outstanding on January 1, 2020</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20200101__20201231_zbEpb8H5Q6J2" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of Warrants, Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">42,015</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iS_pid_c20200101__20201231_zfvxXSflfVz5" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">12.00</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentWarrantsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_ziFiU0y9IoA" title="Remaining Life (yrs) Outstanding, Beginning Balance">1.9</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentWarrantBeginningInPeriodGrantDateIntrinsic_iS_c20200101__20201231_zs7ciuIF1u7a" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Intrinsic Value, Warrants Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">0.037</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20200101__20201231_z6q7vSZ3k2D9" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1028">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zO6YFGwmJFdc" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1030">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20200101__20201231_zU37R4Sw8sJ8" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1032">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231_zlZjfqVx4REk" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1034">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Cancelled</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_pid_di_c20200101__20201231_zU8tqjnhW5Fg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled"><span style="font-family: Times New Roman, Times, Serif">(16,000</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedInPeriodWeightedAverageExercisePrice_c20200101__20201231_zwRDMaZUR1kk" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled"><span style="font-family: Times New Roman, Times, Serif">11.04</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding on December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20211231_zEjgvn7IcOeb" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">26,015</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iS_c20210101__20211231_zljLYWZfxdjl" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">12.50</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentWarrantsOutstandingWeightedAverageRemainingContractualTerm2_dtY0_c20210101__20211231_zmW5YCyWWzUc" title="Remaining Life (yrs.) Warrants Outstanding, Beginning Balance">1.2</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentWarrantBeginningInPeriodGrantDateIntrinsic_iS_c20210101__20211231_znxmW5Xvuj5e" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Intrinsic Value, Warrants Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1046">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231_zjsKxut8ci53" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1048">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zsT70MHQcSsc" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20210101__20211231_z7t6rNUQB4sf" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_zxzuLxuuvSQk" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1054">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Cancelled</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_pid_di_c20210101__20211231_z20sEr5QFUIa" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled"><span style="font-family: Times New Roman, Times, Serif">(26,015</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20211231_z9gN2zEqupCa" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1057">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding on December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20210101__20211231_z1iryFVsBlsk" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1059">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iE_c20210101__20211231_z7iD91JGcjUl" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1061">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentWarrantsOutstandingEndingWeightedAverageRemainingContractualTerm2_dtY0_c20210101__20211231_z0DyppjIVDBg" title="Remaining Life (yrs.) Warrants Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1063">-</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentWarrantBeginningInPeriodGrantDateIntrinsic_iE_c20210101__20211231_zwCMNUDScer3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Intrinsic Value, Warrants Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants exercisable on December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableNumber_iI_pid_c20211231_zZokwryoHAE7" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, exercisable, Ending balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1067">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingExercisableWeightedAverageNumberOfShare_iI_c20211231_zivXCqhbXj2k" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Exercisable, Ending Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1069">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentWarrantsExercisableWeightedAverageRemainingContractualTerm2_dtY0_c20210101__20211231_ztdNo5YFFVsi" title="Remaining Life (yrs.) Warrants Exercisable, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1071">-</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentWarrantExercisableInPeriodGrantDateIntrinsic_iI_c20211231_zJQmO4mrVO29" title="Intrinsic Value, Warrants Outstanding, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1073">-</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A2_zXLP9WMDiGw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 20000000 0.001 1000000 The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of 40 shares per preferred share at the common share value on the date of issuance 3000000 1000000 0.0001 200000 0.0001 2500000 0.0001 1.00 The term “equity securities” shall not include convertible debt securities. The Holders of the Series D Preferred Stock have the right, on all matters subject to the vote of the capital stock of the Corporation, to have the collective vote equal to 70% of the total of all voting capital stock of the Corporation, notwithstanding the number of shares of voting capital stock, including shares of common stock, that may be outstanding from time to time 350000 1.00 200000 200000 920000 920000 1280000 1280000 2021-07-14 1:50 reverse split 1:50 reverse split 47876 1900000000 20000000000 16849013669 1607317 145167 95933 2001666 750 20000 80000 103 160000 30 2500 588332 1604 1643200000 164320 164320 <p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zhqWVzapKUs7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of the status of all Company’s stock options as of December 31, 2021 and changes during the periods ended on December 31, 2021 and 2020, respectively:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><span style="display: none"><span id="xdx_8B9_zqJlCFlwUxC4">Summary of Stock Options Activity</span></span> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">of Stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise Price</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Life (yrs.)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif">Outstanding on January 1, 2020</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20200101__20201231_zPXLcpQnizbh" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of Stock Options Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">57,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200101__20201231_zExYtRERNZb" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">40.00</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_z7T8VyNmnI97" title="Remaining Life (yrs) Outstanding, Beginning Balance">1.1</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20200101__20201231_zGsAxScp3529" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Intrinsic Value Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0966">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200101__20201231_zJQrrGqEHVI5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options Outstanding, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0968">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zjHM91XjToE6" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0970">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20200101__20201231_zsqY5KFP5xpd" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options Outstanding, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0972">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zDvOCBeSUk8l" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0974">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired/cancelled</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20200101__20201231_z6aNp6l8RdDd" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options Outstanding, Cancelled"><span style="font-family: Times New Roman, Times, Serif">(30,000</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zJFkBJ6uXLZ7" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled"><span style="font-family: Times New Roman, Times, Serif">40.00</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardCancelledOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zXYdetDJClH2" title="Remaining Life (yrs) expired/ cancelled">.14</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding on December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_zCA64QHDa5pk" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">27,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zo1EP7t8QG22" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">40.00</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY0_c20210101__20211231_zSiNJPa23zU2" title="Remaining Life (yrs) Outstanding, Beginning Balance">.14</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20210101__20211231_z2rrmrd3nPQ2" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Intrinsic Value Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0988">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231_zrS1RIkq6DU5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options Outstanding, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0990">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zdrxzTylbAh4" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0992">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20210101__20211231_ztWivs2Q6rob" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options Outstanding, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0994">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zfWnnm9WvWwg" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0996">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired/cancelled</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20210101__20211231_zlsIbAWdnOcc" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options Outstanding, Cancelled"><span style="font-family: Times New Roman, Times, Serif">(27,000</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zmbQi4A0lFCf" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1000">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding on December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20210101__20211231_z9Z8xdl0R6Wj" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1002">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zh4oXOWGG0ub" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Outstanding,Ending Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1004">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingEndingWeightedAverageRemainingContractualTerm2_dtY0_c20210101__20211231_zmhYH0rwIKnj" title="Remaining Life (yrs) Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1006">-</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20210101__20211231_z0k7PcLiLJWd" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Intrinsic Value Options exercisable, Ending Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1008">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options exercisable on December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20211231_zQ5eL78CGpw5" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options exercisable, Ending Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1010">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20211231_zIexEyayZqOl" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Options exercisable, Ending Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1012">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY0_c20210101__20211231_zpwBDPi0w562" title="Remaining Life (yrs) Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1014">-</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20211231_zYDdoQBdqUi8" title="Intrinsic Value Options exercisable, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1016">-</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 57000 40.00 P1Y1M6D 30000 40.00 P0Y1M20D 27000 40.00 P0Y1M20D 27000 <p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zVyvTasPi4W5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of the status of the Company’s warrants as of December 31, 2021 and changes during the periods ended on December 31, 2021 and 2020, respectively:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><span style="display: none"><span id="xdx_8BB_zChbWZRtLOdc">Summary of Warrants Activity</span></span> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average <br/> Exercise</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Life (yrs.)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif">Outstanding on January 1, 2020</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20200101__20201231_zbEpb8H5Q6J2" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of Warrants, Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">42,015</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iS_pid_c20200101__20201231_zfvxXSflfVz5" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">12.00</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentWarrantsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_ziFiU0y9IoA" title="Remaining Life (yrs) Outstanding, Beginning Balance">1.9</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentWarrantBeginningInPeriodGrantDateIntrinsic_iS_c20200101__20201231_zs7ciuIF1u7a" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Intrinsic Value, Warrants Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">0.037</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20200101__20201231_z6q7vSZ3k2D9" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1028">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zO6YFGwmJFdc" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1030">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20200101__20201231_zU37R4Sw8sJ8" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1032">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231_zlZjfqVx4REk" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1034">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Cancelled</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_pid_di_c20200101__20201231_zU8tqjnhW5Fg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled"><span style="font-family: Times New Roman, Times, Serif">(16,000</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedInPeriodWeightedAverageExercisePrice_c20200101__20201231_zwRDMaZUR1kk" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled"><span style="font-family: Times New Roman, Times, Serif">11.04</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding on December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20211231_zEjgvn7IcOeb" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">26,015</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iS_c20210101__20211231_zljLYWZfxdjl" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">12.50</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentWarrantsOutstandingWeightedAverageRemainingContractualTerm2_dtY0_c20210101__20211231_zmW5YCyWWzUc" title="Remaining Life (yrs.) Warrants Outstanding, Beginning Balance">1.2</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentWarrantBeginningInPeriodGrantDateIntrinsic_iS_c20210101__20211231_znxmW5Xvuj5e" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Intrinsic Value, Warrants Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1046">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231_zjsKxut8ci53" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1048">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zsT70MHQcSsc" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20210101__20211231_z7t6rNUQB4sf" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_zxzuLxuuvSQk" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1054">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Cancelled</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_pid_di_c20210101__20211231_z20sEr5QFUIa" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled"><span style="font-family: Times New Roman, Times, Serif">(26,015</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20211231_z9gN2zEqupCa" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1057">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding on December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20210101__20211231_z1iryFVsBlsk" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1059">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iE_c20210101__20211231_z7iD91JGcjUl" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1061">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentWarrantsOutstandingEndingWeightedAverageRemainingContractualTerm2_dtY0_c20210101__20211231_z0DyppjIVDBg" title="Remaining Life (yrs.) Warrants Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1063">-</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentWarrantBeginningInPeriodGrantDateIntrinsic_iE_c20210101__20211231_zwCMNUDScer3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Intrinsic Value, Warrants Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants exercisable on December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableNumber_iI_pid_c20211231_zZokwryoHAE7" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, exercisable, Ending balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1067">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingExercisableWeightedAverageNumberOfShare_iI_c20211231_zivXCqhbXj2k" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Exercisable, Ending Balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1069">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentWarrantsExercisableWeightedAverageRemainingContractualTerm2_dtY0_c20210101__20211231_ztdNo5YFFVsi" title="Remaining Life (yrs.) Warrants Exercisable, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1071">-</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentWarrantExercisableInPeriodGrantDateIntrinsic_iI_c20211231_zJQmO4mrVO29" title="Intrinsic Value, Warrants Outstanding, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1073">-</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 42015 12.00 P1Y10M24D 0.037 16000 11.04 26015 12.50 P1Y2M12D 26015 <p id="xdx_807_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zkcgIvRk4ene" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9. <span id="xdx_82B_zqXkPK3p7fW2">Commitments, Contingencies</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business. On August 12, 2020, a former consultant filed suit in the Superior Court of the State of California for Breach of Contract and non-payment of fees per said contract. At the time of the suit, the Company owed to the vendor for contractual fees the total of $<span id="xdx_90E_eus-gaap--LossContingencyDamagesSoughtValue_c20200811__20200812__srt--MajorCustomersAxis__custom--VendorMember_zews2Q4pvwO1" title="Contractual Fees">24,339</span>. On March 14, 2022, the Company accepted a Stipulation and Proposed Order for the payment of <span id="xdx_90F_eus-gaap--LossContingencyDamagesPaidValue_c20220313__20220314__srt--TitleOfIndividualAxis__custom--FormerConsultantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxHrY2Er7jrd" title="Payment of plaintiffs">$38,000</span> to the former consultant with the first payment of $<span id="xdx_90B_eus-gaap--LossContingencyDamagesPaidValue_c20220313__20220314__srt--TitleOfIndividualAxis__custom--FirstPaymentMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zVq1QRO6uV25" title="Payment of plaintiffs">5,000</span> being due immediately and additional $<span id="xdx_902_eus-gaap--LossContingencyDamagesPaidValue_c20220313__20220314__srt--TitleOfIndividualAxis__custom--EverySixtyDaysThereafterMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDcyig09Fg59" title="Payment of plaintiffs">5,000</span> payments to be paid every 60 days thereafter until the total of $<span id="xdx_90B_eus-gaap--LossContingencyDamagesPaidValue_c20220313__20220314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--FormerConsultantMember_zLVAr3w20v99" title="Payment of plaintiffs">38,000</span> is paid</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 24339 38000 5000 5000 38000 <p id="xdx_802_eus-gaap--RevenueFromContractWithCustomerTextBlock_zuoCigLGiwwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10. <span id="xdx_82F_z3RbEMPYeLFi">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC Topic 606, the Company recognizes revenue when the services have been completed. During the years ended December 31, 2021 and 2020, the Company recognized net revenue of $<span id="xdx_90B_eus-gaap--Revenues_c20210101__20211231_zcl9B9jvcvVg" title="Revenue">0</span> and $<span id="xdx_907_eus-gaap--Revenues_c20200101__20201231_zfUwiU7Yn5Df" title="Revenue">255,346</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 255346 <p id="xdx_807_eus-gaap--DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_zStIvxbquLWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11. <span id="xdx_828_zFpTGXcb5WKe">Derivative Valuation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluated the convertible debentures and associated warrants in accordance with ASC Topic 815, “Derivatives and Hedging,” and determined that the conversion feature of the convertible promissory notes was not afforded the exemption for conventional convertible instruments due to their variable conversion rates. The notes have no explicit limit on the number of shares issuable, so they did not meet the conditions set forth in current accounting standards for equity classification. In addition, the warrants have a Most Favoured Nations clause resulting in the exercise price of the warrants also not being fixed. Therefore, these have been characterized as derivative instruments. We elected to recognize the notes under ASU paragraph 815-15-25-4, whereby there would be a separation into a host contract and derivative instrument. We elected to initially and subsequently measure the notes and warrants in their entirety at fair value, with changes in fair value recognized in earnings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The debt discount is amortized over the life of the note and recognized as interest expense. For the years ended December 31, 2021 and 2020, the Company amortized the debt discount of $<span id="xdx_907_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember_z7SxLsablNN4" title="Amortized of debt discount">0 </span>and $<span id="xdx_902_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20200101__20201231__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember_zuqXSigQ2qp" title="Amortized of debt discount">619,799</span>, respectively, to interest expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zjshI4Ap6Vp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2021 and 2020, the Company had the following activity in the derivative liability account:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><span style="display: none"><span id="xdx_8B5_zOaWIGSOHrk1">Schedule of Derivative Liability</span></span> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Notes</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif">Derivative liability at January 1, 2020</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--NotesMember_zYYFpKZ7Jhl7" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Derivative liability, beginning balance"><span style="font-family: Times New Roman, Times, Serif">3,529,967</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsDerivativeMember_zAksAUlPyCol" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Derivative liability, beginning balance"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20200101__20201231_z1xAVrnKNYk7" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Derivative liability, beginning balance"><span style="font-family: Times New Roman, Times, Serif">3,529,974</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Addition of new conversion</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_ecustom--AdditionOfNewConversionOptionDerivatives_pp0p0_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--NotesMember_zfM5rOenBRD1" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Addition of new conversion"><span style="font-family: Times New Roman, Times, Serif">47,620</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--AdditionOfNewConversionOptionDerivatives_pdp0_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsDerivativeMember_zOZXxZXBJXPf" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Addition of new conversion"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1109">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--AdditionOfNewConversionOptionDerivatives_pp0p0_c20200101__20201231_zwyFjNYgJMbi" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Addition of new conversion"><span style="font-family: Times New Roman, Times, Serif">47,620</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Conversion of note derivatives</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--ConversionOfNoteDerivatives_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--NotesMember_pp0p0" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Conversion of note derivatives"><span style="font-family: Times New Roman, Times, Serif">(5,094,792</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--ConversionOfNoteDerivatives_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsDerivativeMember_pdp0" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Conversion of note derivatives"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_ecustom--ConversionOfNoteDerivatives_c20200101__20201231_pp0p0" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Conversion of note derivatives"><span style="font-family: Times New Roman, Times, Serif">(5,094,792</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Change in fair value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--NotesMember_pp0p0" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Change in fair value"><span style="font-family: Times New Roman, Times, Serif">5,442,306</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsDerivativeMember_pp0p0" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Change in fair value"><span style="font-family: Times New Roman, Times, Serif">(2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20200101__20201231_pp0p0" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Change in fair value"><span style="font-family: Times New Roman, Times, Serif">5,442,304</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Derivative liability at December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--NotesMember_z04NnxmEXJp8" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Derivative liability, beginning balance"><span style="font-family: Times New Roman, Times, Serif">3,925,101</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsDerivativeMember_zzIbHrM4FNE" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Derivative liability, beginning balance"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20210101__20211231_zvzT2BcUxd66" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Derivative liability, beginning balance"><span style="font-family: Times New Roman, Times, Serif">3,925,106</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Change in fair value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_pp0p0_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--NotesMember_zbabh4bp1Dql" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Change in fair value"><span style="font-family: Times New Roman, Times, Serif">(2,478,093</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_pp0p0_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsDerivativeMember_zIFps3fvGMK6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Change in fair value"><span style="font-family: Times New Roman, Times, Serif">(5</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_pp0p0_c20210101__20211231_zCNiWPVcRHSa" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Change in fair value"><span style="font-family: Times New Roman, Times, Serif">(2,478,098</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Derivative liability at December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--NotesMember_zKD73jlhrEN1" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Derivative liability, ending balance"><span style="font-family: Times New Roman, Times, Serif">1,447,008</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsDerivativeMember_z3qpyRVXTxge" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Derivative liability, ending balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1139">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20210101__20211231_z7WZTchUMyx7" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Derivative liability, ending balance"><span style="font-family: Times New Roman, Times, Serif">1,447,008</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A2_z7YwLcWWtT41" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zWwlVev56cjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follow:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><span style="display: none"><span id="xdx_8B3_z4WiwswKWqqb">Schedule of Assumptions Used Black Scholes Valuation of Derivative</span></span> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock price at valuation date</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember_z9sTk4wyEtZ3" title="Stock price at valuation date">.0002</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk free interest rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_dp_uPure_c20211231__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z7NcBwzBS3l5" title="Derivative liability, fair value measurement input, percentage">.06</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock volatility factor</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z4SRcjdvkyBg" title="Derivative liability, fair value measurement input, percentage">350.10</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Years to Maturity</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--DerivativeTermOfContract_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember_zLKncvx4K1T6" title="Derivative liability, term">.08</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dpn_uPure_c20211231__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zoM9xpFObIz7" title="Derivative liability, fair value measurement input, percentage">None</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AE_zxtethZcfFs9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 619799 <p id="xdx_898_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zjshI4Ap6Vp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2021 and 2020, the Company had the following activity in the derivative liability account:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><span style="display: none"><span id="xdx_8B5_zOaWIGSOHrk1">Schedule of Derivative Liability</span></span> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Notes</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif">Derivative liability at January 1, 2020</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--NotesMember_zYYFpKZ7Jhl7" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Derivative liability, beginning balance"><span style="font-family: Times New Roman, Times, Serif">3,529,967</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsDerivativeMember_zAksAUlPyCol" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Derivative liability, beginning balance"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20200101__20201231_z1xAVrnKNYk7" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Derivative liability, beginning balance"><span style="font-family: Times New Roman, Times, Serif">3,529,974</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Addition of new conversion</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_ecustom--AdditionOfNewConversionOptionDerivatives_pp0p0_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--NotesMember_zfM5rOenBRD1" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Addition of new conversion"><span style="font-family: Times New Roman, Times, Serif">47,620</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--AdditionOfNewConversionOptionDerivatives_pdp0_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsDerivativeMember_zOZXxZXBJXPf" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Addition of new conversion"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1109">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--AdditionOfNewConversionOptionDerivatives_pp0p0_c20200101__20201231_zwyFjNYgJMbi" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Addition of new conversion"><span style="font-family: Times New Roman, Times, Serif">47,620</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Conversion of note derivatives</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--ConversionOfNoteDerivatives_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--NotesMember_pp0p0" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Conversion of note derivatives"><span style="font-family: Times New Roman, Times, Serif">(5,094,792</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--ConversionOfNoteDerivatives_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsDerivativeMember_pdp0" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Conversion of note derivatives"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_ecustom--ConversionOfNoteDerivatives_c20200101__20201231_pp0p0" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Conversion of note derivatives"><span style="font-family: Times New Roman, Times, Serif">(5,094,792</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Change in fair value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--NotesMember_pp0p0" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Change in fair value"><span style="font-family: Times New Roman, Times, Serif">5,442,306</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsDerivativeMember_pp0p0" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Change in fair value"><span style="font-family: Times New Roman, Times, Serif">(2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20200101__20201231_pp0p0" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Change in fair value"><span style="font-family: Times New Roman, Times, Serif">5,442,304</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Derivative liability at December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--NotesMember_z04NnxmEXJp8" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Derivative liability, beginning balance"><span style="font-family: Times New Roman, Times, Serif">3,925,101</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsDerivativeMember_zzIbHrM4FNE" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Derivative liability, beginning balance"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20210101__20211231_zvzT2BcUxd66" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Derivative liability, beginning balance"><span style="font-family: Times New Roman, Times, Serif">3,925,106</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Change in fair value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_pp0p0_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--NotesMember_zbabh4bp1Dql" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Change in fair value"><span style="font-family: Times New Roman, Times, Serif">(2,478,093</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_pp0p0_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsDerivativeMember_zIFps3fvGMK6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Change in fair value"><span style="font-family: Times New Roman, Times, Serif">(5</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_pp0p0_c20210101__20211231_zCNiWPVcRHSa" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Change in fair value"><span style="font-family: Times New Roman, Times, Serif">(2,478,098</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Derivative liability at December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--NotesMember_zKD73jlhrEN1" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Derivative liability, ending balance"><span style="font-family: Times New Roman, Times, Serif">1,447,008</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsDerivativeMember_z3qpyRVXTxge" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Derivative liability, ending balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1139">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20210101__20211231_z7WZTchUMyx7" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Derivative liability, ending balance"><span style="font-family: Times New Roman, Times, Serif">1,447,008</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 3529967 7 3529974 47620 47620 -5094792 -5094792 5442306 -2 5442304 3925101 5 3925106 -2478093 -5 -2478098 1447008 1447008 <p id="xdx_897_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zWwlVev56cjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follow:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><span style="display: none"><span id="xdx_8B3_z4WiwswKWqqb">Schedule of Assumptions Used Black Scholes Valuation of Derivative</span></span> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock price at valuation date</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember_z9sTk4wyEtZ3" title="Stock price at valuation date">.0002</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk free interest rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_dp_uPure_c20211231__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z7NcBwzBS3l5" title="Derivative liability, fair value measurement input, percentage">.06</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock volatility factor</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z4SRcjdvkyBg" title="Derivative liability, fair value measurement input, percentage">350.10</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Years to Maturity</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--DerivativeTermOfContract_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember_zLKncvx4K1T6" title="Derivative liability, term">.08</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dpn_uPure_c20211231__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zoM9xpFObIz7" title="Derivative liability, fair value measurement input, percentage">None</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 0.0002 0.0006 3.5010 P0Y29D 0 <p id="xdx_804_eus-gaap--CashFlowSupplementalDisclosuresTextBlock_zeYvOYM5okSa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12. <span id="xdx_829_zNJXyiAaYuek">Supplemental Cash Flow Information</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company had the following cash and non-cash investing and financing activities:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued <span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesNewIssue_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zrNyPDlyLR1a">350,000</span> shares of preferred series E convertible stock for $<span id="xdx_90F_ecustom--StockIssuedDuringPeriodValueNewIssue_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zXLUgCS1RlVk">350,000</span> cash received.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued <span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znNM5I6V7u1h" title="Conversion of stock, shares converted">1,643,200,000</span> shares of common stock for conversion of <span id="xdx_908_ecustom--ConversionOfStockShareConverted1_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_z6yw0HbWPDR5">163,400</span> shares preferred series E convertible stock valued at $<span id="xdx_90D_ecustom--ConversionsOfStockAmountConverted1_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7ZBcpLOrDck">163,400</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued <span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesIssuedForService_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdx73752ZZ91" title="Number of common stock shares issued for services">2,001,666</span> shares of common stock valued at $<span id="xdx_902_ecustom--StockIssuedDuringPeriodValueIssuedForService_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zV7qogCvPmfa" title="Value of common stock shares issued for services">750</span> for services</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company had the following non-cash investing and financing activities:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued <span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20200101__20201231_zwsl9gUdsQw2" title="Stock issued during the period for settlement of debt, shares">16,849,013,669</span> shares of common stock for settlement of debt of $<span id="xdx_90C_eus-gaap--DebtConversionOriginalDebtAmount1_c20200101__20201231_zuQYK06WQIqg" title="Stock issued during the period for settlement of debt,value">1,607,317</span>, accrued interest of $<span id="xdx_906_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20201231_z3XWitOFVPNg" title="Accrued interest">145,167</span> and $<span id="xdx_900_eus-gaap--PaymentsOfFinancingCosts_c20200101__20201231_zDTx4YExQYA3" title="Financing costs">95,933</span> of financing costs</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued<span id="xdx_907_ecustom--StockIssuedDuringPeriodSharesIssuedForService_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0uYI5Omhi62" title="Shares issued during period for services, shares"> 668,332</span> shares of common stock valued at $<span id="xdx_902_ecustom--StockIssuedDuringPeriodValueIssuedForService_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfPRpqXHOXue" title="Shares issued during period for services, value">1,737</span> for services</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 350000 350000 1643200000 163400 163400 2001666 750 16849013669 1607317 145167 95933 668332 1737 <p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_zwdMpOYRXZX2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 13. <span id="xdx_823_zhXIXIFkiawc">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 14, 2022, the Company accepted a Stipulation and Proposed Order for the payment of $<span id="xdx_90C_eus-gaap--LossContingencyDamagesPaidValue_c20220313__20220314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--FormerConsultantMember_zQ0oUrmFxQUf" title="Payment of plaintiffs">38,000</span> to the former consultant who had filed a lawsuit on August 12, 2020 in the Superior Court of the State of California for Breach of Contract and non-payment of fees per said contract. See Footnote 9</span></p> 38000 EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 60 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 127 259 1 false 47 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://ewellnesshealth.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://ewellnesshealth.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://ewellnesshealth.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://ewellnesshealth.com/role/StatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Reconciliation of Stockholders' Deficit Sheet http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit Reconciliation of Stockholders' Deficit Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statement of Cash Flows Sheet http://ewellnesshealth.com/role/StatementOfCashFlows Consolidated Statement of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - The Company Sheet http://ewellnesshealth.com/role/Company The Company Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Property and Equipment Sheet http://ewellnesshealth.com/role/PropertyAndEquipment Property and Equipment Notes 9 false false R10.htm 00000010 - Disclosure - Intangible Assets Sheet http://ewellnesshealth.com/role/IntangibleAssets Intangible Assets Notes 10 false false R11.htm 00000011 - Disclosure - Income Taxes Sheet http://ewellnesshealth.com/role/IncomeTaxes Income Taxes Notes 11 false false R12.htm 00000012 - Disclosure - Related Party Transactions Sheet http://ewellnesshealth.com/role/RelatedPartyTransactions Related Party Transactions Notes 12 false false R13.htm 00000013 - Disclosure - Convertible Notes Payable Notes http://ewellnesshealth.com/role/ConvertibleNotesPayable Convertible Notes Payable Notes 13 false false R14.htm 00000014 - Disclosure - Equity Transactions Sheet http://ewellnesshealth.com/role/EquityTransactions Equity Transactions Notes 14 false false R15.htm 00000015 - Disclosure - Commitments, Contingencies Sheet http://ewellnesshealth.com/role/CommitmentsContingencies Commitments, Contingencies Notes 15 false false R16.htm 00000016 - Disclosure - Revenue Recognition Sheet http://ewellnesshealth.com/role/RevenueRecognition Revenue Recognition Notes 16 false false R17.htm 00000017 - Disclosure - Derivative Valuation Sheet http://ewellnesshealth.com/role/DerivativeValuation Derivative Valuation Notes 17 false false R18.htm 00000018 - Disclosure - Supplemental Cash Flow Information Sheet http://ewellnesshealth.com/role/SupplementalCashFlowInformation Supplemental Cash Flow Information Notes 18 false false R19.htm 00000019 - Disclosure - Subsequent Events Sheet http://ewellnesshealth.com/role/SubsequentEvents Subsequent Events Notes 19 false false R20.htm 00000020 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies 21 false false R22.htm 00000022 - Disclosure - Income Taxes (Tables) Sheet http://ewellnesshealth.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://ewellnesshealth.com/role/IncomeTaxes 22 false false R23.htm 00000023 - Disclosure - Equity Transactions (Tables) Sheet http://ewellnesshealth.com/role/EquityTransactionsTables Equity Transactions (Tables) Tables http://ewellnesshealth.com/role/EquityTransactions 23 false false R24.htm 00000024 - Disclosure - Derivative Valuation (Tables) Sheet http://ewellnesshealth.com/role/DerivativeValuationTables Derivative Valuation (Tables) Tables http://ewellnesshealth.com/role/DerivativeValuation 24 false false R25.htm 00000025 - Disclosure - The Company (Details Narrative) Sheet http://ewellnesshealth.com/role/CompanyDetailsNarrative The Company (Details Narrative) Details http://ewellnesshealth.com/role/Company 25 false false R26.htm 00000026 - Disclosure - Summary of Assets and Liabilities Fair Value on Recurring Basis (Details) Sheet http://ewellnesshealth.com/role/SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails Summary of Assets and Liabilities Fair Value on Recurring Basis (Details) Details 26 false false R27.htm 00000027 - Disclosure - Schedule of Estimated Useful Lives for Significant Property and Equipment (Details) Sheet http://ewellnesshealth.com/role/ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentDetails Schedule of Estimated Useful Lives for Significant Property and Equipment (Details) Details 27 false false R28.htm 00000028 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://ewellnesshealth.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 28 false false R29.htm 00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesTables 29 false false R30.htm 00000030 - Disclosure - Property and Equipment (Details Narrative) Sheet http://ewellnesshealth.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://ewellnesshealth.com/role/PropertyAndEquipment 30 false false R31.htm 00000031 - Disclosure - Intangible Assets (Details Narrative) Sheet http://ewellnesshealth.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://ewellnesshealth.com/role/IntangibleAssets 31 false false R32.htm 00000032 - Disclosure - Schedule of Deferred Tax Liabilities (Details) Sheet http://ewellnesshealth.com/role/ScheduleOfDeferredTaxLiabilitiesDetails Schedule of Deferred Tax Liabilities (Details) Details 32 false false R33.htm 00000033 - Disclosure - Schedule of Pre-tax from Continuing Operations (Details) Sheet http://ewellnesshealth.com/role/ScheduleOfPre-taxFromContinuingOperationsDetails Schedule of Pre-tax from Continuing Operations (Details) Details 33 false false R34.htm 00000034 - Disclosure - Income Taxes (Details Narrative) Sheet http://ewellnesshealth.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://ewellnesshealth.com/role/IncomeTaxesTables 34 false false R35.htm 00000035 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://ewellnesshealth.com/role/RelatedPartyTransactions 35 false false R36.htm 00000036 - Disclosure - Convertible Notes Payable (Details Narrative) Notes http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative Convertible Notes Payable (Details Narrative) Details http://ewellnesshealth.com/role/ConvertibleNotesPayable 36 false false R37.htm 00000037 - Disclosure - Summary of Stock Options Activity (Details) Sheet http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails Summary of Stock Options Activity (Details) Details 37 false false R38.htm 00000038 - Disclosure - Summary of Warrants Activity (Details) Sheet http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails Summary of Warrants Activity (Details) Details 38 false false R39.htm 00000039 - Disclosure - Equity Transactions (Details Narrative) Sheet http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative Equity Transactions (Details Narrative) Details http://ewellnesshealth.com/role/EquityTransactionsTables 39 false false R40.htm 00000040 - Disclosure - Commitments, Contingencies (Details Narrative) Sheet http://ewellnesshealth.com/role/CommitmentsContingenciesDetailsNarrative Commitments, Contingencies (Details Narrative) Details http://ewellnesshealth.com/role/CommitmentsContingencies 40 false false R41.htm 00000041 - Disclosure - Revenue Recognition (Details Narrative) Sheet http://ewellnesshealth.com/role/RevenueRecognitionDetailsNarrative Revenue Recognition (Details Narrative) Details http://ewellnesshealth.com/role/RevenueRecognition 41 false false R42.htm 00000042 - Disclosure - Schedule of Derivative Liability (Details) Sheet http://ewellnesshealth.com/role/ScheduleOfDerivativeLiabilityDetails Schedule of Derivative Liability (Details) Details 42 false false R43.htm 00000043 - Disclosure - Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details) Sheet http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details) Details 43 false false R44.htm 00000044 - Disclosure - Derivative Valuation (Details Narrative) Sheet http://ewellnesshealth.com/role/DerivativeValuationDetailsNarrative Derivative Valuation (Details Narrative) Details http://ewellnesshealth.com/role/DerivativeValuationTables 44 false false R45.htm 00000045 - Disclosure - Supplemental Cash Flow Information (Details Narrative) Sheet http://ewellnesshealth.com/role/SupplementalCashFlowInformationDetailsNarrative Supplemental Cash Flow Information (Details Narrative) Details http://ewellnesshealth.com/role/SupplementalCashFlowInformation 45 false false R46.htm 00000046 - Disclosure - Subsequent Events (Details Narrative) Sheet http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://ewellnesshealth.com/role/SubsequentEvents 46 false false All Reports Book All Reports form10-k.htm ewll-20211231.xsd ewll-20211231_cal.xml ewll-20211231_def.xml ewll-20211231_lab.xml ewll-20211231_pre.xml ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm form10-k_001.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 65 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-k.htm": { "axisCustom": 0, "axisStandard": 15, "contextCount": 127, "dts": { "calculationLink": { "local": [ "ewll-20211231_cal.xml" ] }, "definitionLink": { "local": [ "ewll-20211231_def.xml" ] }, "inline": { "local": [ "form10-k.htm" ] }, "labelLink": { "local": [ "ewll-20211231_lab.xml" ] }, "presentationLink": { "local": [ "ewll-20211231_pre.xml" ] }, "schema": { "local": [ "ewll-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 421, "entityCount": 1, "hidden": { "http://ewellnesshealth.com/20211231": 56, "http://fasb.org/us-gaap/2021-01-31": 131, "http://xbrl.sec.gov/dei/2021q4": 3, "total": 190 }, "keyCustom": 52, "keyStandard": 207, "memberCustom": 23, "memberStandard": 24, "nsprefix": "EWLL", "nsuri": "http://ewellnesshealth.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://ewellnesshealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Intangible Assets", "role": "http://ewellnesshealth.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Income Taxes", "role": "http://ewellnesshealth.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Related Party Transactions", "role": "http://ewellnesshealth.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Convertible Notes Payable", "role": "http://ewellnesshealth.com/role/ConvertibleNotesPayable", "shortName": "Convertible Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Equity Transactions", "role": "http://ewellnesshealth.com/role/EquityTransactions", "shortName": "Equity Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Commitments, Contingencies", "role": "http://ewellnesshealth.com/role/CommitmentsContingencies", "shortName": "Commitments, Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Revenue Recognition", "role": "http://ewellnesshealth.com/role/RevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Derivative Valuation", "role": "http://ewellnesshealth.com/role/DerivativeValuation", "shortName": "Derivative Valuation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Supplemental Cash Flow Information", "role": "http://ewellnesshealth.com/role/SupplementalCashFlowInformation", "shortName": "Supplemental Cash Flow Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Subsequent Events", "role": "http://ewellnesshealth.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets", "role": "http://ewellnesshealth.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Income Taxes (Tables)", "role": "http://ewellnesshealth.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Equity Transactions (Tables)", "role": "http://ewellnesshealth.com/role/EquityTransactionsTables", "shortName": "Equity Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Derivative Valuation (Tables)", "role": "http://ewellnesshealth.com/role/DerivativeValuationTables", "shortName": "Derivative Valuation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfessionalFees", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - The Company (Details Narrative)", "role": "http://ewellnesshealth.com/role/CompanyDetailsNarrative", "shortName": "The Company (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-04-19", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Summary of Assets and Liabilities Fair Value on Recurring Basis (Details)", "role": "http://ewellnesshealth.com/role/SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails", "shortName": "Summary of Assets and Liabilities Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Schedule of Estimated Useful Lives for Significant Property and Equipment (Details)", "role": "http://ewellnesshealth.com/role/ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentDetails", "shortName": "Schedule of Estimated Useful Lives for Significant Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "role": "http://ewellnesshealth.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "shortName": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "role": "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "EWLL:GoingConcernPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "lang": null, "name": "EWLL:WorkingCapitalDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://ewellnesshealth.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Property and Equipment (Details Narrative)", "role": "http://ewellnesshealth.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "Property and Equipment (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Intangible Assets (Details Narrative)", "role": "http://ewellnesshealth.com/role/IntangibleAssetsDetailsNarrative", "shortName": "Intangible Assets (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Schedule of Deferred Tax Liabilities (Details)", "role": "http://ewellnesshealth.com/role/ScheduleOfDeferredTaxLiabilitiesDetails", "shortName": "Schedule of Deferred Tax Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "EWLL:IncomeTaxReconciliationNondeductibleExpenseBookIncome", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Schedule of Pre-tax from Continuing Operations (Details)", "role": "http://ewellnesshealth.com/role/ScheduleOfPre-taxFromContinuingOperationsDetails", "shortName": "Schedule of Pre-tax from Continuing Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "EWLL:IncomeTaxReconciliationNondeductibleExpenseBookIncome", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Income Taxes (Details Narrative)", "role": "http://ewellnesshealth.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income Taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Related Party Transactions (Details Narrative)", "role": "http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestPayableCurrentAndNoncurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Convertible Notes Payable (Details Narrative)", "role": "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative", "shortName": "Convertible Notes Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_ConvertibleNotesPayableMember", "decimals": "0", "lang": null, "name": "us-gaap:InterestPayableCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Summary of Stock Options Activity (Details)", "role": "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails", "shortName": "Summary of Stock Options Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Summary of Warrants Activity (Details)", "role": "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails", "shortName": "Summary of Warrants Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "span", "span", "p", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-04-19", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Equity Transactions (Details Narrative)", "role": "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "shortName": "Equity Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:DeferredCompensationEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations", "role": "http://ewellnesshealth.com/role/StatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-03-132022-03-14_custom_FormerConsultantMember_us-gaap_SubsequentEventMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LossContingencyDamagesPaidValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Commitments, Contingencies (Details Narrative)", "role": "http://ewellnesshealth.com/role/CommitmentsContingenciesDetailsNarrative", "shortName": "Commitments, Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-03-132022-03-14_custom_FirstPaymentMember_us-gaap_SubsequentEventMember", "decimals": "0", "lang": null, "name": "us-gaap:LossContingencyDamagesPaidValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Revenue Recognition (Details Narrative)", "role": "http://ewellnesshealth.com/role/RevenueRecognitionDetailsNarrative", "shortName": "Revenue Recognition (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Schedule of Derivative Liability (Details)", "role": "http://ewellnesshealth.com/role/ScheduleOfDerivativeLiabilityDetails", "shortName": "Schedule of Derivative Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31", "decimals": "0", "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_custom_DerivativeLiabilityMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details)", "role": "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails", "shortName": "Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_custom_DerivativeLiabilityMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfDebtDiscountPremium", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - Derivative Valuation (Details Narrative)", "role": "http://ewellnesshealth.com/role/DerivativeValuationDetailsNarrative", "shortName": "Derivative Valuation (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_custom_DerivativeLiabilityMember", "decimals": "0", "lang": null, "name": "us-gaap:AmortizationOfDebtDiscountPremium", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - Supplemental Cash Flow Information (Details Narrative)", "role": "http://ewellnesshealth.com/role/SupplementalCashFlowInformationDetailsNarrative", "shortName": "Supplemental Cash Flow Information (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "0", "lang": null, "name": "us-gaap:DebtConversionOriginalDebtAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-03-132022-03-14_custom_FormerConsultantMember_us-gaap_SubsequentEventMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LossContingencyDamagesPaidValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - Subsequent Events (Details Narrative)", "role": "http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Reconciliation of Stockholders' Deficit", "role": "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit", "shortName": "Reconciliation of Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statement of Cash Flows", "role": "http://ewellnesshealth.com/role/StatementOfCashFlows", "shortName": "Consolidated Statement of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - The Company", "role": "http://ewellnesshealth.com/role/Company", "shortName": "The Company", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Summary of Significant Accounting Policies", "role": "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Property and Equipment", "role": "http://ewellnesshealth.com/role/PropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 47, "tag": { "EWLL_AccruedLiabilitiesRelatedPartiesCurrent": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued liabilities related parties current.", "label": "Accrued expenses - related party" } } }, "localname": "AccruedLiabilitiesRelatedPartiesCurrent", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "EWLL_AdditionOfNewConversionOptionDerivatives": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Addition of new conversion option derivatives.", "label": "Addition of new conversion" } } }, "localname": "AdditionOfNewConversionOptionDerivatives", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfDerivativeLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "EWLL_AdjustmentsToAdditionalPaidInCapitalContributedServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital contributed services.", "label": "Contributed services" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalContributedServices", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "EWLL_BistromaticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bistromatics Inc. [Member]", "label": "Bistromatics Inc. [Member]" } } }, "localname": "BistromaticsIncMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/CompanyDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_BoardOfDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Board of Directors [Member]", "label": "Board of Directors [Member]" } } }, "localname": "BoardOfDirectorsMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_CashPaidAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash paid for:" } } }, "localname": "CashPaidAbstract", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "EWLL_ConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consultant [Member]", "label": "Consultant [Member]" } } }, "localname": "ConsultantMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_ContributedServices": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contributed services.", "label": "ContributedServices", "verboseLabel": "Contributed services" } } }, "localname": "ContributedServices", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EWLL_ConversionOfNoteDerivatives": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Conversion of note derivatives.", "label": "Conversion of note derivatives" } } }, "localname": "ConversionOfNoteDerivatives", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfDerivativeLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "EWLL_ConversionOfStockShareConverted1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "[custom:ConversionOfStockShareConverted1]" } } }, "localname": "ConversionOfStockShareConverted1", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/SupplementalCashFlowInformationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "EWLL_ConversionsOfStockAmountConverted1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "[custom:ConversionsOfStockAmountConverted1]" } } }, "localname": "ConversionsOfStockAmountConverted1", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/SupplementalCashFlowInformationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "EWLL_ConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Notes [Member]", "label": "Convertible Notes [Member]" } } }, "localname": "ConvertibleNotesMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_DeferredTaxAssetsTaxDepreciation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Depreciation.", "label": "Depreciation [Default Label]", "verboseLabel": "Depreciation" } } }, "localname": "DeferredTaxAssetsTaxDepreciation", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfDeferredTaxLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "EWLL_DerivativeLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Derivative liability.", "label": "DerivativeLiability", "verboseLabel": "Derivative liability" } } }, "localname": "DerivativeLiability", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "EWLL_DerivativeLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Liability [Member]", "label": "Derivative Liability [Member]" } } }, "localname": "DerivativeLiabilityMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/DerivativeValuationDetailsNarrative", "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "domainItemType" }, "EWLL_DescriptionOfChangesInParValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes in par value.", "label": "Description of change in par value" } } }, "localname": "DescriptionOfChangesInParValue", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/CompanyDetailsNarrative" ], "xbrltype": "stringItemType" }, "EWLL_EverySixtyDaysThereafterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Every Sixty Days Thereafter [Member]", "label": "Every Sixty Days Thereafter [Member]" } } }, "localname": "EverySixtyDaysThereafterMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/CommitmentsContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_FirstPaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First Payment [Member]", "label": "First Payment [Member]" } } }, "localname": "FirstPaymentMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/CommitmentsContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_FormerConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Consultant [Member]", "label": "Former Consultant [Member]" } } }, "localname": "FormerConsultantMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/CommitmentsContingenciesDetailsNarrative", "http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_GainOnExtinguishmentOfDebt": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain on extinguishment of debt.", "label": "GainOnExtinguishmentOfDebt", "negatedLabel": "Gain on extinguishment of debt" } } }, "localname": "GainOnExtinguishmentOfDebt", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EWLL_GoingConcernPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Going Concern [Policy Text Block]", "label": "Going Concern" } } }, "localname": "GoingConcernPolicyTextBlock", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "EWLL_IncomeTaxReconciliationNondeductibleExpenseBookIncome": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income Tax Reconciliation Nondeductible Expense Book Income.", "label": "Book loss" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseBookIncome", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfPre-taxFromContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "EWLL_IncomeTaxReconciliationNondeductibleExpenseGainOnDebtExtinguishment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation nondeductible expense gain on debt extinguishment.", "label": "Gain on debt extinguishment" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseGainOnDebtExtinguishment", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfPre-taxFromContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "EWLL_IncomeTaxReconciliationNondeductibleExpenseLossOnDisposal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation nondeductible expense loss on disposal", "label": "Loss on disposal" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseLossOnDisposal", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfPre-taxFromContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "EWLL_IncomeTaxReconciliationNondeductibleExpenseRelatedPartyAccruals": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation nondeductible expense related party accruals", "label": "Related party accruals" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseRelatedPartyAccruals", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfPre-taxFromContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "EWLL_IncomeTaxReconciliationNondeductibleExpenseStockForConsulting": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation nondeductible expense stock for consulting.", "label": "Stock for consulting" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseStockForConsulting", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfPre-taxFromContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "EWLL_IncomeTaxReconciliationNondeductibleExpenseStockForPrepaids": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation nondeductible expense stock for prepaids.", "label": "Stock for prepaids" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseStockForPrepaids", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfPre-taxFromContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "EWLL_IncreaseDecreaseInAccountsReceivableNet": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in accrued receivables net", "label": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivableNet", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EWLL_IncreaseDecreaseInAccruedLiabilitiesRelatedParties": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in accrued liabilities related parties.", "label": "IncreaseDecreaseInAccruedLiabilitiesRelatedParties", "verboseLabel": "Accrued expenses - related party" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesRelatedParties", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EWLL_IncreaseDecreaseInPrepaidExpenseNet": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in prepaid expenses.", "label": "Prepaid expense" } } }, "localname": "IncreaseDecreaseInPrepaidExpenseNet", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EWLL_InterestPayableNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest payable current and Noncurrent.", "label": "InterestPayableNoncurrent", "verboseLabel": "Accrued interest" } } }, "localname": "InterestPayableNoncurrent", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "EWLL_NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes [Member]", "label": "Notes [Member]" } } }, "localname": "NotesMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfDerivativeLiabilityDetails" ], "xbrltype": "domainItemType" }, "EWLL_OfficersAndDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Officers and Directors [Member]", "label": "Officers and Directors [Member]" } } }, "localname": "OfficersAndDirectorsMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_OfficersDirectorsAndConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Officers, Directors and Consultants [Member]", "label": "Officers, Directors and Consultants [Member]" } } }, "localname": "OfficersDirectorsAndConsultantsMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_OperatingLossCarryforwardLossExpirationTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating loss carry forward loss expiration Term.", "label": "Income taxable description" } } }, "localname": "OperatingLossCarryforwardLossExpirationTerm", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "EWLL_PreferredSeriesEConversionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Series E Conversion [Member]", "label": "Preferred Series E Conversion [Member]" } } }, "localname": "PreferredSeriesEConversionMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_SeriesCConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C Convertible Preferred Stock [Member]", "label": "Series C Convertible Preferred Stock [Member]" } } }, "localname": "SeriesCConvertiblePreferredStockMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_SeriesDVotingPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D Voting Preferred Stock [Member]", "label": "Series D Voting Preferred Stock [Member]" } } }, "localname": "SeriesDVotingPreferredStockMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_SeriesEConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series E Convertible Preferred Stock [Member]", "label": "Series E Convertible Preferred Stock [Member]" } } }, "localname": "SeriesEConvertiblePreferredStockMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_ServicesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Services Agreement [Member]", "label": "Services Agreement [Member]" } } }, "localname": "ServicesAgreementMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/CompanyDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_SettlementAndCompromiseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Settlement and compromise agreement [Member]", "label": "Settlement and compromise agreement [Member]" } } }, "localname": "SettlementAndCompromiseAgreementMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Warrants, exercisable, Ending balance.", "label": "Number of Warrants, exercisable, Ending balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableNumber", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "EWLL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Forfeited Or Expired In Period Weighted Average Exercise Price.", "label": "Weighted Average Exercise Price, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedInPeriodWeightedAverageExercisePrice", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "EWLL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingExercisableWeightedAverageNumberOfShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price, Exercisable Ending.", "label": "Weighted Average Exercise Price Exercisable, Ending Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingExercisableWeightedAverageNumberOfShare", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "EWLL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Weighted Average Number Of Share.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare", "periodEndLabel": "Weighted Average Exercise Price, Warrants Outstanding, Ending Balance", "periodStartLabel": "Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "EWLL_ShareBasedCompensationArrangementByShareBasedPaymentWarrantBeginningInPeriodGrantDateIntrinsic": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intrinsic Value, Warrants Outstanding.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentWarrantBeginningInPeriodGrantDateIntrinsic", "periodEndLabel": "Intrinsic Value, Warrants Outstanding, Ending Balance", "periodStartLabel": "Intrinsic Value, Warrants Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentWarrantBeginningInPeriodGrantDateIntrinsic", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "EWLL_ShareBasedCompensationArrangementByShareBasedPaymentWarrantExercisableInPeriodGrantDateIntrinsic": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price, Warrants Exercisable", "label": "Intrinsic Value, Warrants Outstanding, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentWarrantExercisableInPeriodGrantDateIntrinsic", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "EWLL_SharebasedCompensationArrangementBySharebasedPaymentAwardCancelledOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intrinsic Value, Warrants Outstanding, Cancelled", "label": "Remaining Life (yrs) expired/ cancelled" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCancelledOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "EWLL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingEndingWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remaining Life (yrs), Ending.", "label": "Remaining Life (yrs) Outstanding, Ending Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingEndingWeightedAverageRemainingContractualTerm2", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "EWLL_SharebasedCompensationArrangementBySharebasedPaymentWarrantsExercisableWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remaining Life (yrs), Exercisable Ending.", "label": "Remaining Life (yrs.) Warrants Exercisable, Ending Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentWarrantsExercisableWeightedAverageRemainingContractualTerm2", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "durationItemType" }, "EWLL_SharebasedCompensationArrangementBySharebasedPaymentWarrantsOutstandingEndingWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remaining Life (yrs), Ending.", "label": "Remaining Life (yrs.) Warrants Outstanding, Ending Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentWarrantsOutstandingEndingWeightedAverageRemainingContractualTerm2", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "durationItemType" }, "EWLL_SharebasedCompensationArrangementBySharebasedPaymentWarrantsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remaining Life (yrs), Beginning.", "label": "Remaining Life (yrs.) Warrants Outstanding, Beginning Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentWarrantsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "durationItemType" }, "EWLL_SharesIssuedForConsultingServices": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Shares issued for consulting services.", "label": "Shares issued for consulting services" } } }, "localname": "SharesIssuedForConsultingServices", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EWLL_SharesIssuedForDebtConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares issued for debt conversion.", "label": "SharesIssuedForDebtConversion", "verboseLabel": "Shares issued for debt conversion" } } }, "localname": "SharesIssuedForDebtConversion", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EWLL_SharesIssuedForFinancingCosts": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Shares issued for financing costs.", "label": "Shares issued for financing costs" } } }, "localname": "SharesIssuedForFinancingCosts", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EWLL_SharesIssuedToOfficersDirectorsAndConsultants": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Shares issued to officers directors and consultants.", "label": "SharesIssuedToOfficersDirectorsAndConsultants", "verboseLabel": "Shares issued to officers, directors and consultants" } } }, "localname": "SharesIssuedToOfficersDirectorsAndConsultants", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EWLL_SharesToBeIssued": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares to be issued.", "label": "Shares to be issued" } } }, "localname": "SharesToBeIssued", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "EWLL_SharesToBeIssuedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares to be Issued [Member]", "label": "Shares to be Issued [Member]" } } }, "localname": "SharesToBeIssuedMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "EWLL_StockIssuedDuringPeriodSharesDebtConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares issued for debt conversion, shares.", "label": "Shares issued for debt conversion, shares" } } }, "localname": "StockIssuedDuringPeriodSharesDebtConversion", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "EWLL_StockIssuedDuringPeriodSharesIssuedForService": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Shares issued during period for services, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForService", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/SupplementalCashFlowInformationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "EWLL_StockIssuedDuringPeriodSharesNewIssue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "[custom:StockIssuedDuringPeriodSharesNewIssue]" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssue", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/SupplementalCashFlowInformationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "EWLL_StockIssuedDuringPeriodSharesOfficersAndDirectors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares officers and directors", "label": "StockIssuedDuringPeriodSharesOfficersAndDirectors", "verboseLabel": "Shares issued to officers, directors and consultants, shares" } } }, "localname": "StockIssuedDuringPeriodSharesOfficersAndDirectors", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "EWLL_StockIssuedDuringPeriodSharesToBeIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares to be issued.", "label": "Number of sharesto be issued" } } }, "localname": "StockIssuedDuringPeriodSharesToBeIssued", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "EWLL_StockIssuedDuringPeriodSharesValueToBeIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares value to be issued.", "label": "Number of sharesto be issued, value" } } }, "localname": "StockIssuedDuringPeriodSharesValueToBeIssued", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "EWLL_StockIssuedDuringPeriodValueDebtConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares issued for debt conversion.", "label": "Shares issued for debt conversion" } } }, "localname": "StockIssuedDuringPeriodValueDebtConversion", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "EWLL_StockIssuedDuringPeriodValueDiscontinuedOperations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value discontinued operations.", "label": "Discontinued operations" } } }, "localname": "StockIssuedDuringPeriodValueDiscontinuedOperations", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "EWLL_StockIssuedDuringPeriodValueIssuedForService": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares issued for services.", "label": "Shares issued during period for services, value" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForService", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/SupplementalCashFlowInformationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "EWLL_StockIssuedDuringPeriodValueNewIssue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "[custom:StockIssuedDuringPeriodValueNewIssue]" } } }, "localname": "StockIssuedDuringPeriodValueNewIssue", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/SupplementalCashFlowInformationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "EWLL_StockIssuedDuringPeriodValueReverseStockSplits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period value reverse stock splits.", "label": "Shares issued for rounding - 50:1 split" } } }, "localname": "StockIssuedDuringPeriodValueReverseStockSplits", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "EWLL_TransferredComputersAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Transferred computers and equipment.", "label": "Transferred computers and equipment" } } }, "localname": "TransferredComputersAndEquipment", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "EWLL_TwelveMonthAdvisoryServicesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "12- month Advisory Services Agreement [Member]", "label": "12- month Advisory Services Agreement [Member]" } } }, "localname": "TwelveMonthAdvisoryServicesAgreementMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_TwelvePercentConvertiblePromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "12% Convertible Promissory Note [Member]", "label": "12% Convertible Promissory Note [Member]" } } }, "localname": "TwelvePercentConvertiblePromissoryNoteMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_TwoThousandNineteenConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Convertible Notes [Member]", "label": "2019 Convertible Notes [Member]" } } }, "localname": "TwoThousandNineteenConvertibleNotesMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_VendorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vendor [Member]", "label": "Vendor [Member]" } } }, "localname": "VendorMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/CommitmentsContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_WarrantsDerivativeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants Derivative [Member]", "label": "Warrants Derivative [Member]" } } }, "localname": "WarrantsDerivativeMember", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfDerivativeLiabilityDetails" ], "xbrltype": "domainItemType" }, "EWLL_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Working capital deficit.", "label": "Working capital deficit", "negatedLabel": "Working capital deficit" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://ewellnesshealth.com/20211231", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r448", "r450", "r451" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r448", "r450", "r451" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r448", "r450", "r451" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r448", "r450", "r451" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents incorporated by reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/CompanyDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/CompanyDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r143", "r262", "r264", "r421" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CommitmentsContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r184", "r220", "r281", "r282", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r420", "r422", "r435", "r436" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r184", "r220", "r281", "r282", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r420", "r422", "r435", "r436" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r143", "r262", "r264", "r421" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CommitmentsContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r184", "r220", "r268", "r281", "r282", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r420", "r422", "r435", "r436" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r184", "r220", "r268", "r281", "r282", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r420", "r422", "r435", "r436" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r144", "r373" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CommitmentsContingenciesDetailsNarrative", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CommitmentsContingenciesDetailsNarrative", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://ewellnesshealth.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": { "auth_ref": [ "r402", "r415" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.", "label": "Accrued director's fees" } } }, "localname": "AccruedProfessionalFeesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r27", "r158" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r19", "r303", "r378" ], "calculation": { "http://ewellnesshealth.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r93", "r94", "r95", "r300", "r301", "r302", "r345" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income (loss) to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r60", "r70", "r204", "r365" ], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount and prepaids", "verboseLabel": "Amortized of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/DerivativeValuationDetailsNarrative", "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r70", "r151", "r153" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive potential earnings per share, amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CompanyDetailsNarrative", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r87", "r130", "r133", "r139", "r147", "r168", "r169", "r170", "r172", "r173", "r174", "r175", "r176", "r177", "r179", "r180", "r329", "r331", "r356", "r376", "r378", "r398", "r410" ], "calculation": { "http://ewellnesshealth.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r7", "r42", "r87", "r147", "r168", "r169", "r170", "r172", "r173", "r174", "r175", "r176", "r177", "r179", "r180", "r329", "r331", "r356", "r376", "r378" ], "calculation": { "http://ewellnesshealth.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r285", "r299" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/DerivativeValuationDetailsNarrative", "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferred policy acquisition costs, including the nature, type, and amount of capitalized costs incurred to write or acquire insurance contracts, and the basis for and methodologies applied in capitalizing and amortizing such costs.", "label": "Debt Issuance Costs" } } }, "localname": "CapitalizationOfDeferredPolicyAcquisitionCostsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r24", "r72" ], "calculation": { "http://ewellnesshealth.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r10", "r73" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r66", "r72", "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, end of period", "periodStartLabel": "Cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r66", "r357" ], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Net increase (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Supplemental Cash Flow Information" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SupplementalCashFlowInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r84", "r87", "r105", "r106", "r107", "r109", "r111", "r115", "r116", "r117", "r147", "r168", "r173", "r174", "r175", "r179", "r180", "r218", "r219", "r223", "r227", "r356", "r453" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets", "http://ewellnesshealth.com/role/BalanceSheetsParenthetical", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit", "http://ewellnesshealth.com/role/SupplementalCashFlowInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CompanyDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r38", "r164", "r403", "r414" ], "calculation": { "http://ewellnesshealth.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r161", "r162", "r163", "r167", "r431" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments, Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CommitmentsContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r93", "r94", "r345" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit", "http://ewellnesshealth.com/role/SupplementalCashFlowInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value", "verboseLabel": "Common stock par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheetsParenthetical", "http://ewellnesshealth.com/role/CompanyDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheetsParenthetical", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r18", "r234" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r18", "r378" ], "calculation": { "http://ewellnesshealth.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, authorized 20,000,000,000 shares, $.001 par value, 18,507,683,627 and 16,862,481,961 issued and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r75", "r76", "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Shares issued for conversion", "verboseLabel": "Shares issued during period for conversion, value" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockDescription": { "auth_ref": [ "r75", "r76", "r77" ], "lang": { "en-us": { "role": { "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of stock, description" } } }, "localname": "ConversionOfStockDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r75", "r76", "r77" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Shares issued for conversion, shares", "terseLabel": "Conversion of stock, shares converted", "verboseLabel": "Conversion of Stock, Shares Converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit", "http://ewellnesshealth.com/role/SupplementalCashFlowInformationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://ewellnesshealth.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible debt, net of discount" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities [Member]" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r13", "r399", "r409", "r428" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r57", "r87", "r147", "r168", "r169", "r170", "r173", "r174", "r175", "r176", "r177", "r179", "r180", "r356" ], "calculation": { "http://ewellnesshealth.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r75", "r77" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Shares issued for debt conversion,shares", "verboseLabel": "Stock issued during the period for settlement of debt, shares" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/SupplementalCashFlowInformationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r75", "r77" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Stock issued during the period for settlement of debt,value" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SupplementalCashFlowInformationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r83", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r198", "r205", "r206", "r207", "r214" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Convertible Notes Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r13", "r14", "r15", "r86", "r91", "r181", "r182", "r183", "r184", "r185", "r186", "r188", "r194", "r195", "r196", "r197", "r199", "r200", "r201", "r202", "r203", "r204", "r208", "r209", "r210", "r211", "r368", "r399", "r400", "r409" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Convertible debt percentage" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Number of trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r181", "r208", "r209", "r366", "r368", "r369" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, principal amount", "verboseLabel": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r35", "r182" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt interest stated rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r36", "r184", "r351" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt instrument maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r37", "r86", "r91", "r181", "r182", "r183", "r184", "r185", "r186", "r188", "r194", "r195", "r196", "r197", "r199", "r200", "r201", "r202", "r203", "r204", "r208", "r209", "r210", "r211", "r368" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r194", "r365", "r369" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Original issue discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationEquity": { "auth_ref": [ "r41", "r283" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.", "label": "Deferred compensation" } } }, "localname": "DeferredCompensationEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r28", "r194", "r367" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Transaction costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r312" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax asset" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfDeferredTaxLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r316", "r317" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "NOL carryover" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfDeferredTaxLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": { "auth_ref": [ "r316", "r317" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.", "label": "Accrued payroll" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfDeferredTaxLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r311" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfDeferredTaxLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r70", "r156" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r70", "r156" ], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "auth_ref": [ "r333" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.", "label": "Derivative Liability" } } }, "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfDerivativeLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r337" ], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://ewellnesshealth.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Gain (loss) on derivative liability", "negatedLabel": "(Gain) loss on derivative liability" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows", "http://ewellnesshealth.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r45", "r336", "r338", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfDerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r344", "r347" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Valuation" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/DerivativeValuation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r335", "r336", "r339", "r340", "r341", "r342", "r343" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfDerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfDerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r43", "r44", "r45", "r355" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability [Default Label]", "periodEndLabel": "Derivative liability, ending balance", "periodStartLabel": "Derivative liability, beginning balance" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfDerivativeLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://ewellnesshealth.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liability" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityMeasurementInput": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure derivative liability.", "label": "Derivative liability, fair value measurement input, percentage" } } }, "localname": "DerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_DerivativeTermOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative liability, term" } } }, "localname": "DerivativeTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DerivativesReportingOfDerivativeActivity": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.", "label": "Derivative Financial Instruments" } } }, "localname": "DerivativesReportingOfDerivativeActivity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsPayableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Dividends Payable [Line Items]" } } }, "localname": "DividendsPayableLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SupplementalCashFlowInformationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsPayableTable": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "A table that contains information regarding dividends that have been declared but not paid as of the financial reporting date. This information may contain the amount, amount per share, declared date, and date to be paid.", "label": "Dividends Payable [Table]" } } }, "localname": "DividendsPayableTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SupplementalCashFlowInformationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r29", "r90", "r171", "r173", "r174", "r178", "r179", "r180", "r372" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to related parties, current" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Basic and diluted (loss) per common share" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r112", "r113" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Loss per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://ewellnesshealth.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued compensation", "verboseLabel": "Accrued executive compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets", "http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r49", "r50", "r51", "r93", "r94", "r95", "r97", "r102", "r104", "r114", "r148", "r234", "r241", "r300", "r301", "r302", "r319", "r320", "r345", "r358", "r359", "r360", "r361", "r362", "r363", "r423", "r424", "r425", "r458" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit", "http://ewellnesshealth.com/role/SupplementalCashFlowInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CompanyDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Schedule of Assumptions Used Black Scholes Valuation of Derivative" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/DerivativeValuationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r196", "r208", "r209", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r280", "r349", "r382", "r383", "r384" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r196", "r269", "r270", "r275", "r280", "r349", "r382" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r196", "r208", "r209", "r269", "r270", "r275", "r280", "r349", "r383" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r196", "r208", "r209", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r280", "r349", "r384" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r196", "r208", "r209", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r280", "r382", "r383", "r384" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetAssetLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of asset after deduction of liability.", "label": "Total Liabilities measured at fair value" } } }, "localname": "FairValueNetAssetLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": { "auth_ref": [ "r352" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) recognized in income for derivative asset (liability) after deduction of derivative liability (asset), measured at fair value using unobservable input (level 3) and still held.", "label": "Change in fair value" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfDerivativeLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r353", "r354" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r336" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Derivative (Gain)/Loss" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfPre-taxFromContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfIntangibleAssets": { "auth_ref": [ "r70" ], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://ewellnesshealth.com/role/StatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.", "label": "Loss on disposal of asset", "negatedLabel": "Loss on disposal of asset" } } }, "localname": "GainLossOnDispositionOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows", "http://ewellnesshealth.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r70", "r212", "r213" ], "calculation": { "http://ewellnesshealth.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r59" ], "calculation": { "http://ewellnesshealth.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r56", "r87", "r130", "r132", "r135", "r138", "r140", "r147", "r168", "r169", "r170", "r173", "r174", "r175", "r176", "r177", "r179", "r180", "r356" ], "calculation": { "http://ewellnesshealth.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Net Revenue" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r70", "r155" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r53", "r130", "r132", "r135", "r138", "r140", "r397", "r404", "r406", "r417" ], "calculation": { "http://ewellnesshealth.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Net Income (Loss) before Income Taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r88", "r308", "r309", "r314", "r321", "r323", "r325", "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r89", "r103", "r104", "r129", "r306", "r322", "r324", "r418" ], "calculation": { "http://ewellnesshealth.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax expense benefit", "negatedLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfPre-taxFromContinuingOperationsDetails", "http://ewellnesshealth.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r48", "r304", "r305", "r309", "r310", "r313", "r318" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r307" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfPre-taxFromContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization": { "auth_ref": [ "r307" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible amortization.", "label": "Amortization of debt discount" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfPre-taxFromContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseCharitableContributions": { "auth_ref": [ "r307" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible charitable contributions expense.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Charitable Contributions, Amount", "verboseLabel": "Contributed services" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseCharitableContributions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfPre-taxFromContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseDepreciation": { "auth_ref": [ "r307" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible depreciation.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation, Amount", "verboseLabel": "Depreciation" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseDepreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfPre-taxFromContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment": { "auth_ref": [ "r307" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.", "label": "Meals & entertainment" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfPre-taxFromContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r307" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount", "verboseLabel": "Accrued payroll" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfPre-taxFromContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r74" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r69" ], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "auth_ref": [ "r69" ], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Accounts payable - related party" } } }, "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r69" ], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "verboseLabel": "Accrued compensation" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r81", "r152", "r392", "r393", "r394", "r396" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "verboseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/StatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest Expense, Other", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r65", "r67", "r74" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Expense" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r8", "r9", "r33" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "verboseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r402", "r415" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Accrued interest" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ewellnesshealth.com/role/SupplementalCashFlowInformationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r58" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Monthly base fee" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r32", "r87", "r134", "r147", "r168", "r169", "r170", "r173", "r174", "r175", "r176", "r177", "r179", "r180", "r330", "r331", "r332", "r356", "r376", "r377" ], "calculation": { "http://ewellnesshealth.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r23", "r87", "r147", "r356", "r378", "r401", "r412" ], "calculation": { "http://ewellnesshealth.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r34", "r87", "r147", "r168", "r169", "r170", "r173", "r174", "r175", "r176", "r177", "r179", "r180", "r330", "r331", "r332", "r356", "r376", "r377", "r378" ], "calculation": { "http://ewellnesshealth.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayable": { "auth_ref": [ "r15", "r400", "r408" ], "calculation": { "http://ewellnesshealth.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Loan payable" } } }, "localname": "LoansPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesPaidValue": { "auth_ref": [ "r164", "r165", "r166" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of damages paid to the plaintiff in the legal matter.", "label": "Payment of plaintiffs" } } }, "localname": "LossContingencyDamagesPaidValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CommitmentsContingenciesDetailsNarrative", "http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r164", "r165", "r166" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Contractual Fees" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CommitmentsContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r118", "r126" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "The Company" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/Company" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r66" ], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r66", "r68", "r71" ], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r46", "r47", "r51", "r54", "r71", "r87", "r96", "r98", "r99", "r100", "r101", "r103", "r104", "r108", "r130", "r132", "r135", "r138", "r140", "r147", "r168", "r169", "r170", "r173", "r174", "r175", "r176", "r177", "r179", "r180", "r346", "r356", "r405", "r416" ], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://ewellnesshealth.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net Income (Loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit", "http://ewellnesshealth.com/role/StatementOfCashFlows", "http://ewellnesshealth.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash items:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER INCOME (EXPENSE)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OfficersCompensation": { "auth_ref": [ "r55" ], "calculation": { "http://ewellnesshealth.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Executive compensation" } } }, "localname": "OfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r130", "r132", "r135", "r138", "r140" ], "calculation": { "http://ewellnesshealth.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from Operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r315" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r63" ], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Original issue discount and debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Financing cost", "verboseLabel": "Financing costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/SupplementalCashFlowInformationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockConvertibleConversionDate": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Date when preferred stock can be converted into common shares, in YYYY-MM-DD format.", "label": "Shares issued date" } } }, "localname": "PreferredStockConvertibleConversionDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r17", "r218" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value", "verboseLabel": "Preferred stock par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheetsParenthetical", "http://ewellnesshealth.com/role/CompanyDetailsNarrative", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheetsParenthetical", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r17", "r218" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r17", "r378" ], "calculation": { "http://ewellnesshealth.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value", "verboseLabel": "Preferred stock value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r17", "r235" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred Stock, Voting Rights" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r6", "r149", "r150" ], "calculation": { "http://ewellnesshealth.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromConstructionLoansPayable": { "auth_ref": [ "r62" ], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from borrowings to finance the cost of construction.", "label": "Proceeds from Construction Loans Payable", "verboseLabel": "Loan payable" } } }, "localname": "ProceedsFromConstructionLoansPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r62" ], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from issuance of convertible debt" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r61" ], "calculation": { "http://ewellnesshealth.com/role/StatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from issuance of preferred series E" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r429", "r430" ], "calculation": { "http://ewellnesshealth.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees", "verboseLabel": "Professional Fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CompanyDetailsNarrative", "http://ewellnesshealth.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r27", "r159" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r160", "r432", "r433", "r434" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r26", "r157" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r11", "r12", "r159", "r378", "r407", "r413" ], "calculation": { "http://ewellnesshealth.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property & equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r25", "r159", "r432", "r433" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r11", "r159" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of Estimated Useful Lives for Significant Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r11", "r157" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r370", "r371", "r372", "r374", "r375" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r241", "r303", "r378", "r411", "r426", "r427" ], "calculation": { "http://ewellnesshealth.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Accumulated loss" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets", "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r93", "r94", "r95", "r97", "r102", "r104", "r148", "r300", "r301", "r302", "r319", "r320", "r345", "r423", "r425" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r127", "r128", "r131", "r136", "r137", "r141", "r142", "r143", "r261", "r262", "r395" ], "calculation": { "http://ewellnesshealth.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r82", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r265" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "verboseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r263", "r265" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/RevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r52", "r87", "r127", "r128", "r131", "r136", "r137", "r141", "r142", "r143", "r147", "r168", "r169", "r170", "r173", "r174", "r175", "r176", "r177", "r179", "r180", "r356", "r406" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "verboseLabel": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/RevenueRecognitionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "REVENUE" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CompanyDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r266", "r267" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r276", "r277", "r278", "r279", "r280" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative liabilities at fair value.", "label": "Schedule of Derivative Liability" } } }, "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/DerivativeValuationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Pre-tax from Continuing Operations" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r348", "r349" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Summary of Assets and Liabilities Fair Value on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r27", "r159" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r285", "r299" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/DerivativeValuationDetailsNarrative", "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r287", "r295", "r296" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Summary of Stock Options Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r39", "r84", "r115", "r116", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r223", "r227", "r232", "r235", "r236", "r237", "r238", "r239", "r240", "r241" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r243", "r284" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Summary of Warrants Activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets", "http://ewellnesshealth.com/role/BalanceSheetsParenthetical", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series C Preferred Stock [Member]" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets", "http://ewellnesshealth.com/role/BalanceSheetsParenthetical", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesDPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series D preferred stock or outstanding series D preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series D Preferred Stock [Member]" } } }, "localname": "SeriesDPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets", "http://ewellnesshealth.com/role/BalanceSheetsParenthetical", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesEPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series E preferred stock or outstanding series E preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series E Preferred Stock [Member]" } } }, "localname": "SeriesEPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets", "http://ewellnesshealth.com/role/BalanceSheetsParenthetical", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit", "http://ewellnesshealth.com/role/SupplementalCashFlowInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/DerivativeValuationDetailsNarrative", "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Number of Warrants, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures", "negatedLabel": "Number of Warrants, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Number of Warrants, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r288", "r290" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Number of Warrants, Outstanding, Ending Balance", "periodStartLabel": "Number of Warrants, Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails", "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Number of Stock Options exercisable, Ending Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Options exercisable, Ending Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of Stock Options Outstanding, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Number of Stock Options Outstanding, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r299" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Intrinsic Value Options exercisable, Ending Balance", "periodStartLabel": "Intrinsic Value Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r289", "r299" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodStartLabel": "Number of Stock Options Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r284", "r286" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/DerivativeValuationDetailsNarrative", "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails", "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted Average Exercise Price Outstanding,Ending Balance" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails", "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Stock price at valuation date" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r299" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Intrinsic Value Options exercisable, Ending Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "verboseLabel": "Remaining Life (yrs) Outstanding, Ending Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Remaining Life (yrs) Outstanding, Beginning Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Offering price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r80", "r92" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internally developed software for sale, licensing or long-term internal use.", "label": "Software Development [Member]" } } }, "localname": "SoftwareDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r16", "r17", "r18", "r84", "r87", "r105", "r106", "r107", "r109", "r111", "r115", "r116", "r117", "r147", "r168", "r173", "r174", "r175", "r179", "r180", "r218", "r219", "r223", "r227", "r234", "r356", "r453" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets", "http://ewellnesshealth.com/role/BalanceSheetsParenthetical", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit", "http://ewellnesshealth.com/role/SupplementalCashFlowInformationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r40", "r49", "r50", "r51", "r93", "r94", "r95", "r97", "r102", "r104", "r114", "r148", "r234", "r241", "r300", "r301", "r302", "r319", "r320", "r345", "r358", "r359", "r360", "r361", "r362", "r363", "r423", "r424", "r425", "r458" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit", "http://ewellnesshealth.com/role/SupplementalCashFlowInformationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets", "http://ewellnesshealth.com/role/BalanceSheetsParenthetical", "http://ewellnesshealth.com/role/CommitmentsContingenciesDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r93", "r94", "r95", "r114", "r395" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets", "http://ewellnesshealth.com/role/BalanceSheetsParenthetical", "http://ewellnesshealth.com/role/CommitmentsContingenciesDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Shares issued for services, shares", "verboseLabel": "Shares issued during period for services,shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r17", "r18", "r234", "r241" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Shares issued for cash, shares", "verboseLabel": "Shares issued during period shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Shares issued to officers, directors and consultants, shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.", "label": "Shares issued for rounding - 50:1 split, shares" } } }, "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r17", "r18", "r234", "r241", "r293" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Number of Stock Options Outstanding, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Shares issued for services", "verboseLabel": "Shares issued during period for services, value" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r17", "r18", "r234", "r241" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Shares issued for cash", "verboseLabel": "Stock issued during the period, value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Shares issued to officers, directors and consultants" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r18", "r21", "r22", "r87", "r145", "r147", "r356", "r378" ], "calculation": { "http://ewellnesshealth.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Stockholders\u2019 Deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r85", "r219", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r233", "r241", "r244" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Equity Transactions" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Reverse Stock Split", "verboseLabel": "Reverse stock split, description" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CompanyDetailsNarrative", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r364", "r380" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CommitmentsContingenciesDetailsNarrative", "http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r364", "r380" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r364", "r380" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CommitmentsContingenciesDetailsNarrative", "http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r364", "r380" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CommitmentsContingenciesDetailsNarrative", "http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r379", "r381" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CompanyDetailsNarrative", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r119", "r120", "r121", "r122", "r123", "r124", "r125" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted average basic and diluted shares outstanding" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r126": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2611-110228" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r163": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r167": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r214": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r265": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r327": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=117331979&loc=d3e41228-113958" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r347": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r375": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r381": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16)(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=35755530&loc=d3e11264-158415" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r437": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r438": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r439": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r440": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r441": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r442": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r443": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r444": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r445": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r446": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r447": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r448": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r449": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r450": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r451": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r452": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r453": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r454": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r455": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r456": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r457": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r79": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "http://asc.fasb.org/topic&trid=2134446" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" } }, "version": "2.1" } ZIP 66 0001493152-22-008404-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-008404-xbrl.zip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